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Functional Role of PKCα in Endometrial 
Carcinogenesis 
Abstract 
Alice H. Hsu, Ph.D. 
University of Nebraska Medical Center, 2018 
Supervisor: Jennifer D. Black, Ph.D. 
 
Protein kinase Cα (PKCα) is a member of the PKC family of serine/threonine kinases that 
regulate many fundamental cellular processes, including cell proliferation, differentiation, survival 
and transformation.  The impact of PKCα on tumorigenesis, and whether it acts as an oncogene or 
tumor suppressor, has been debated over the years.  The overall goal of this study was to establish 
the functional role of PKCα in endometrial carcinogenesis.  Results from this study broaden our 
knowledge of PKCα signaling and add to our understanding of its role in tumor development. 
As understanding of the role of PKCα signaling in the uterus is limited, we first examined 
the expression and activation of PKCα in the normal endometrium.  Our analysis revealed cyclical 
activation of PKCα, linked to hormonal fluctuations and negatively correlated with epithelial 
proliferation, suggesting that PKCα is a growth inhibitory kinase in the endometrium.  
Historically, PKC isozymes have been recognized as oncoproteins as they are activated by 
the tumor promoting phorbol esters. However, accumulating evidence indicates that PKCs can be 
inhibitory in some cancers, with recent findings propelling a shift in focus to understanding tumor 
suppressive functions of these enzymes. Here, we report that PKCα acts as a tumor suppressor in 
PI3K/AKT-driven endometrial cancer.  PKCα deficiency, due to transcriptional repression, is 
associated with aggressive disease and poor prognosis in endometrial cancer patients.  Activation 
of PKCα induces PP2A activity, leading to hypophosphorylation of AKT and potently inhibiting 
the growth of endometrial cancer cells under anchorage-independent conditions.  In murine models, 
PKCα loss is a rate-limiting event for initiation of endometrial tumorigenesis, as demonstrated by 
vi 
 
increased tumor burden in mice lacking PKCα.  
More than 90% of endometrial cancer cases are characterized by AKT hyperactivation as 
the result of mutations in multiple PI3K/AKT pathway components, including PTEN, PIK3CA, 
PIK3R1, and AKT.  Mutations in these molecules often coexist in EC, indicating that EC 
development requires full, unopposed activation of PI3K/AKT signaling.  Results from our study 
show that PKCα is a negative regulator of AKT activation in the endometrium, which can override 
hyperactivation of the PI3K/AKT pathway in endometrial cancer cells.  Loss of this kinase in the 
context of other molecular aberrations, such as mutations in PTEN or PI3K, leads to further 
hyperactivation of AKT, enhancing tumor cell growth.  Together, our data point to PKCα as a 
crucial tumor suppressor in the endometrium, with deregulation of a PKCα→PP2A signaling axis 
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1.1 The protein kinase C (PKC) family 
Protein kinase C (PKC) is a member of the family of AGC kinases (including protein kinase 
A, G, and C) that phosphorylates serine and threonine residues. It was discovered in the brain by 
Nishizuka and colleagues in 1977 as a kinase whose activation is dependent on the presence of 
phosphatidylserine (PS) and calcium (Ca2+) (Inoue et al., 1977; Kishimoto et al., 1977).  In 1979, 
the same group showed that PKC can be activated by sn-1,2-diacylglycerol (DAG), a membrane-
associated lipid generated by phosphoinositide hydrolysis, in the presence of low Ca2+ (Kishimoto 
et al., 1980; Takai et al., 1979).  Later, PKC was identified as a cellular target for tumor promoting 
phorbol esters, such as 12-O-tetra-decanoylphorbol-13-acetate (TPA, also referred to as phorbol 
12-myristate 13-acetate (PMA)) (Castagna et al., 1982; Kikkawa et al., 1983), that bind to PKC at 
the same site as DAG.  This study demonstrated the first link of PKC to cell proliferation and 
pointed to its potential contribution to carcinogenesis.  After years of intensive study of these 
isozymes, PKC has been shown to be involved in the regulation of many fundamental cellular 
processes such as cell cycle progression, differentiation, cell survival and apoptosis. Subsequent 
studies have established the pathogenic association of PKC to important health concerns such as 
cardiovascular disease and diabetes (Ferreira et al., 2011; Geraldes and King, 2010; Inagaki et al., 
2006).  In the late 1980s, multiple isoforms of PKCs were identified by molecular cloning 
(Coussens et al., 1986; Parker et al., 1986).  More than 30 years since its debut, current 
understanding defines PKC as a family of serine/threonine kinase consisting of ten isozymes, 
categorized into three classes based on their structure and coactivator requirements and has 
isozyme-specific, context-dependent functions.   
 
1.1.1 Structure, maturation, and activation of PKC isozymes 
There are three classes of PKC isozymes: the classical or conventional PKCs (cPKCs), the 




structural similarities, with an N-terminal regulatory domain linked by a flexible hinge region to 
the C-terminal carboxyl kinase domain.  The catalytic C3 and C4 domains are conserved in all the 
PKCs, which is similar to the catalytic domain of protein kinase A.  However, each class of PKCs 
has a unique regulatory domain that determines cofactor requirements for activation. The 
pseudosubstrate domain is common to the regulatory domains of all PKCs, and plays a central role 
in regulating PKC activity (House and Kemp, 1987; House et al., 1987).  It contains a sequence 
that binds to the substrate binding pocket of the catalytic domain and blocks the substrate binding, 
keeping the kinase in its inactive state (House et al., 1987; Orr and Newton, 1994).  The regulatory 
domain of cPKCs consists of two cysteine-rich motifs (C1A and C1B) in the C1 domain and a Ca2+-
sensitive C2 domain.  The C1 domain binds to DAG and phosphatidylserine, while the C2 domain 
binds to Ca2+. The presence of Ca2+ in the C2 domain increases the affinity of cPKCs for DAG. 
Fig. 1-1: Domain structure of PKC family members 
(The three classes of PKCs – cPKCs, nPKCs, and aPKCs – share structural similarities in the catalytic 
domain (C3 and C4) and the hinge region, which connects the regulatory and kinase domains.  Differences 
in the regulatory domains define the activation requirements for each class of PKCs: cPKC activation 
requires DAG, Ca2+, and phosphatidylserine (PS); nPKC activation requires DAG and 
phosphatidylserine; aPKC activation is mediated by protein-protein interactions.  Adapted from (Mackay 












Thus, activation of cPKCs (including PKCα, the splice variants PKCβI and βII, and PKCγ) requires 
DAG, Ca2+, and phosphatidylserine. While the nPKCs also have two cysteine-rich motifs in their 
C1 domain, they have an “atypical” C2 domain that lacks Ca2+ binding residues. Differing from 
cPKCs, activation of the nPKCs (PKCδ, ε, η, θ) requires DAG and phosphatidylserine but not Ca2+, 
as DAG exhibits higher binding affinity for the C1B component of nPKCs than for the C1A domain 
of cPKCs before Ca2+ binding.  The activating phorbol ester, PMA, binds to the C1B motif of the 
regulatory domain of both cPKCs and nPKCs to enhance their membrane association and 
activation. Unlike other members of the family, activation of the aPKCs (PKCζ, λ/ι) is independent 
of both DAG and Ca2+. Atypical PKCs have a variant of the C1 domain that has only one cysteine-
rich motif and does not bind to DAG or phorbol esters. They also lack the C2 domain in their 
regulatory region.  Instead, aPKCs have a Phox Bem 1 (PB1) domain that is involved in protein-









Maturation of PKC requires a series of highly regulated, ordered phosphorylation events 
at three distinct sites of the kinase domain (Figure 1-2).  While these events do not directly activate 
PKC, each phosphorylation induces a conformational change that stabilizes the kinase in its 
inactive form and protects it from phosphatase activity. The first of the three priming 
phosphorylations occurs at the activation loop mediated by phosphoinositide-dependent kinase-1 
Fig. 1-2: Sequential maturation and activation of PKCs 
The newly synthesized, immature PKC associates with the membrane where it is sequentially 
phosphorylated at the activation loop, turn motif, and hydrophobic motif mediated by PDK-1, and 
facilitated by mTORC2 and HSP90.  The mature, phosphorylated PKC is then released into the cytosol. 
Subsequently, PLC-mediated lipid hydrolysis generates membrane associated DAG and increased 
intracellular Ca2+ levels.  Interaction with DAG creates a strong bond between the phospholipid in the 
membrane and the open, activated PKC, allowing it to act on appropriate downstream substrates. Adapted 













(PDK-1) (Chou et al., 1998; Edwards et al., 1999; Le Good et al., 1998).  The newly synthesized 
PKC associates with the membrane in its open conformation, in which the substrate binding cavity 
is free of the pseudosubstrate domain, allowing PDK-1 to access the threonine residue at the 
activation loop (Dutil and Newton, 2000).  It has been shown that cells lacking PDK-1 have 
markedly reduced PKC levels (Balendran et al., 2000). This phosphorylation initiates the 
maturation process of PKC and is required for subsequent phosphorylation (Dutil and Newton, 
2000; Dutil et al., 1998). The second phosphorylation at the turn motif requires the mammalian 
target of rapamycin complex 2 (mTORC2), as cells lacking mTORC2 have diminishing levels of 
PKC (Facchinetti et al., 2008; Ikenoue et al., 2008; Jacinto and Lorberg, 2008). Despite its essential 
role in the phosphorylation of the turn motif, mTORC2 was unable to phosphorylate PKC in vitro 
(Ikenoue et al., 2008), raising the question whether mTORC2 mediates direct phosphorylation of 
PKC.  It has been proposed that mTORC2 might act as a chaperone to position the newly 
synthesized PKC for priming phosphorylation or activates another upstream kinase that 
phosphorylates the turn motif. The last step of this priming process is the autophosphorylation at 
the hydrophobic motif.  Both heat shock protein 90 (HSP90) and mTORC2 have been shown to 
modulate the phosphorylation at this motif (Gould et al., 2009; Ikenoue et al., 2008; Ziegler et al., 
1999).  However, this might be because mTORC2 is required for mediating the prerequisite 
phosphorylating event that is necessary for hydrophobic motif autophosphorylation. Completion of 
these sequential phosphorylation results in a mature, catalytically competent form of PKC.  The 
fully phosphorylated PKC is then released from the membrane into the cytosol with its 
pseudosubstrate domain occupying the active site, preventing full activation of the kinase (Newton, 
2010).    
Extracellular signals trigger signaling events leading to the generation of cofactors that are 
required for PKC activation.  Binding of ligands to their cognate tyrosine kinase receptors or G-
coupled protein receptors stimulates signal transduction that elicits intracellular molecular changes 




phosphatidylinositol 4,5-bisphosphate (PIP2)  to generate inositol 1, 4, 5-trisphosphoate (IP3) and 
DAG, the physiological agonist of both cPKCs and nPKCs.  DAG binds to the C1 domain of PKC 
and anchors it to the plasma membrane. Thus, membrane translocation serves as a readout for PKC 
activation (Kraft et al., 1982).  IP3 binds to receptors in the smooth endoplasmic reticulum (ER) 
and promotes the release of Ca2+ into the cytoplasm, resulting in elevated intracellular Ca2+ 
concentrations.  To compensate for the weaker DAG binding affinity to cPKCs, Ca2+ enhances the 
binding between DAG and the C1 domain and is required for cPKC but not nPKC activation.  
Because of their rapid metabolism at the cell membrane, DAG and its analogs are only transient 
PKC-inducing signals. Works from our laboratory and others has shown that the activation of 
DAG-stimulated PKC is acutely terminated by ‘reverse translocation’ - i.e., redistribution of the 
kinase to the cytoplasm (Akita, 2002; Di Mari et al., 2005; Leitges et al., 1996; Lum et al., 2016). 
Additionally, prolonged activation of PKC such as that mediated by phorbol esters or chronic DAG 
stimulation, is terminated by enzyme degradation.  
 
1.1.2 PKC modulating agents 
As PKC signaling is associated with diseases such as cancer (Griner and Kazanietz, 2007), 
hypertension, and diabetes (Ferreira et al., 2011; Geraldes and King, 2010; Inagaki et al., 2006), 
deciphering the roles of individual PKCs in signal transduction and the dysregulation of these 
processes is pertinent to further our understanding of human disorders.  Pharmacological agents 
that modulate PKC activity are valuable tools for the study of effects of this kinase family. Many 
PKC modulating agents have been widely used experimentally, allowing for easy manipulation of 
PKC activity.  Yet, because of their promiscuous nature, these agents are also the culprits of 
exacerbating the inherent complexity of PKC signaling, adding confusion to the interpretation of 
results from their use.  This following section provides an overview of the commonly used PKC 




utilizing these compounds in experimental settings. Other pharmacological agents that also affect 
PKC activity are reviewed in detail in (Wu-Zhang and Newton, 2013). 
There are two major types of PKC agonists: DAG and its analogs and phorbol esters.  Both 
are capable of activating cPKC and nPKC through their interaction with the C1 domain, but do not 
activate aPKC. As activation of PKC occurs at the plasma membrane (or possibly in other 
membrane compartments), all of these compounds promote membrane translocation of the enzyme, 
where it can interact with additional activating cofactors such as phosphatidylserine.  In addition to 
binding to PKC, these compounds can also interact with other families of signaling molecules that 
also have the C1 domain (e.g. PKDs, RasGRPs, and DGKs) (Blumberg et al., 2010). DAG, a 
product of PLC-mediated lipid hydrolysis, is the physiological agonist for typical C1-containing 
PKC isozymes. Of note, elevated intracellular Ca2+ concentrations can also increase DAG levels 
(Kunkel and Newton, 2010).  The two short-chain synthetic analogs of DAG, DiC8 (1,2-dioctanoyl-
sn-glycerol) and OAG (oleoacetyle glycerol), have improved aqeous solubility compared with 
DAG and are more commonly used in laboratories.  DAG and its analogs are rapidly metabolized 
in the cell, therefore, only inducing transient PKC activation.  Although these compounds can bind 
and activate both classical and novel isozymes, they exhibit preferential binding to the C1B motif 
in nPKCs and interact with the C1A motif of cPKCs at reduced affinity.  Interestingly, rather than 
serving as an activating signal, interaction with the lipid kinase, DGK, converts DAG to 
phosphatidic acid (PA) to abrogate its signaling ability (Baldanzi et al., 2016; Cai et al., 2009). 
Tumor promoting phorbol esters are the active component derived from croton oil (Van 
Duuren and Sivak, 1968). The most commonly used phorbol ester is PMA (phorbol 12-myristate 
13-acetate), also known as TPA (12-O-tetradecanoylphorbol 13-acetate).  The identification of 
PKC as a receptor for PMA establishes its first association to carcinogenesis (Castagna et al., 1982; 
Kikkawa et al., 1983).  The phorbol ester derivative, PDBu (phorbol 12,13-dibutyrate) has 
optimized potency and reduced lipophilicity comparing to  PMA, making it more water soluble for 




more potent PKC activators than DAG, effective at the nanomolar range.  Unlike DAG and its 
analogs, phorbol esters are not readily metabolized and are capable of generating prolonged 
activation of PKC.  Despite their shared high potency as PKC activators, the phorbol ester 
derivatives can induce different cellular responses (Blumberg, 1980, 1981). 
The C1 ligand, bryostatin-1 (Kunkel and Newton, 2010), provides an example of a PKC 
agonist that can produce different effects when compared with PMA. Bryostatins are macrocyclic 
lactones that also bind to the C1 domain.  Although these large complex molecules elicit the same 
effects as phorbol esters, albeit transiently, they actually antagonizes tumor formation (Blumberg 
et al., 2010).  It is unclear how bryostatin-1 acts like a phorbol ester (binding to the C1 domain) to 
activate PKC on the one hand, while failing to contribute to carcinogenesis on the other.  However, 
this unique property has brought bryostatin into clinical trials for cancer and Alzheimer’s disease 
(Kortmansky and Schwartz, 2003; Mayer et al., 2010; Roffey et al., 2009).  
The vast majority of effective PKC inhibitors are small molecules that target the ATP-
binding site of PKC.  These ATP-competitive PKC inhibitors have been the focus of the 
development of PKC-targeting drugs. There are two distinct chemical classes of these prototypical 
ATP-binding inhibitors, bisindolylmaleimides and indolocarbazoles. All of the currently known 
PKC inhibitors show some degree of promiscuity toward other kinases, despite some of them being 
highly selective for PKC.  While these active site inhibitors target all three classical or novel PKCs, 
the inhibition effect is selective, rather than specific for certain isozymes (Wu-Zhang and Newton, 
2013).  For example, the non-isozyme specific inhibitors Gӧ6983 and bisindolylmaleimide 1 (BIM-
1 or BisI), when used at 500 nM, have been shown to be more effective at inhibiting PKC activity 
than other kinases (Wu-Zhang and Newton, 2013).  Other bisindolylmaleimides, including Ro-31-
8220 and Ro-32-0432 developed by Roche, have been marketed as PKC inhibitors but also have 
the non-selective nature of other similar compounds. Among the ATP-competitive PKC 
antagonists, Gӧ6976 and staurosporine are the more widely used indolocarbazole-based inhibitors.  




studies (Anastassiadis et al., 2011; Bain et al., 2007; Davies et al., 2000), demonstrating that it is 
highly selective for cPKCs at the nanomolar range while having limited effects on other isozymes 
or non-PKC kinases.  Thus, Gӧ6976 is commonly regarded as a cPKC selective inhibitor.  On the 
other hand, staurosporine is one of the most promiscuous commercially available kinase inhibitors. 
It binds to and potently inhibits all cPKC, nPKC, and even aPKC, as well as other non-PKC kinases 
(Anastassiadis et al., 2011; Davis et al., 2011; Karaman et al., 2008).   
Structure-based PKC inhibitors targeting less conserved domains have been designed with 
the hope of inhibiting these kinases with improved specificity.  One example of these allosteric 
inhibitors is BisIV.  Despite its chemical similarity to BIM-1 and its specificity for PKC, it is a 
much less potent inhibitor.  Other non-active-site inhibitors targeting DAG-binding sites (e.g. 
calphostin C), the PKC priming kinases PDK-1 and mTORC2, or the maturation process by 
inhibiting HSP90 (e.g. 17-AAG), have also been employed to inhibit PKC activity.  In addition to 
weak PKC inhibition, these agents also affect other molecular processes and present their own sets 
of caveats as PKC inhibitors. 
Incorporation of PKC modulating agents in understanding the signaling roles of these 
kinases is a double-edged sword for the PKC field.  While these agents allow in vitro manipulation 
of PKC activities and alteration of its interaction with other signaling molecules, their selective but 
non-specific nature makes it difficult to link the induced effects to PKC function.  Therefore, 
interpretation of results generated from experiments using PKC modulating agents must be 
critically reviewed and confirmed with genetic approaches to exclude the involvement of other 
molecules that might also be targeted by these compounds.   
 
1.1.3 Functions of PKC isozymes 
PKC signaling is involved in a wide variety of molecular pathways, among which impact 
on cell cycle control and apoptosis are the most well-studied cellular processes influenced by this 




dependent kinases (Cdks) regulated by their association with cyclins, whose levels are determined 
by the cellular environment (e.g., mitogenic signals or DNA damage) (Otto and Sicinski, 2017).  
PKC signaling can exert either positive or negative regulation of cell cycle progression primarily 
at the G1/S and G2/M transitions. At early G1, pocket proteins such as the retinoblastoma protein 
(RB), p107, and p130 bind to and inhibit the transcriptional activity of growth-related E2F 
transcription factors. Under appropriate mitogenic induction signals, Cdk4 and Cdk6 are activated 
by associating with one of the three D-type cyclins (D1, D2, and D3), leading to phosphorylation 
of pocket proteins, which relieves E2F repression and upregulates cyclin E (Cobrinik, 2005). The 
elevated cyclin E in late G1 binds and activates Cdk2 to initiate a program of transcriptional events 
necessary for S phase entry (Malumbres and Barbacid, 2005).  Alternatively, when there are 
insufficient mitogenic signals for Cdk activation or pocket protein phosphorylation, the cell halts 
cell cycle progression and enters G0, the quiescent phase of the cell cycle.  Continued inactivation 
of pocket proteins at the end of G1 phase allows accumulation of cyclin A. Once the cell enters S 
phase, cyclin E is degraded through a proteasome-mediated mechanism to avoid re-initiation of 
DNA replication.  Instead, Cdk2 binds to cyclin A to facilitate completion and exit from S phase. 
Cyclin A also binds to Cdk1 (Cdc2) at the end of S phase to sequester its activation.   As the cell 
progresses through G2, cyclin A is degraded while there is active synthesis and accumulation of 
cyclin B.  This results in the association of Cdk1 and cyclin B, triggering the cell to enter mitosis.   
 The effect of PKC signaling on cell cycle progression is highly dependent on the 
timing and duration of PKC activation, the isozymes present in the cell, and the cellular 
environment. Of the crucial molecules involved in cell cycle progression, PKC has been shown to 
mediate its effect through regulation of cyclin D1 and p21 at the G1/S transition (Figure 1-3) and 
lamin B at G2/M (Figure 1-4).  At early G1, PKC signaling can lead to increased transcription of 
cyclin D1 (Li et al., 2006; Soh and Weinstein, 2003) and the destabilization of p21 (Walker et al., 
2006), resulting in hyperphosphorylation of pocket proteins and progression into S phase.  




translation of cyclin D1 (Hizli et al., 2006; Pysz et al., 2009; Soh and Weinstein, 2003) and induce 
p21 expression (Black, 2000; Griner and Kazanietz, 2007), leading to inhibition of Cdk4/6 and 
Cdk2 and cell cycle arrest at G0/G1. Lamin B is one of the essential proteins for nuclear structure 
and function.   During G2, PKCβII activation has been shown to result in lamin B phosphorylation 
and the disassembly of the nuclear envelope, allowing the cell to enter M phase and proceed to 
chromosome segregation (Thompson and Fields 1996).  Alternatively, PKC can negatively regulate 
the G2/M transition by downregulation of Cdc25, preventing the dephosphorylation and activation 
of Cdk1 (Arita et al., 1998; Barth and Kinzel, 1994; Kosaka et al., 1993).  PKC signaling can also 
induce p21 levels, likely through an ERK-dependent mechanism (Arita et al., 1998; Barboule et 






Fig. 1-3: PKC-mediated regulation of G1/ S transition 
PKC-mediated regulation of the G1-S transition can have either positive (upper portion) or negative (lower 
portion) effects.  In early G1, PKC activation increases cyclin D1 levels but leads to destabilization of p21, 
resulting in hyperphosphorylation of pocket proteins (e.g., Rb and p107) and progression into S phase.  
However, activation of PKC in mid-late G1 reduces cyclin D1 levels while elevating p21.  This results in 
hypophosphorylation of pocket proteins and G0 arrest. 















 Apoptosis is another fundamental cellular processes that is regulated by PKC 
signaling.  Appropriate induction of apoptosis is important for the maintenance of tissue 
homeostasis and prevents diseases relating to abnormal cellular growth such as cancer.  Apoptosis 
Fig. 1-4: PKC-mediated regulation of G2/ M transition 
Similar to its impact on the G1-S transition, PKC signaling can have opposing effects on G2-M 
progression. PKC-mediated phosphorylation of nuclear lamins promotes nuclear lamina disassembly 
and G2-M transition as depicted in the upper portion. Alternatively, PKC activation can block Cdc25 
phosphorylation and result in accumulation of p21, in order to inhibit progression into M phase (bottom 





pathways are defined by their upstream initiation signals; the extrinsic pathway is related to the 
activation of death receptors (e.g., TRAILR or Fas) and the intrinsic pathway is initiated by stimuli 
that trigger cytochrome c release from the mitochondria (Figure 1-5) (Ichim and Tait, 2016).  The 
opposing regulatory roles of PKCε and δ in apoptosis are a clear example of the differential 
response of PKC isozymes as described in (Griner and Kazanietz, 2007) and (Reyland and 
Bradford, 2010).  The pro-survival effect of PKCε has been attributed to its ability to activate ERK 
and AKT, which are two well-known pro-mitogenic, pro-survival effector molecules (Lu et al., 
2006). This signaling crosstalk leads to the upregulation of pro-survival factors BCL-XL and XIAP 
and protects the cell against TRAIL-induced apoptosis (Pardo et al., 2006). On the contrary, 
activation of PKCδ can promote both intrinsic and extrinsic apoptosis. Upon DNA-damaging insult, 
PKCδ undergoes caspase-3 mediated proteolysis, freeing the catalytic domain of the kinase to 
translocate to the nucleus where it induces the phosphorylation of apoptotic related substrates 
(Bharti et al., 1998; Cross et al., 2000; Frasch et al., 2000; Yuan et al., 1998). Additionally, PKCδ 
translocates to the mitochondria and leads to cytochrome c release, which further amplifies caspase-
3 activation (Denning et al., 2002; Li et al., 1999a; Majumder et al., 2000).  Therefore, PKCδ also 
serves a positive feedback signal to trigger intrinsic apoptosis.  
Much of our understanding of PKC functions is based on studies using non-specific phorbol 
esters and pharmacological agents, which makes parsing the functional role of each of the ten PKC 
isozymes a constant challenge of the field.  Other factors that have contributed to the discrepancies 
in the field include lack of antibody specificity, inclusion of validated controls in the analysis, 
discordant levels of mRNA and protein expression, and the activation status of the enzyme (Garg 
et al., 2014; Leitges, 2007).  Studies using genetic approaches can provide important functional 
insights of PKC enzymes. Despite some phenotypic abnormalities, mice lacking PKC isozyme do 
not exhibit developmental defects with the exception of PKCι, in which deletion of this enzyme 
was embryonic lethal (Suzuki et al., 2003), making it possible to examine the effect of PKC deletion 




utilizing both pharmacological and molecular approaches with the incorporation of transgenic 





Fig. 1-5: Mechanism of PKCδ-mediated apoptosis 
Upon DNA damage, either by exposure to UV or DNA-damaging agents, PKCδ is cleaved by caspase-3, 
resulting in the release of its catalytic domain, which is constitutively active without its regulatory 
domain.  The catalytic fragment can then translocate to the mitochondria to stimulate cytochrome C 
release and initiate the intrinsic apoptotic pathway as shown in part a.  Alternatively, the cleaved catalytic 
fragment of PKCδ can translocate into the nucleus to phosphorylate substrates involved in cell cycle or 
apoptosis.  The full-length PKCδ can initiate extrinsic apoptosis by modulating the response of death 




1.2 PKC in cancer 
The observation that exposure to PMA, which activates PKCs, promotes carcinogenesis in the 
presence of an additional initiating event (Barrett, 1993; Blumberg et al., 1983) sparked decades of 
research to develop PKC-targeted therapeutics for cancer. However, these earlier efforts have been 
futile as most of the inhibitors that were developed showed limited benefit in clinical trials 
(Mochly-Rosen et al., 2012).  As shown in later studies, this strategic failure was inevitable, due to 
the complex, context-dependent signaling roles of PKCs, their effects on carcinogenesis, and the 
promiscuous nature of the pharmacological agents. The reported enzyme depletion under prolonged 
activation raises the question whether tumor promotion is the result of PKC activity or its loss under 
prolonged stimulation, further challenging the role of PKC as a tumor promoting kinase. Using 
gene targeting approaches, PKC isozyme-specific knock-out transgenic mouse models were 
developed to identify and analyze PKC functions in vivo (Leitges, 2007).  From the observations 
made in genetically modified PKC models, it is evident that the effect of PKC isozymes on 
carcinogenesis is isozyme-specific and cancer type-dependent (Garg et al., 2014). In human tumors, 
alterations in PKC expression can result in either increased or decreased levels of the enzyme (Garg 
et al., 2014). The following section summarizes the evidence supporting oncogenic as well as tumor 
suppressive properties of PKC from in vivo models and discusses the recent shift in the paradigm 
to focus on its tumor suppressive effects.  
 
1.2.1 PKC as a tumor promoter 
The concept of PKC as tumor promoter stemmed from its activation by phorbol esters, a 
class of compounds well-known for their ability to promote skin papilloma formation.  In the two-
step mouse model of skin carcinogenesis, the mutagen 7,12-dimethylbenz[a]anthracene (DMBA) 
was first applied to the skin.  Subsequently, repeated exposure to phorbol esters led to the 




Kazanietz, 2007). Of note, no tumor was observed in mice treated with either DMBA or phorbol 
esters alone, suggesting that both agents have unique contributions to skin carcinogenesis.  
Interestingly, reversing the sequence of exposure to these agents (repeated application of phorbol 
esters followed by DMBA), or lengthening the time between doses of phorbol ester, was 
insufficient to form papillomas. These observations indicated that, in this model, DMBA was an 
“initiator” that acted to induce cell transformation, but was insufficient for tumor development.  
Additional insults to the initiated cells, such as exposure to phorbol esters at the appropriate strength 
and timing, function as “promoters” and are necessary to complete the transformation and result in 
tumor formation. As signal transduction molecules, several PKC isozymes have been implicated in 
important pathways that promote tumor growth and proliferation, including crosstalk with 














Fig. 1-6: Phorbol ester as a tumor promoter 
In a mouse model, skin papillomas were only observed when treatment with a mutagenic initiator (e.g. 
DMBA) was followed by repeated, frequent exposure to a tumor promoter (e.g., phorbol ester).  No 
tumors were observed when only the initiator or promoter were applied, the order of initiator and promoter 
application was reversed, or the time between administrations of promoter was extended.  This model 
defines the multi-stage nature of carcinogenesis and demonstrates the tumor promoting properties of 






Elevated levels of PKCβII, one of the cPKCs, has been reported in colon cancer patients 
(Davidson 1998, Spindler 2009) (although a recent study reported the opposite trend (Dowling et 
al., 2016)).  Transgenic mice overexpressing PKCβII in the intestinal epithelium led to hyper-
proliferation of the colonic epithelium and heightened sensitivity to carcinogens.  These mice 
showed increased formation of aberrant crypt foci (ACF), preneoplastic lesions of the colon, after 
5-week administration of azoxymethane (AOM) compared with the wild-type (Murray et al., 1999). 
In this context, PKCβII functions as an oncoprotein through 1) activation of the Wnt/adenomatous 
polyposis coli (APC)/β-catenin pathway leading to decreased glycogen synthase kinase 3β activity 
(GSK3β), a known inhibitor of AKT signaling (Murray et al., 1999); and 2) induction of ERK 
activation through a RAS-PKCι/RAC1-MEK signaling axis (Zhang et al., 2004). Interestingly, the 
colonic epithelial cells from PKCβII-overexpressing mice showed reduced levels of other cPKCs, 
PKCα and PKCβI, suggesting possible opposing functions of these isozymes (Gokmen-Polar et al., 
2001).   
PKCε, a member of nPKC subclass, is another oncogenic PKC isozyme that acts through 
activation of the RAF/MEK/ERK pathway (Cacace et al., 1996).  Overexpression of PKCε has 
been reported in many human tumor types including breast cancer, non-small cell lung cancer 
(NSCLC), and prostate cancer, and is associated with more invasive disease (Bae et al., 2007; 
Cornford et al., 1999; Schleifenbaum et al., 2004).  In the TRAMP prostate cancer model, deletion 
of PKCε inhibited cancer development and metastasis (Hafeez et al., 2013), whereas its deletion in 
the epidermis protected the skin from UV-induced transformation (Hafeez et al., 2016).  Consistent 
with its tumor promoting role in the prostate, tissue-specific overexpression of PKCε regulated by 
the probasin promoter led to elevated phosphorylation of AKT and activation of its downstream 
effectors S6 kinase and mTOR, as well as an increase in preneoplastic lesions (Benavides et al., 
2011).  In the epidermis, PKCε overexpression resulted in induced inflammation, hyperkeratosis, 




In recent years, PKCι has gained tremendous momentum as an oncogene and a prognostic 
marker in cancer. Accumulating studies have consistently demonstrated PKCι as an oncogene in 
many human cancers (Murray et al., 2011; Regala et al., 2005b). Because of its distinct features as 
an aPKC, PKCι has attracted much attention as a therapeutic target as inhibitors of this kinase might 
not affect other PKC isozymes. Overexpression of PKCι has been reported in many cancer types 
as summarized in (Murray et al., 2011).  In most of these cancers, high PKCι expression is 
predictive of poor patient survival, recurrence, and metastatic disease (Eder et al., 2005; Ishiguro 
et al., 2009; Li et al., 2008; Murray et al., 2011; Regala et al., 2005b; Scotti et al., 2010; Weichert 
et al., 2003). Elevated PKCι mRNA and protein can be attributed to gene amplification as reported 
in NSCLC (Regala et al., 2005b), serous ovarian tumors (Eder et al., 2005; Zhang et al., 2006), 
lung squamous cell carcinoma (LSCC) (Regala et al., 2005b), and esophageal squamous cell cancer 
(Yang et al., 2008), or the result of aberrant signaling leading to transcriptional activation of PKCι 
(Gustafson et al., 2004).  While overexpression due to gene mutation is possible, it is an unlikely 
culprit in this case as the most frequent mutation of PKCι affects the substrate binding dibasic motif 
rather than increasing its expression (Linch et al., 2013; Murray et al., 2011).  Functional analysis 
of PKCι in vivo has focused on its oncogenic role in NSCLC, pancreatic ductal adenocarcinoma 
(PDAC), and ovarian cancer. Disruption of PKCι expression in cells harboring KRAS mutation 
inhibited the tumorigenicity of NSCLC and PDAC cells in a subcutaneous or orthotopic model, 
respectively (Regala et al., 2005a; Scotti et al., 2010). In these tumors, PKCι acts as a critical 
effector dowmstream of RAS, activating the RAC1/MEK/ERK signaling axis to drive cellular 
transformation (Murray et al., 2004; Regala et al., 2005a; Scotti et al., 2010).  In ovarian cancer, 
PKCι is required for the maintenance of the tumor-initiating phenotype (Wang et al., 2013). 
Additionally, PKCι has been found to co-amplify with SOX2 in LSCC, and is required for 
hedgehog (Hh) signaling and activation of the related transcription factor, GLI1 (Justilien et al., 
2014). These studies provided strong evidence for the ability of PKCι to functions as an oncogene.  




context, currently, no studies have reported PKCι as having tumor suppressive properties, further 
cementing PKCι as a bona fide oncogene.   
 
1.2.2 PKC as a tumor suppressor 
Although PKC is well-known for being activated by the tumor promoting phorbol esters, 
several of these isozymes have been shown to inhibit cellular transformation and suppress tumor 
growth. One example is PKCα; mice lacking this kinase exhibited enhanced intestinal and lung 
tumorigenesis (Hill et al., 2014; Oster and Leitges, 2006).  Using the DMBA/PMA skin tumor 
model, PKCδ, one of the nPKCs, was similarly identified to function as a tumor suppressor. Mice 
with elevated PKCδ expression were resistant to chemically-induced transformation (Reddig et al., 
1999), but PKCδ deficiency did not have the same protective effect against UV radiation-induced 
squamous cell carcinoma (Aziz et al., 2006).  PKCζ has received little attention compared with the 
other aPKC, PKCι. While both up- and down-regulation of PKCζ has been reported in human 
cancers (Garg et al., 2014), observation from the Par4-deleted model suggested a tumor suppressive 
role of PKCζ.  As mentioned in the previous section (chapter 1.1.1.), aPKCs are activated by 
protein-protein interaction; interaction with Par4 leads to PKCζ activation. Without this activating 
protein-protein interaction, as seen in Par4 knockout transgenic mice, reduced PKCζ activation 
enhanced Ras-induced lung carcinoma (Joshi 2008), supporting the tumor suppressive function of 
this PKC isozyme.  
A recent survey of cancer-associated PKC mutations has propelled the paradigm shift to 
focusing on the tumor suppressive function of PKCs.  In Antal et al., despite the previously reported 
low mutation frequency in genes encoding PKCs, analysis of 50 of the now more than 1000 
mutations identified in these isozymes revealed that the majority lead to loss of function (LOF) of 
the kinase (Antal et al., 2015).  Two-thirds of identified mutations were found to be inactivating 
while the rest were inert. These mutations can render the kinase inactive by impeding the binding 




heterozygous, yet mice completely devoid of individual PKC isozymes were not embryonic lethal 
(with the exception of PKCι knockout mice) and exhibited limited phenotypic aberrations.  Taken 
together, these observations raise the possibility that mutant PKC might have dominant negative 
functions, or can act as a scaffold to modulate signal transduction (Newton and Brognard, 2017). 
It is also likely that maintenance of a threshold of PKC signaling is necessary for its oncogenic 
effect – hyperactivation or complete loss of a signaling pathway can be detrimental to 
tumorigenesis (Chen et al., 2015).  In many of these tumors, the tumor suppression exerted by PKC 
is dominant even in context of potent oncogenes such as KRAS (Antal et al., 2015; Hill et al., 
2014), suggesting a regulatory role of PKC in hindering the effect of oncogenes.  Taken together, 
these paradigm-shifting, yet conflicting views on the tumor-related properties of PKC isozymes 
indicate an incomplete understanding of PKC functions in tumorigenesis, and warrant a thorough 
examination of each isozyme in a tumor-specific manner to better understand the signaling role of 
PKC and its impact on tumor biology.   
 
1.3 Protein kinase C alpha (PKCα) 
PKCα is a member of the cPKC subclass of PKC isozymes that are activated by DAG (in the 
presence of Ca2+ and phosphotidylserine) and phorbol esters.  Experimentally, PKCα can be 
stimulated by pharmacological activators such as PMA, DiC8, and bryostatin-1 and inhibited by 
bisindolylmaleimide I (Bim-1; a pan-PKC inhibitor) and Gӧ6976 (a classical PKC inhibitor). PKCα 
activity is involved in the crosstalk of many signaling pathways that regulate a plethora of cellular 
processes including cell cycle progression, differentiation, and apoptosis (Nakashima, 2002). 
Because this kinase is ubiquitously expressed in many tissue, the role of PKCα in normal tissue 
development as well as tumorigenesis has been the focus of many studies.  However, these efforts 
have generated conflicting results and further mystified the signaling impact of PKCα.  The current 




positively or negatively impacts cell growth or acts to promote or suppress tumor formation is 
dependent on the cellular context (Garg et al., 2014).  As summarized in Griner 2007, 
overexpression of PKCα has been reported in glioma, breast and bladder cancers, while its 
downregulation was observed in cancers such as in the colon and renal cell carcinoma (Griner and 
Kazanietz, 2007) (Figure 1-7).  Specifically, 60% of colorectal tumors reported loss of or reduced 
PKCα expression (Suga et al., 1998). In T cell acute lymphoblastic leukemia (T-ALL), low PKCα 
levels were predictive of poor clinical outcome (Milani et al., 2014).  
Ex vivo manipulation of PKCα expression has generated evidence for the pro-tumorigenic 
function of this kinase in some cancer types. In glioma cells, PKCα enhances proliferation and 
confers resistance to radiation and chemotherapy agents (Baltuch et al., 1995; Blackburn et al., 
1998; Cameron et al., 2008; Mandil et al., 2001). Interestingly, depletion of PKCα but not the 
inhibition of its activity impairs growth of glioma cell lines, indicating PKCα functions independent 
of its activity to promote the growth of glioma cells (Cameron et al., 2008).  Similarly, ectopic 
expression of PKCα in MCF-7 breast cancer cells led to phenotypic changes consistent with 
increased tumorigenic potential, including increased proliferation, enhanced anchorage-
independent growth, and change in cell morphology that was indicative of EMT (Ways et al., 1995).  
In addition, PKCα has been implicated in facilitating the loss of estrogen receptor (ER) expression 
in breast cancer cells (Tonetti et al., 2000; Ways et al., 1995), leading to more aggressive disease 
that is insensitive to tamoxifen (Chisamore et al., 2001).  Assessment of human breast tumors 
further corroborated the correlation of elevated PKCα levels with reduced progesterone receptor 
(PR) expression, poor response to endocrine treatment, and worse prognosis in patients (Assender 











Despite the evidence supporting an oncogenic role of PKCα, transgenic models 
demonstrated its tumor suppressive effect in both intestinal and lung carcinogenesis (Figure 1-8).   
In an ApcMin/+ background, mice lacking PKCα developed more aggressive intestinal tumors, larger 
in size, and had poor survival compared with their PKCα wild type littermate controls (Oster and 
Leitges, 2006).  Additionally, deletion of PKCα alone increased the number of spontaneous 
intestinal lesions independently of the ApcMin/+ mutation.  Another key evidence of PKCα as a tumor 
suppressor was from Fields and colleagues (Hill et al., 2014). As reported in this study, PKCα is 
Fig. 1-7: PKCα expression in human cancers 
PKCα expression levels in multiple human cancer types based on the RNA-seq data generated from The 





frequently lost in the tumors of lung cancer patients, and is associated with more advanced disease.  
In mutant Kras-driven lung tumorigenesis, PKCα deletion enhanced tumor development and 
progression by facilitating the bypass of oncogene-induced senescence and expansion of the tumor-
initiating bronchoalveolar stem cells (BASCs).  Mechanistically, PKCα acts as a tumor suppressor 
in BASCs through activation of p38MAPK-TGFβ signaling axis, in part through inhibition of the 
expression of inhibitor of DNA binding 1-3 (Id1-3), which promote cell proliferation and inhibit 
differentiation (Ling et al., 2006).  PKCα has also been shown to negatively regulate Id family 
protein expression in colon cancer (Hao et al., 2011; Pysz et al., 2009).  In the skin, PKCα confers 
protection against skin tumor formation in a two-stage carcinogenesis system using DMBA as an 
initiator and PMA as a tumor promoter (as previously described in Chapter 1.2.1) (Hara et al., 
2005).  However, there was no difference in tumor growth or progression between PKCα-/- or wild 
type mice, suggesting PKCα is involved in the early events of carcinogenesis but not progression 










1.3.1 PKCα in intestinal homeostasis and carcinogenesis 
The mammalian intestinal epithelium comprises many crypt-villus units that undergo 
constant renewal every 4-5 days (for the small intestine).  Within the crypt reside the proliferating 
cells whose self-renewal capability repopulates the mucosal compartment. Starting at the crypt 
bottom, the self-renewing stem cells give rise to proliferating progenitor cells, establishing the 
proliferation zone.  As these cells travel upwards along the crypt onto the villus, they undergo cell 
cycle arrest and become committed differentiated cells.  Near the tip of the villus, the cells undergo 
apoptosis and eventually bud off into the lumen of the intestine (Figure 1-11 Picture of the small 
Fig. 1-8: PKCα as a tumor suppressor 
In the intestine, knockout of PKCα alone increased the number of spontaneous lesions formed. When 
paired with an initiating event such as in APCMin/+ and mutant Kras mouse models, loss of PKCα 





intestine).  Emerging from the extensive studies of the intestinal system are the crypt base columnar 
stem cell and the +4 stem cell models, whose namesake defined the cell population responsible for 
intestinal regeneration as described in (Clevers, 2013; van der Flier and Clevers, 2009). The 
uniquely, well-defined progression from proliferation to differentiation as the cells migrate along 
the crypt-villus axis makes the intestinal epithelium a valuable system for studying how the 
intestine maintains its homeostasis and regeneration, as well as the aberrant molecular changes 
associated with its malignant transformation.  
One of the pivotal role of PKC isozymes in cellular growth is to regulate components of 
the cell cycle machinery, primarily at the G1S and the G2-M transitions (Black, 2000).  Research 
from our laboratory has focused on understanding the role of PKCs (and PKCα in particular) in the 
tightly regulated intestinal regenerative process and its link to intestinal tumor development (Figure 
1-9). In the non-transformed, immortalized rat intestinal epithelial cell (IEC-18) model system, our 
biochemical analyses detected multiple PKC isozymes, including α, βII, δ, ε, η, ζ and ι (Saxon et 
al., 1994). Among these isozymes, several PKCs (α, βII, δ, and ζ) are activated at the crypt-villus 
junction where the cells cease to proliferate and start to differentiate, as marked by their 
translocation from the cytoplasm to membrane compartments (Frey et al., 2000).  This observation 
suggested that several PKC isozymes may be involved in negative regulation of intestinal cell 
proliferation.  Data from our laboratory have further shown that activation of PKCs, and PKCα in 
particular, triggers a cascade of growth regulatory events, partly through an ERK-dependent 
mechanism (Clark et al., 2004). Contrary to the more well-known growth promoting property of 
RAS/RAF/ERK signaling, sustained ERK activation as caused by prolonged PKCα activation 
resulted in growth inhibitory effects (Clark et al., 2004).  Additionally, selective inhibition of PKCα 
or inhibition of ERK signaling abolished the ability of PKC agonists to induce cell cycle withdrawal 
(Clark et al., 2004). Treatment of unsynchronized IEC-18 cells with non-selective pharmacological 
PKC agonists led to cell cycle arrest in late G1 phase, as well as delayed transition through G2/M. 




inhibitors p21 and p27, decrease expression of p107 but increase expression of p130, as well as 
alterations in the expression and alteration in the phosphorylation of pocket proteins (e.g. p107, 
pRb, and p130) (Frey et al., 2000; Frey et al., 1997).  These effects could be recapitulated by 
selective activation of PKCα alone (Frey et al., 2000). Furthermore, PKCα-mediated ERK 
activation was shown to downregulate growth promoting effectors (e.g., cyclin D1 and Id-1) 
through translational and/or transcriptional repression.  Cyclin D1 senses extracellular mitogenic 
signals and promotes G1 transition through association with cdk4 and cdk6.  In intestinal epithelial 
cells, PKCα signaling induces the binding of the translational repressor 4E-BP1 with the cap-
dependent translational machinery, sequestering cyclin D1 mRNA and preventing its translation 
(Guan et al., 2007; Hizli et al., 2006).   In the case of the inhibitor of DNA binding (Id1-4) family 
proteins, their decreased expression is attributed to the negative impact of PKCα activation on their 
transcription (Hao et al., 2011).  Members of Id family proteins are dominant negative antagonists 
of antiproliferative, differentiation-inducing transcription factors such as basic helix-loop-helix 
factors, Ets2, and Pax family members.  Binding of Id1 negates the transcription activating function 
of these factors by blocking their interaction with DNA.  Interestingly, Id1 expression is generally 
restricted to the proliferating crypt, opposite of the pattern observed for PKCα activity in the 
intestine. Our work thus far demonstrated that PKCα helps to maintain intestinal homeostasis by 








Fig. 1-9: PKCα activation in the intestinal systems 
PKCα activation, as indicated by its membrane association, correlates with intestinal epithelial cell growth 







The importance of PKCα as a gatekeeper for intestinal epithelial growth is further 
supported by the loss of its expression in intestinal tumors (Figure 1-10).  Reduced PKCα 
expression is observed in multiple genetic models that develop intestinal neoplasms due to mutation 
or loss of Apc, β-catenin, KRas, and Muc2, (Pysz et al., 2009) and PKCα deficiency sensitizes the 
animals to azoxymethane-induced carcinogenesis (unpublished data).  Loss or reduction of PKCα 
expression is also observed in human colon tumors (Chen et al., 2016; Gwak et al., 2009; Hao et 
al., 2011).  These findings strongly suggest that loss of PKCα is a general characteristic of intestinal 
tumors and is a critical step in colon tumor development. While PKCα signaling reduces intestinal 
tumorigenicity by blocking anchorage-independent growth of colon cancer cells, the disruption of 
PKCα signaling results in a growth promoting cellular milieu, through modulation of the 
transcription and/or translation of cyclin D1 and Id1 (Hao et al., 2011; Pysz et al., 2009).  While 
both PKCα and δ expression are reduced in intestinal tumors, restoration of PKCα confers stronger 
antitumor effects in colon cancer cells.  Consistent with previous results in IEC-18 cells, the ability 
of PKCα to regulate cyclin D1 and Id1 in colon cancer cells requires ERK activation (likely via 
crosstalk at the level of Raf-1), and is independent of effects on PI3K/AKT signaling (Hao et al., 
2011).  Our findings, together with the enhanced tumor formation in PKCα KO animals (Oster and 
Leitges, 2006), provide strong in vivo and in vitro evidence for the growth and tumor suppressive 








Fig. 1-10: PKCα expression in lost in intestinal tumors 
Expression of PKCα is lost in A) multiple in vivo models of intestinal tumors; and B) human colon 





1.3.2 Impact of PKCα signaling in cancer 
As mentioned in previous sections, the active form of PKCα resides at the plasma 
membrane, allowing it to transduce signals from upstream receptors to many signaling pathways 
that are important in cancer, regulating major cellular processes like proliferation, apoptosis, 
differentiation, and motility. However, the biological outcome of PKCα signaling can be influenced 
by the duration of its activation, the interacting substrates available, and the molecular context of 
the cell.  In breast cancer, PKCα may confer estrogen-independent, tamoxifen-resistant growth 
through Notch and ERK signaling (Pham and Tonetti, 2016; Tonetti et al., 2003; Yun et al., 2013), 
whereas PKCα-mediated ERK activation led to growth inhibition in hepatoma and intestinal 
epithelial cells (Clark et al., 2004; Wen-Sheng and Jun-Ming, 2005).  Additionally, PKCα has also 
been shown to promote cell invasion and migration through NFκB activation (Cheng et al., 2009; 
Mahanivong et al., 2008; Mut et al., 2010), while crosstalk with Wnt (Gwak et al., 2009) and 
Hedgehog (Neill et al., 2003) signaling pathways inhibits tumor growth. PKCα activity has been 
shown to have opposing effects on AKT phosphorylation.  Overexpression of PKCα has been 
shown to induce AKT activation in immune cells (Li et al., 1999b; Yang et al., 2010), keratinocytes 
(Li et al., 2006), and endothelial cells (Partovian and Simons, 2004). In other cellular systems, 
PKCα activity was found to suppress AKT phosphorylation (Motley et al., 2002) and dampen the 
activity of other components of the PI3K signaling pathway (Motley et al., 2003; Sipeki et al., 
2006). Despite the overwhelming evidence showing that PKCα indeed intercepts a wide network 
of signaling axes, understanding the biological impact of PKCα involvement requires careful 
examination in the cell type of interest. Our study presented here focuses on the role of PKCα on 
PI3K/AKT signaling, specifically its impact on endometrial carcinogenesis driven by 







1.4 AKT signaling network 
The discovery and cloning of AKT, which is also named protein kinase B (PKB) because of its 
similarity with PKA and PKC, identified it as a serine/threonine specific kinase activated 
downstream of PI3K (Bellacosa et al., 1991; Coffer and Woodgett, 1991; Jones et al., 1991; Staal, 
1987).  The mammalian genome encodes three isoforms of AKT - AKT1 (PKBα), AKT2 (PKBβ), 
and AKT3 (PKBγ).  Many cell lines express all three isoforms of AKTs; however, AKT1 and 
AKT2 are more ubiquitously expressed. Defining the isoform-specific functions of AKTs has been 
an exciting new frontier for the AKT field.  Thus far, data from isoform-specific knockout models 
and RNA interference experiments have shown that AKT1 has significant developmental roles, 
AKT2 is involved in glucose homeostasis, and AKT3 is important for brain development (Dummler 
and Hemmings, 2007). The importance of AKT as a signaling molecule is underscored by its 
numerous downstream targets that regulate key biological processes (e.g. metabolism, growth and 
survival) to establish a pro-proliferative cellular milieu.  To promote cell survival, AKT blocks the 
function and expression of pro-apoptotic BH3-only proteins. AKT activity leads to activation of 
mTORC1 signaling, which in turn promotes protein translation and cell growth.  Additionally, AKT 
is involved in responses to insulin and other metabolic events such as nutrient uptake and lipid and 
glucose metabolism.  The following sections will discuss the regulation of AKT activation, the 
functions of its downstream targets GSK3β, PRAS40, and FOXO proteins, and hyperactivation of 
PI3K/AKT signaling in cancer. 
 
1.4.1 Regulation of AKT activation 
When growth factors interact with their cognate receptor tyrosine kinases (e.g. EGFR, 
HER2, and KIT) or G-protein coupled receptors (GPCRs) (Katso et al., 2001; Vanhaesebroeck and 
Waterfield, 1999), PI3K is recruited to the cytoplasmic portion of the receptors either by direct 




subunit of PI3K, p110, then phosphorylates the lipid second messenger phosphoatidylinositol-3,4-
P2 (PIP2) to generate phosphoatidylinositol -3,4,5-P3 (PIP3) at the plasma membrane (Fruman et al., 
1998).  Due to the high affinity of PIP3 for the N-terminal PH domain of AKT, the accumulation 
of PIP3 relocates inactive AKT to the plasma membrane.  While PIP2 also binds to the PH domain, 
it only induces partial AKT activation (Franke et al., 1997; Frech et al., 1997; Klippel et al., 1997).  
Binding of PIP3 induces a conformational change in AKT, exposing two key residues – Thr308 in 
AKT1 and 2/ Thr309 in AKT3 in the kinase domain and Ser473 in AKT1/ Ser474 in AKT2/ Ser472 
in AKT3 in the C-terminal regulatory domain – giving kinases access to carry out phosphorylation 
at these two sites for maximal AKT activation (Alessi et al., 1996). PIP3 also recruits the 
phosphoinositide-dependent protein kinase 1 (PDK-1) to the membrane and puts it in proximity 
with AKT, leading to the phosphorylation of Thr308 (Alessi et al., 1997; Andjelkovic et al., 1997). 
The full activation of AKT requires the mechanistic target of rapamycin complex (mTORC2) to 
phosphorylate AKT at Ser473 (Sarbassov et al., 2005). A phosphomimetic mutant of AKT 
(T308D/S473D) generates constitutively active kinase that is PI3K independent (Alessi et al., 
1996).  Both PDK-1 and mTORC2 also phosphorylate other AGC kinases such as PKC and S6K1. 
However, unlike other kinases that are constitutively phosphorylated by PDK-1 and mTORC2, 
phosphorylation of AKT is PIP3-obligatory (Collins et al., 2003; Huang et al., 2008; McManus et 
al., 2005; Sarbassov et al., 2005). Recent evidence has shown that the pool of PIP3 and PIP2 found 
on the endosomal membrane can also lead to AKT redistribution and activation, suggesting there 
is an additional layer of spatial control of AKT phosphorylation and function yet to be explored 
(Jethwa et al., 2015).  
Termination of AKT signaling is achieved by a number of phosphatases that either 
counteract upstream lipid synthesis or directly dephosphorylate AKT.  In the late 1990s, the 
phosphatase and tensin homolog (PTEN) was cloned and identified as a key regulator of PI3K 
signaling (Frech et al., 1997; Li et al., 1997; Maehama and Dixon, 1998). PTEN possesses dual 




The lipid phosphatase function of PTEN dephosphorylates PIP3 at the 3-position and converts it to 
P(4,5)P2, thus decreasing membrane PIP3 concentration and negating the effects of PI3K. Because 
of this intricate balance of PTEN and PI3K functions, the lipid synthesis in response to growth 
factor stimulation is often rapid and transient (Auger et al., 1989).  Alternatively, the Src homology 
2 domain-containing inositol 5’-phosphatase (SHIP) can dephosphorylate PIP3 at the 5-position 
and convert it to P(3,4)P2.  The phospholipid is further hydrolyzed by inositol polyphosphate 4-
phosphatase (INPP4B) to P(3)P. This step-wise dephosphorylation of P(3,4,5)P3  P(3,4)P2  
P(3)P preferentially acts on phospholipids at endosomes and loss of INPP4B leads to AKT2 
activation (Braccini et al., 2015; Fedele et al., 2010; Gewinner et al., 2009; Li Chew et al., 2015). 
These observations suggest there is spatial restriction on the species of PI3K lipids present on 
membranes that might be involved in isoform-specific regulation of AKT activation. Together, 
PTEN, SHIP, and INPP4B negatively regulate PI3K-mediated lipid synthesis and reduce the 
membrane concentration of P(3,4,5)P3.  This reduction in membrane P(3,4,5)P3 not only affects the 
recruitment and activation of AKT but also other PH-domain containing proteins including PDK-
1, thus further exerting negative pressure on PI3K/AKT signaling (Manning and Toker, 2017; 
Salmena et al., 2008).   
Activation of AKT can also be terminated through direct modulation of its 
phosphorylation. Specific phosphatases act directly on AKT by removing the phosphate group from 
Ser473 and Thr308, whose phosphorylation is critical for AKT activation.  Protein phosphatase 2A 
(PP2A) represents a family of holoenzymes that effectively dephosphorylate AKT (Andjelkovic et 
al., 1996)). This serine and threonine specific phosphatase is ubiquitously expressed in eukaryotic 
cells. Its involvement in major signaling pathways that regulate processes such as cell cycle, 
metabolism, migration, and survival demonstrates that reversible phosphorylation is a crucial 
means to ensure proper firing and fine tuning of signaling events in cells (Janssens and Goris, 2001; 
Perrotti and Neviani, 2013; Schonthal, 2001; Seshacharyulu et al., 2013).  The PP2A holoezyme 




specificity is dictated by the regulatory subunit (B), which binds to the subunit A/C dimer. In 
humans, 26 different B regulatory subunits have been identified and are categorized into 4 
subfamilies: B/B55/PR55, B’/B56/PR61, B’’/B72/PR72, and B’’’/PR93 (SG2NA)/PR110 
(Striatin). While the isoforms of the A and C subunits share high sequence homology, the B subunit 
subfamilies are distinct in their sequences and structures, which confers their substrate selectivity 
and contributes to the diverse functions and location of PP2A holoenzymes (Chen et al., 2013; 
Eichhorn et al., 2009; Sents et al., 2013). The PP2A-B55alpha holoenzyme has been shown to 
mediate AKT dephosphorylation at Thr308 (Kuo et al., 2008), while the PP2A-B56 holoenzyme 
acts to reverse phosphorylation of Ser473 (Rocher et al., 2007; Van Kanegan et al., 2005), making 
this phosphatase a prominent negative regulator of PI3K signaling.  In 2005, the Pleckstrin 
homology domain leucine-rich repeat protein phosphatase (PHLPP) was identified as another 
family of serine/threonine specific phosphatases that act on Ser473 of AKT (Gao et al., 2005).  
There are three members in the PHLPP family: the splice variants PHLPP1alpha and PHLPP1beta 
and PHLPP2.  The PHLPP isoforms display preferential dephosphorylation of AKT isoforms. 
PHLPP1 mainly acts on AKT2 and AKT3, while PHLPP2 mediates inactivation of AKT 1 and 
AKT3 (Brognard et al., 2007).   
In addition, other mechanisms triggered by active PI3K signaling can lead to negative 
feedback inhibition.  AKT activates mTOR signaling to enhance protein translation and cell growth.  
As a result, mTORC1 promotes IRS1 and IRS2 degradation and phosphorylates GRB10 to 
attenuate insulin-induced signaling (Harrington et al., 2004; Hsu et al., 2011; Shah and Hunter, 
2006; Tzatsos and Kandror, 2006; Yu et al., 2011). Another kinase activated by mTOR signaling, 
S6K, has been shown to phosphorylate mTORC2 component Rictor and decrease phosphorylation 
of Ser473 of AKT by mTORC2 (Dibble et al., 2009; Julien et al., 2010; Liu et al., 2013a).  Being 
one of the most potent growth promoting molecules, a multitude of regulatory pathways 
coordinated by phosphatases and intrinsic feedback responses ensure tight control of the timing and 




stimulation and is usually short-lived. Defects in these regulatory mechanisms can result in 
detrimental developmental abnormalities and are associated with overgrowth syndromes and 
cancer in humans. 
 
1.4.2 Downstream targets of AKT 
As the key effector of the PI3K signaling axis, AKT acts on over 100 downstream 
substrates that contribute to the expanding repertoire of AKT functions.  The enzymatic property 
of AKT kinases is fully activated by phosphorylation at Thr308 and Ser473, and the active enzymes 
then phosphorylate its downstream targets at the serine and threonine residues within the minimal 
consensus motif R-X-R-X-X-S/T-Φ (X is any amino acid, Φ is a large hydrophobic residue).  This 
phosphorylation leads to activation or inhibition of downstream targets.  As summarized in the 
review by Manning and Toker (Manning and Toker, 2017), the most recognized signaling role of 
AKT is mediated through three functional nodes: glycogen synthase kinase-3, TSC2/mTORC1, 















Fig. 1-11: AKT signaling network 
When receptor tyrosine kinases are stimulated by extracellular signaling (e.g., insulin), PI3K is activated 
and converts PIP2 to PIP3, resulting in membrane recruitment of AKT to the proximity of its activating 
kinases (e.g., mTORC2 and PDK1).  The phospholipid conversion can be reversed by PTEN to oppose 
AKT activation.  The fully activated AKT phosphorylates its downstream targets such a GSK3β, 
PRAS40, and FOXO to regulate apoptosis, metabolism, translation, and protein and lipid synthesis. 





Glycogen synthase kinase-3 (GSK-3) was the first reported AKT substrate (Cross et al., 
1995).  This serine/threonine protein kinase is ubiquitously expressed in all tissues and highly 
conserved across species. In 1990, cloning of cDNA from rat brain identified two distinct genes 
that encoded two different GSK-3 isozymes – GSK-3α and GSK-3β.  Overall, the two GSK-3 
proteins share 85% sequence homology, with an almost identical kinase domain, making specific 
targeting of these two isoenzymes a challenge.  GSK-3α and GSK-3β are mostly functionally 
redundant; however, some studies have identified isozyme-specific functions in certain tissues 
(Kaidanovich-Beilin and Woodgett, 2011). The multitude of GSK-3 functions is demonstrated by 
its extensive number of downstream targets, which are involved in biological processes ranging 
from development to circadian rhythm, affecting diseases such as diabetes and cancer  
(Kaidanovich-Beilin and Woodgett, 2011).  Amongst the vast number of targets is glycogen 
synthase, the first known protein targeted by GSK-3. Initial discovery of GSK-3 identified it as the 
regulatory kinase for glycogen synthase, a rate limiting enzyme in glycogen formation whose 
activity is regulated by phosphorylation (Embi et al., 1980; Vandenheede et al., 1980). Unlike most 
kinases, GSK-3 is active under steady state and becomes inactivated by extracellular signaling such 
as insulin stimulation.  Phosphorylation at tyrosine residue 270 for GSK3α and 216 for GSK3β, 
mediated by kinases such as FYN2 and PYK2 or by autophosphorylation (Cole et al., 2004; 
Lochhead et al., 2006), positively regulates GSK-3 activity. On the other hand, phosphorylation at 
a serine residue at the N-terminal (Ser 21 for GSK3α and Ser9 for GSK3β) mediated by AKT 
results in GSK-3 inhibition (Stambolic and Woodgett, 1994; Sutherland and Cohen, 1994; 
Sutherland et al., 1993).  It has been shown that the phosphorylated serine generates an 
intramolecular pseudosubstrate that binds to the substrate binding pocket of the kinase and obstructs 
actual substrate binding (Dajani et al., 2001; Frame and Cohen, 2001). Without stimulation, active 
GSK-3 has inhibitory effects on its targets either by blocking their activity or destabilizing the 
protein.  Under the stimulation of extracellular factors, serine phosphorylation inhibits GSK-3 




mediated phosphorylation hinders the activity of glycogen synthase and glycogen production. 
When AKT is activated upon insulin stimulation, AKT phosphorylates GSK-3 at its serine residue, 
causing it to dissociate from glycogen synthase. Following this relief, there is an induction in 
glycogen synthase activity and an increase in glycogen formation and deposition in multiple tissues 
(e.g. muscle and liver).  This crucial involvement of GSK-3 in glycogen synthesis demonstrated its 
direct influence on cell metabolism. Later studies have identified additional GSK-3 targets such as 
sterol regulatory element binding protein 1 c (SREBP1c), hypoxia inducible factor 1 α (HIF-1α), 
and nuclear factor erythroid 2-related factor 2 (NRF2), showing that GSK-3 can also regulate 
metabolism in an indirect manner. For other targets, GSK-3-mediated phosphorylation results in 
their degradation. Proteins such as the pro-apoptotic protein Mcl-1 and pro-proliferative 
transcription factor c-Myc are first primed by kinases such as JNK and ERK respectively, which 
allows their phosphorylation by GSK-3 (Ding et al., 2007; Maurer et al., 2006; Morel et al., 2009; 
Sears et al., 2000; Welcker et al., 2003). GSK-3-mediated phosphorylation of Mcl-1 and c-Myc 
marks them for recognition by specific E3 ubiquitin ligases, directing them to proteosomal 
degradation.  Therefore, activation of AKT and subsequent GSK-3 inhibition stabilize both Mcl-1 
and c-Myc to promote cell survival and proliferation.  Additionally, GSK-3 activity can be 
regulated by its subcellular localization.  Although GSK-3 is mostly observed in the cytoplasm, 
there is evidence that its nuclear localization occurs dynamically depending on cell cycle phase 
(Bechard and Dalton, 2009; Liu et al., 2013b; Meares and Jope, 2007).  It has also been reported 
that AKT can decrease nuclear levels of GSK-3 (Bijur and Jope, 2001, 2003).  However, the 
significance of nuclear localization on regulation of GSK-3 activity and function remains unclear.  
The second key signaling node regulated by AKT involves TSC2/mTORC1. Cellular 
growth requires increased production of proteins, lipids, and nucleotides. The mTOR signaling 
network, whose activation is controlled by AKT, is crucial in regulating the production of these 
biomolecules and the maintenance of metabolic balance in response to the cellular environment 




target of rapamycin, or mTOR was first identified in 1994 as the direct binding target of the 
FKBP12-rapamycin complex (Brown et al., 1994; Sabatini et al., 1994; Sabers et al., 1995).  This 
interaction inhibited mTOR kinase activity, thus hindering cell growth and proliferation. This 
inhibitory effect on growth attracted significant attention to the clinical potential of rapamycin as 
well as the pro-growth function of mTOR signaling.  More than 20 years since its discovery, mTOR 
is now identified as the catalytic component of two distinct complexes, mTORC1 and mTORC2 
differing in their interacting partners. The core complex of mTORC1 consists of mTOR, mLST8, 
and Raptor (Nojima et al., 2003; Schalm et al., 2003), which is substituted by Rictor in mTORC2 
(Jacinto et al., 2006; Sarbassov et al., 2004).  Functionally, the two mTORC complexes act at 
different points along the PI3K/AKT signaling axis.  As previously mentioned, mTORC2 activates 
AKT by phosphorylating it at the Ser473 residue (Sarbassov et al., 2005).  It is worth noting that 
PKCα and other members of the PKC family are also phosphorylated by mTORC2 (Gan et al., 
2012; Jacinto et al., 2004; Li and Gao, 2014; Sarbassov et al., 2004; Thomanetz et al., 2013). On 
the other hand, AKT acts upstream of mTORC1 to regulate its activation.  Activated mTORC 
signaling leads to increased production of biomolecules essential for cellular growth (e.g. protein, 
nucleotides, and lipid) through phosphorylation of key effectors such as S6K1, 4EBP1, ATF4, 
Lipin1, and HIF-1α and heightened glucose metabolism to meet the needs of a proliferating cell.  
Additionally, mTORC1 suppresses catabolic pathways such as autophagy, shifting the metabolic 
balance in favor of cellular growth.  Under nutrient or serum deprivation, binding of the proline-
rich AKT substrate of 40 kDa (PRAS40) keeps mTOR in an inactive state (Sancak et al., 2007; 
Vander Haar et al., 2007; Wang et al., 2007).  As a direct substrate of AKT, PRAS40 is 
phosphorylated upon insulin stimulation.  This modification significantly weakens the physical 
interaction between PRAS40 and mTORC1, thus relieving the inhibitory regulation on mTORC1, 
allowing it to activate the aforementioned downstream, pro-growth effectors (Sancak et al., 2007). 
To ensure unperturbed mTORC1 activation, phosphorylated PRAS40 is further sequestered by 




The third important signaling node is through the Forkhead Box O (Fox) transcription 
factor family, specifically the “O” class proteins that are regulated by the insulin/PI3K/AKT 
signaling.  The four members in this class – FOXO1, 3, 4, and 6 – share structural similarity and 
have four distinct functional motifs including forkhead, nuclear localization, nuclear export, and 
transactivation domains.  Among the FOXO proteins, FOXO1, FOXO3, and FOXO4 are 
ubiquitously expressed, although at different levels (Anderson et al., 1998; Furuyama et al., 2000), 
whereas FOXO6 is primarily restricted to the central nervous system (Jacobs et al., 2003). The 
FOXO genes encoding FOXO 1, 3, and 4 were first identified in chromosomal translocation events 
in rhabdomyosarcoma and acute myeloid leukemia (Dumont et al., 2012; Linardic, 2008; Schmitt-
Ney and Camussi, 2015; Wachtel and Schafer, 2015), suggesting their possible role in 
carcinogenesis. Soon after, studies of DAF-16, the homolog of FOXO proteins in C. elegans found 
the transcription factor to be crucial for the longevity of the organism and was negatively regulated 
by the insulin/PI3K/AKT signaling pathway (Hesp et al., 2015; Lin et al., 2001; Sun et al., 2017). 
In C. elegans, the phenotype caused by deletion of AKT1 and 2 can be rescued if DAF-16 is also 
lost (Paradis and Ruvkun, 1998).  This negative regulation of DAF-16/FOXO proteins is 
evolutionarily conserved. In mice, FOXO deletion (mainly FOXO1 in the liver) can reverse the 
severe hepatic insulin resistance and hyperglycemia caused by liver-specific deletion of AKT 1 and 
2 (Lu et al., 2012).  In vivo genetic manipulation reveals that the different FOXO proteins have 
non-redundant functions. Mice lacking FOXO1 succumb to defects at embryonic day 10.5 due to 
incomplete vascular development (Hosaka et al., 2004).  On the other hand, FOXO3 null mice are 
viable, despite lymphocyte proliferation and autoinflammation associated with abnormal regulation 
of NFκB signaling (Lin et al., 2004), age-dependent infertility due to abnormal ovarian follicle 
development (Hosaka et al., 2004), and a decline in the neural stem cell pool (Renault et al., 2009).  
Mice with FOXO4 deletion are also viable with exacerbated colitis in response to inflammatory 
stimuli (Zhou et al., 2009).  As FOXO6 is mostly detected in the neural system, deletion of this 




transcription factors, FOXO proteins are subjected to regulation by phosphorylation that alters their 
subcellular localization. Inactive FOXO proteins are found in the cytoplasm. Under oxidative or 
nutrient stress, kinases such as JNK, Mst1, or AMPK have been shown to phosphorylate FOXOs 
and induce their translocation from the cytoplasm to the nucleus (Coomans de Brachene and 
Demoulin, 2016; Wang et al., 2014).  On the other hand, AKT-mediated phosphorylation at three 
conserved sites (T24, S256, S319 for FOXO1; T32, S253, S315 for FOXO3A; and T32, S197, 
S262 for FOXO4) generates a recognition motif for 14-3-3.  This interaction facilitates the nuclear 
export of FOXO proteins and sequesters them in the cytosol, thus inhibits FOXO-regulated gene 
expression. Other post-translational modifications such as acetylation by SIRT1 and 
monoubiquitination have been shown to enhance FOXO-mediated transcription under oxidative 
stress (Boccitto and Kalb, 2011; Daitoku et al., 2011; Hariharan et al., 2010; Huang and Tindall, 
2011). Similar to other transcription factors, the activity of FOXO proteins is also influenced by 
their binding to either coactivator or corepressors.   FOXO-mediated transcription governs multiple 
cellular processes including proliferation, apoptosis, oxidative stress, etc. (Wang et al., 2014). In 
regard to cancinogenesis, FOXO proteins act as tumor suppressors.  In colorectal cancer, there is 
decreased expression of FOXO4 (Xiang-qiang et al., 2011), while FOXO3 contributes to the 
repression of Myc function (Delpuech et al., 2007). Studies have shown that FOXO1 upregulates 
the expression of TNFα and FasL in prostate cancer and glioma, respectively (Ciechomska et al., 
2003; Modur et al., 2002), to initiate apoptosis.  In CML and breast cancer, FOXO3 increases Bim 
expression in response to the chemotherapeutic agents STI571 and paclitaxel and inhibits tumor 
growth (Essafi et al., 2005; Sunters et al., 2003). In HER2+ breast cancer, FOXO4 promotes G1 and 
G2 cell cycle arrest by induction of p27 and GADD45 (Yang et al., 2005).  Both FOXO1 and 
FOXO4 have been shown to limit metastasis by inhibiting RUNX2 activity or increasing ANX8 
expression, respectively (Lee et al., 2009; Zhang et al., 2011).  On the other hand, FOXO1- and 
FOXO3-mediated transcription leads to expression of genes such as PIK3CA and confers chemo 




1.4.3 Hyperactivation of AKT in cancer 
As described above, AKT alters a wide range of downstream effectors through GSK3β, 
mTOR, and FOXO signaling nodes to exert its pro-growth and pro-survival functions, making it a 
powerful oncogenic force in carcinogenesis.  Indeed, hyperactivation of AKT is one of the most 
frequently observed molecular features in human solid and hematological malignancies (Samuels 
and Ericson, 2006; Shi et al., 2005). In cancer, AKT hyperactivation is often the result of defects 
in its upstream regulators, either through 1) amplification or oncogenic mutations in EGFR, HER2, 
or other RTKs, or kinases such as PDK1 and PI3K, and/or 2) inactivating mutations or loss of 
heterozygosity in genes that negatively regulate PI3K/AKT signaling such as PTEN, INPP4B, 
LKB1, and PHLPP as summarized in Table 1 (Cheung and Testa, 2013; Mayer and Arteaga, 2016).  
Interestingly, PI3KCA mutations alone do not always correlate with hyperactivation of AKT and 
mutations in multiple proteins involved in the PI3K/AKT signaling axis is often observed in tumors 
(Lien et al., 2017; Vasudevan et al., 2009). This suggests that components of the PI3K/AKT 
signaling network function co-operatively to regulate tumorigenesis. Although AKT mutation 
occurs at a lower frequency than its upstream regulators, an activating somatic E17K mutant has 
been observed in breast, colorectal, lung, ovarian, and endometrial cancers, as well as melanoma 
(Carpten et al., 2007; Davies et al., 2008; Rudolph et al., 2016).  This mutation occurs in the PH 
domain of AKT and allows constitutive membrane localization of AKT (Carpten et al., 2007; 
Landgraf et al., 2008).  Interestingly, the E17K mutant is insufficient for tumor transformation in 
the absence of other driver mutations (Lauring et al., 2010; Mancini et al., 2016), likely because 
the full activation of this AKT mutant still requires phosphorylation at the serine 473 and threonine 
308 residues. However, tumors carrying mutant AKT have been reported to be more aggressive 
and have poorer prognosis (Bellacosa et al., 1995; Cheng et al., 1996; Parsons et al., 2005).  In 
gastric cancer, AKT1 with E17K mutation correlated with resistance to cisplatin treatment (Liu et 
al., 2007) whereas a less common Q79K AKT1 mutant confers resistance to BRAF inhibitors in 




In accordance with hyperactive AKT being a prominent oncogenic driver, many 
pharmacological compounds have been developed to target AKT with the aim to suppress cancer 
growth. There are generally two classes of AKT inhibitors – the ATP-competitive inhibitors that 
target the ATP-binding pocket in its kinase domain and the allosteric AKT inhibitors that target the 
PH and catalytic domains of the kinase (Manning and Toker, 2017).  Most of these agents are in 
either phase I or phase II clinical trials; however, results so far have been less than promising.  Such 
outcomes could possibly be due to the associated toxicity of the agents or the lack of a patient 
stratification system as the molecular profile of the disease is likely to influence therapeutic 
response.  Currently there are four ATP-competitive inhibitors of AKT - GSK690693, AZD5364, 
GDC0068 or Ipatasertib, and GSK2110183 or Afuresertib.  All of these inhibitors target all three 
AKT isoforms except GSK2110183, which showed slight selective for AKT1 at subnanomolar 
concentrations and inhibition of AKT2 and 3 at the nanomolar range. Despite being efficacious in 
preclinical models, GSK690693 and GDC0068 did not fare well in phase I trials due to dose-
limiting, on-target toxicity including hyperglycemia (Crouthamel et al., 2009; Rhodes et al., 2008) 
or lack of antitumor effects (Lin et al., 2013; Saura et al., 2017) respectively. GSK2110183 is 
currently being tested in phase I trials in combination with MEK inhibitors and appears to be well-
tolerated (Dumble et al., 2014), while the efficacy of AZD5364 is being examined in phase II 
clinical trials for advanced breast cancer (Martini et al., 2014).  Two allosteric inhibitors of AKT 
have been developed – MK2206 and ARQ092.  Mechanistically, MK2206 targets the closed, 
inactive conformation of AKT, hindering its phosphorylation and activation (Barnett et al., 2005; 
Hirai et al., 2010).  As a single agent, MK2206 failed to elicit clinical efficacy (Ma et al., 2016); 
however, it is being tested in phase I trials in combination with trastuzumab in HER2-positive solid 
tumors (Hudis et al., 2013).  One caveat of targeting the inactive form of AKT is the reduced 
sensitivity of mutant AKTs such as the E17K mutant that are constitutively membrane-associated, 
bypassing the function of the PH domain (Parikh et al., 2012).  The structural allosteric inhibitor 




carrying E17K mutant AKT.  Phase I trials are underway to evaluate ARQ092 in patients with 
AKT-E17K and PIK3CA mutations (Lapierre et al., 2016; Yu et al., 2015). 
 
1.5 Dissertation objectives 
Since the discovery of PKCs, the field has made tremendous advances in understanding 
the differential function of PKC isozymes in certain tissues. Previous work from our laboratory has 
established PKCα as a key regulator of intestinal cell growth whose loss contributes to the 
development of intestinal tumors (Frey et al., 2000; Frey et al., 1997; Pysz et al., 2009; Saxon et 
al., 1994).  This dissertation describes our effort to profile PKCα in the endometrium as well as to 
establish its functional contribution to endometrial carcinogenesis.  
The first study, reported in chapter three, is our examination of PKCα expression and 
activation in the cycling uterus. Within a cycle, the rise and fall of steroid hormones regulates a 
program of coordinated molecular and physiological changes in the endometrium, which are 
necessary for the constant turnover of the tissue. Although PKCα is detected in multiple tissues, 
little is known of its expression, activation, or function in the endometrium. Therefore, the first 
objective of this dissertation was to examine PKCα in the human menstrual cycle and the mouse 
estrous cycle, to provide a basis for our understanding of PKCα expression and activation in the 
endometrium.  
In the second study, presented in chapter four, our goal was (a) to survey alterations in 
PKCα expression in human endometrial tumors and in lesions arising in mice harboring mutant 
Pten, which are commonly used as in vivo models for oncogenic PI3K/Akt driven endometrial 
cancer, and (b) to identify the signaling functions of PKCα and its impact on endometrial cancer 
development.  In light of the recent renewed understanding of PKC function in cancer and the 
increasing health risk posed by rising endometrial cancer incidence, a thorough examination of the 




PI3K/Akt driven cancer as well its potential as a molecular biomarker for stratifying endometrial 
tumors.  
Taken together, findings in this dissertation expand current knowledge of PKCα in the 
uterus.  Our profiling of PKCα in the endometrium identifies the kinase as a potential regulator of 
endometrial renewal and function, and its ability to modulate AKT activation points to tumor 
suppressive properties in this tissue. Such understanding warrants further studies to examine the 
relationship between steroid hormones and PKCα activation in reproductive biology, and to 
determine whether PKCα impacts the clinical outlook of endometrial cancer such as patient 



















2.1 Cell lines and reagents  
Human endometrial cancer cell lines with diverse genetic mutations were obtained from the 
following sources:   
Cell line Catalog # Source 
HEC-1-A HTB-112 ATCC 
HEC-1-B HTB-113 ATCC 
HEC-50Co  Dr. Kimberly K. Leslie (University of Iowa) 
KLE CRL-1622 ATCC 
AN3CA HTB-111 ATCC 
Ishikawa  Dr. Tim Hui-Ming (Ohio State University) 
SK-UT-1B HTB-115 ATCC 
RL95-2 CRL-1671 ATCC 
ECC-1 CRL-2923 ATCC (discontinued) 
SNG-II IFO50312 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
SNG-M IFO50313 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
HEC-6 JCRB1118 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
HEC-59 JCRB1120 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
HEC-108 JCRB1123 Japanese Collection of Research Bioresources (JCRB) Cell Bank 




HEC-151 JCRB1122 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
HEC-251 JCRB1141 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
HEC-265 JCRB1142 Japanese Collection of Research Bioresources (JCRB) Cell Bank 
HEK293 CRL-1573 ATCC 
 
All cells were maintained in culture conditions recommended by the providing source as 
described below: 
Cell line Culture Media 
HEC-1-A McCoy’s 5a + 10 % FBS 
HEC-1-B, SK-UT-1B MEM + 10% FBS, 1% NEAA, 1 mM sodium pyruvate 
HEC-50Co DMEM + 10% FBS, 1 mM sodium pyruvate 
KLE DMEM F12 + 10% FBS 
AN3CA, Ishikawa DMEM + 10% FBS, 1% NEAA, 1 mM sodium pyruvate 
RL95-2 DMEM F12 + 10% FBS, 10 mM HEPES, 0.005 mg/ml insulin 
ECC-1 RPMI-1640 + 5% FBS, 10 mM HEPES, 10 mM glucose, 1 mM sodium pyruvate 
SNG-II, SNG-M Ham’s 12 + 10% FBS 
HEC-6, 59, 116, 151, 
251, 265 
MEM + 15% FBS 





Mechanistic studies were performed in cultured cells with the following pharmacological agents 
dissolved in the solvent listed:  
 Compound Concentration Solvent Source  
PKC agonist PMA 100 nM EtOH Biomol 
 DiC8 20 µg/ml acetonitrile Caymen 
cPKC inhibitor Gӧ6976 2.5 µM DMSO Calbiochem 
PI3K inhibitor LY294002 40 µM DMSO Cell Signaling 
AKT inhibitor MK-2206 100 or 250 nM DMSO EMD Millipore 
Phosphatase inhibitors Calyculin A 10 nM DMSO Santa Cruz 
 Okadaic acid 1 µM DMSO Santa Cruz 
 NSC 45586 50 µM DMSO NCI 
 NSC 117079 50 µM DMSO NCI 
 
Because of its rapid metabolism in cells, DiC8 was replaced every 30 minutes during the treatment 
period. All phosphatase inhibitors and cPKC inhibitor were added to cells 30 minutes prior to 
addition of PKC agonists, except for calyculin A, which was added 15 minutes prior to PKC 
activation. 
2.2 Transgenic mice 
The allele-specific Pten mutant mice (PtenΔ4-5/+, PtenG129E/+, and PtenC124R/+) were generated and 
characterized by Dr. Gustavo Leone (Ohio State University) (Wang et al., 2010).  The Pten 




driven- or lactoferrin promoter driven-Cre animals (PR-Cre or Ltf-Cre respectively) by Dr. Takiko 
Daikoku and Dr. Sudhansu K. Dey (Cincinnati Children’s Hospital Medical Center) (Daikoku et 
al., 2008; Daikoku et al., 2014).  Tissues from the aforementioned Pten transgenic models were 
provided by the corresponding laboratories for this study.  
To generate Pten mutant mice lacking PKCα, SV129J/C57 BL6 Prkca-/- mice obtained from Dr. J. 
Molkentin (Braz et al., 2004) were crossed with mixed strains of PtenΔ4-5/+ mice provided by Dr.  
G. Leone (Wang et al., 2010). The Prkca+/-; PtenΔ4-5/+ mice were then intercrossed to generate 
animals with the following genotypes: Prkca+/+; Pten+/+, Prkca+/-; Pten+/+, Prkca-/-; Pten+/+, 
Prkca+/+; PtenΔ4-5/+, Prkca+/-; PtenΔ4-5/+, and Prkca-/-; PtenΔ4-5/+.  The “Y” shaped uterine horn was 
halved at the cervix and cryopreserved in OCT or fixed in formalin for paraffin embedding.  Uterine 
tissue was collected from female mice from all six genotypes at 3, 5, 7, and 9 months of age; 
however, 1- and 2-month uterine tissue was collected from Prkca+/+; PtenΔ4-5/+ and Prkca-/-; PtenΔ4-
5/+ only.  The functional effects of PKCα were only examined in Prkca+/+; PtenΔ4-5/+ and Prkca-/-; 
PtenΔ4-5/+ as we did not observe any uterine phenotypes in Prkca knockout only animals.  The 
genotypes were confirmed by PCR using the following primers and conditions:  
Gene 5’-3’ 
Prkca  
Primer 1 CCAAGTGTGAAGTGTGTGAG 
Primer 2 AGCTAGGTCCTGTTGGTAAC 
Primer 3 GCGCATCGCCTTCTTCGC 
Cycling conditions 95°C       3 min 
95°C       30 sec       35 cycles 
57°C       30 sec 




72°C       3 min 





Cycling conditions 95°C       3 min 
95°C       30 sec       35 cycles 
58°C       30 sec 
72°C       1 min 
72°C       3 min 
4°C         Hold 
 
2.3 Determination of estrous phases 
The phases of the estrous cycle of the mouse can be determined from visual observation or cytology 
of vaginal discharge as described in (Byers et al., 2012). In this study, estrous cycle phases (diestrus, 
proestrus, estrus, metestrus) were determined based mainly on the cellular makeup of the vaginal 
smear, using visual observation as a supporting tool.  To ensure accuracy of phase determination, 
vaginal smears were obtained from 5-6 week-old virgin, female mice (when they reach sexual 
maturity) twice a day (once in the light cycle, once in the dark cycle) for a week to track the 
progression of estrous cycling.  The vaginal discharge was collected using Pasteur pipets whose 
tips had been rounded by flaming and cooled prior to use.  The vaginal opening of the mice was 
rinsed with 20-50 µl of 1X PBS and the vaginal discharge was collected in an Eppendorf tube, 




with a coverslip.  The phase of the estrous cycle was then determined based on the presence or 
absence of leukocytes, nucleated or cornified epithelial cells.  
2.4 Human tissue microarray 
Human endometrial cancer TMAs were generated by Dr. Carl Morrison at Ohio State University 
(OSU) and Roswell Park Cancer Institute (RPCI).  Two TMAs, displaying a total of 384 de-
identified endometrial cancer tumors (304 endometrioid and 80 non-endometrioid), were generated 
at OSU with approval from OSU Institutional Review Board.  All patients in the TMA were 
diagnosed with uterine malignancy between January 1, 1980 and July 31, 2003 at the Arthur James 
Cancer Hospital of the Ohio State University Medical School. Specimens for controls within the 
TMA consisted of 37 secretory endometrium, 30 proliferative endometrium, as well as multiple 
cores of normal tissue from 10 different organs including heart, colon, kidney, adrenal, ovary, 
myometrium, brain, thyroid, lung, and prostate. A third endometrial cancer TMA, consisting of 52 
de-identified cases (26 endometrioid and 26 non-endometrioid) was generated at RPCI 
(RPCI_GYNCa09) with RPCI Institutional Review Board approval.  Cases were diagnosed at 
RPCI between 1992 and 2011.  For any case with variation in grade or cytological atypia, TMA 
cores of the donor block were always taken from the areas of the highest-grade tumor. Matching 
frozen tissue was also available for all of the RPCI cases and was used for determination of PKCα 
mRNA levels. Scoring of IHC staining was performed by three independent examiners who were 
blind to sample information. Patient survival analysis in correlation with PKCα expression was 
performed using the MDACC-endometrial-L3-S40 data set, consisting of 244 endometrial tumors 
of which 80% were of the endometrioid subtype or using TCGA data set. To perform parallel 
analysis of PKCα mRNA and protein levels in endometrial tumors, total RNA was isolated from 
frozen samples of 50 of the tumors included in the TMA. The correlation between PKCα mRNA 






Murine uterine tissue was formalin-fixed, paraffin-embedded, and cross-sectioned or 
longitudinally-sectioned at 4 µm. Human and murine tissue sections were deparaffinized in xylene 
and rehydrated by incubation in serially diluted alcohol. Antigen retrieval used DAKO Targeting 
Retrieval Solution (DAKO S1699) for 30 minutes in a steamer. Sections were blocked with 0.03% 
casein for 30 minutes at room temperature before incubation with primary antibody conditions 
listed below: 
Antibodies Concentration Conditions Source Catalog #  
PKCα 1:3000 - 6000 4°C overnight Abcam 32376 
PTEN 1:100 4°C overnight Cell signaling 9559 
pAKT Ser473 1:300 - 600 Room temperature 1 hour Cell signaling 4060 
Id-1 1:1200 4°C overnight Biocheck BCH-1/195-14 
Ki67 Stained by the Tissue Science Facility at UNMC 
 
Following washes, incubation with secondary antibody (Vector BA-1000) was performed at room 
temperature for 30 minutes, followed by addition of Vectastain Elite ABC reagent (Vector 
Laboratories) and DAB chromogen solution (DAB Quanto; Thermo Scientific TA-060-QHDX).  
Sections were counterstained with hematoxylin. Specificity of these antibodies was validated in 
previous studies; PKCα and Id-1 were detected as described in (Hao et al., 2011), and pAKT Ser473 
and PTEN IHC followed procedures detailed in (Wang et al., 2010). PKCα immunostaining 





2.6 Immunofluorescence  
Uterine tissue in various phases of the estrous cycle, as determined by vaginal smears, was collected 
and frozen in OCT. Frozen sections (4-6 µm) were fixed in 2% freshly depolymerized 
paraformaldehyde/PBS for 15 minutes at room temperature and 100% methanol for 10 minutes at 
-20°C, prior to blocking and antibody incubation. Antibodies were as follows: anti-PKCα (1:250; 
Abcam 32376), or Ki67 (1:1000; eBiosciences 11-5678) for 1 hour at room temperature, and anti-
rabbit Alexa 594 (1:300; Invitrogen A-21207) for 30 minutes at room temperature.  All images 
were obtained at the same exposure. Nuclei were detected by Hoechst dye.  
 
A guide slide consisted of 2 serial sections (10 µm) was prepared and stained with 
immunofluorescence to use for identification normal vs. tumor regions for LCM. The tissue was 
stained with primary antibodies: anti-PKCα (1:250; Abcam 32376) or anti-pAKT (1:200; Cell 
Signaling 4060) for 1 hour and anti-rabbit Alexa 488 (1:300; Invitrogen A-32723) for 30 minutes 
at room temperature and stained with Hoechst dye for 5 minutes.  
 
2.7 Western blot analysis  
To prepare lysate for immunoblot analysis, cells were rinsed twice with cold 1X PBS before 
addition of pre-warmed lysis buffer (1% SDS, 10 mM Tris-HCl, pH 7.4).  Cell lysates were 
collected, passed through a 27 g needle 5-10 times to shear DNA, and centrifuged at 16,000 x g for 
20 minutes. Protein concentration was determined using the BCA Assay Kit (Pierce).  Equal 
amounts of protein were subjected to SDS-PAGE and transferred to nitrocellulose membrane.  
Membranes were blocked with 5% milk and probed with primary antibodies at 4°C overnight as 




mouse IgG (1:2000) and detection used SuperSignal West (Pierce). Signal intensity was quantified 
using ImageJ. 
Antibodies Concentration Source Catalog #  
PKCα 1:10,000  Abcam 32376 
PKCαa 1:20,000 - 30,000 Santa Cruz SC-208 
PKCβI 1:2000 Abcam 195039 
PKCβII 1:1000 Santa Cruz SC-210 
PKCγ 1:1000 Santa Cruz SC-211 
PKCδ 1:1000 Santa Cruz SC-213 
PKCε 1:1000 Santa Cruz Sc-214 
PKCθ 1:1000 BD Transduction Laboratories  610084 
PKCη 1:500 Santa Cruz SC-215 
PKCζ 1:8000 Santa Cruz SC-216 
PKCι 1:1000 BD trans  610175 
PTEN 1:1000 Cell signaling 9559 
pAKT Ser473 1:8000 - 10,000 Cell signaling 4060 
pAKT Thr308 1:8000 - 20,000 Cell signaling 2965 




pPRAS40 1:15,000 – 20,000 Cell Signaling  13175 
PRAS40 1:10,000 Cell Signaling 2691 
pFOXO1 1:1000 Cell Signaling 9401 
FOXO1 1:1000 Cell Signaling  2880 
pGSK3β 1:500 Cell Signaling 9323 
GSK3β 1:10,000 BD Transduction Laboratories 610202 
PP2AC 1:3000 Upstate 05-421 
Id-1 1:1500-3000 Biocheck  BCH-1/195-14 
β-actin 1:15000 Sigma  A2066 
a To assess PKCα levels in adenoviral vector mediated PKCα overexpression experiments. 
 
2.8 Laser-capture microdissection (LCM) 
Murine uterine tissue was placed in OCT and frozen immediately after dissection. For LCM, the 
tissue was longitudinally sectioned at 10 µm and mounted on PET-membrane FrameSlides (Leica). 
Slides were air-dried briefly, fixed in 70% EtOH for 30 seconds, washed in dH2O to remove excess 
OCT, stained with hematoxylin until tissue was visible, and washed in dH2O to remove excess dye, 
followed by incubation in 95% and 100% EtOH for 30 seconds. Stained PET-slides were air-dried 
and placed in a cold dessicator until LCM.  Additional serial sections were prepared on charged 
glass slides for IF analysis for PKCα and pAKT to serve as a guide to distinguish normal vs. tumor 
regions. Laser capture was performed at optimal laser strength that ensures precise dissection while 




the cap of the collection tube.  RNA was isolated from dissected sections using the RNAqueous-
MicroKit (Ambion) as directed by manufacturer’s instructions. All reagents used were RNAse free.  
Slides and working surface were cleaned with RNaseZap. 
2.9 Quantitative RT-PCR analysis 
RNA was isolated using the RNAspin mini RNA isolation kit (GE Health) or Trizol reagent 
(Thermo Fisher) and 10 ng total cellular RNA was analyzed using Brilliant II SYBR® Green 
QRT-PCR 1-Step Master Mix (Agilent).  In the nascent RNA capture experiments, cDNA was 
generated using the iScript™ cDNA Synthesis Kit and quantified using iTaq Universal SYBR 





















2.10 RNA interference 
For siRNA-mediated knockdown of PKCα or PP2AC, cells were transfected with 10 nM siRNA 
using RNAiMAX transfection reagent (Invitrogen) as per manufacturer’s protocol. Cell lysates 
were collected for Western blot analysis 72 hours after transfection. Knockdown of the catalytic 
subunits of PP2A was achieved by pooling PPP2CA and PPP2CB siRNAs. Information on the 
siRNAs used is provided below: 
siRNAs Part/ Catalog number Source 
siPKCα #1 4390827  
sense - GGAUUGUUCUUUCUUCAUATT 
antisense - UAUGAAGAAAGAACAAUCCGA 
Ambion Life Technologies  
siPKCα #2 4390771 
sense - GAAGGGUUCUCGUAUGUCATT 
antisense - UGACAUACGAGAACCCUUCAA  
Ambion Life Technologies 
siPP2CA ON-TARGET plus Human siRNA SMARTpool L-
003598-01 
GE Dharmacon 
siPP2CB ON-TARGET plus Human siRNA SMARTpool L-
003599-00 
GE Dharmacon 
Non-targeting  D-001810-01-05 GE Dharmacon 
 
Lentiviral vectors expressing PTEN targeting shRNAs were used to generate stable knockdown 
endometrial cancer cell lines.  Cells were transduced with either or both clones of shPTEN vectors 
or a non-targeting vector at 20 moi (at 1×106 CFU/ml) in serum-free medium containing 8 µg/ml 




passaged 4 days after transduction, selected with puromycin (10 µg/ml) on day 6, and cultured for 
at least 10 passages before collecting cell lysate for analysis or subsequent experiments.  
Information on shRNAs used are listed as below:  
shRNA Clone/ Catalog number Source 
shPTEN #1 V2LHS_92317 Open Biosystems  
shPTEN #2 V2LHS_231477 Open Biosystems 
Non-targeting shRNA RHS 4348 GE Dharmacon 
 
2.11 Nascent RNA capture 
Labeling and capture of nascent RNA was performed using the Click-iT Nascent RNA Capture Kit 
(Life Technologies) according to the manufacturer’s protocol. In brief, EU was added to cells for 
incorporation into nascent RNA to allow biotinylation of the synthesized RNA.  The biotinylated 
RNA was then captured using Streptavidin magnetic beads and cDNA was generated using the 
iScript cDNA Synthesis Kit (Bio-Rad).  cDNA for PKCα and GAPDH was quantified by qPCR 
using iTaq Universal SYBR Green Supermix. 
 
2.12 Subcellular fractionation 
To analyze PKCα subcellular partitioning after PMA-induced activation, cytosolic and particulate 
fractions were prepared from endometrial cancer cells after 6 hours of treatment with 100 nM 
phorbol 12-myristate 13-acetate (PMA; Biomol) dissolved in ethanol as previously described 
(Saxon et al., 1994). Cells were rinsed twice with PBS, lysed with digitonin buffer (0.5 mg/ml 
digitonin, 20 mM Tris-HCL pH7.4, 2 mM EGTA, 2 mM EDTA, 10 mM NaF, and 1:100 protease 
inhibitor cocktail) and centrifuge at 100,000 x g at 4°C for 30 minutes to separate the cytosolic (in 




precipitated by adding 100% trichloroacetic acid (TCA) to a final concentration of 10% TCA and 
incubate briefly on ice.  The pellet was washed with acetone four times and dissolved by incubation 
with 100 mM NaOH at 4°C overnight.  The cytosolic fraction was then neutralized with an equal 
volume of 100 mM HCl. The pellet containing the particulate fraction was solubilized by addition 
of 200-300 µl of 1% SDS-digitonin buffer with 1:100 protease inhibitor cocktail.  The pellet was 
fragmented by syringing and incubated on ice for 30 minutes at 4°C to further solubilize the 
particulate fraction. An equal ratio of cytosolic and particulate fractions (relative to total protein) 
was analyzed for the presence of PKCα. 
 
2.13 PP2A activity assay 
PP2A phosphatase activity was measured using a PP2A immunoprecipitation phosphatase assay 
kit (Millipore) and as previously described in (Guan et al., 2007).  Specifically, cells were 
transfected with 30 pmole of non-targeting or a combination of two siRNAs targeting PKCα for 
three consecutive days to ensure sufficient knockdown.  24 hours after the last transfection, cells 
were treated with PMA or vehicle control for 10 minutes,  washed twice in cold TBS, lysed in lysis 
buffer (20 mM imidazole-HCl, 2 mM EGTA, 2 mM EGTA, pH 7.0 with 1:100 protease inhibitor 
cocktail) and subjected to immunoprecipitation and measurement of free phosphate with malachite 
green following the manufacturer’s protocol.  
 
2.14 Establishing EC cell lines stably expressing mutant AKT 
To determine if the tumor suppressive effects of PKCα in the endometrium involves inhibition of 
AKT hyperactivation, EC cell lines stably expressing constitutively active mutants, either the AKT 
E17K mutant found in breast and endometrial cancers (Mancini et al., 2016; Rudolph et al., 2016; 




retroviral vector-mediated integration.  Retroviral vector pBabe-puro-AKT1 was a gift from 
Xinjiang Wang (RPCI, NY) and the E17K mutation was generated through site-directed 
mutagenesis. The plasmid encoding pEGFP-AKT-DD was a gift from Julian Downward (Addgene 
plasmid # 39536) (Watton and Downward, 1999) and was subcloned into retroviral vector pBMN-
I-GFP, which was gifted by Garry Nolan (Addgene plasmid # 1736).  First, pEGFP-AKT-DD was 
digested with BamH1 and pBMN-I-GFP was digested with NotI.  The ends of the digested 
fragments were filled in by Klenow-mediated DNA polymerization.  The cloning vector and insert 
were digested by XhoI and SalI, respectively, and ligated to generate pBMN-AKT-DD for 
subsequent viral vector production.  Retroviral vectors expressing AKT mutants were generated by 
transfecting the packaging cell line 293GP (stably expressing gag and pol viral components) with 
pVSVG and either control vector (pBabe-puro or pBMN-I-GFP) or the mutant AKT encoding 
plasmids (pBabe-AKT-E17K or pBMN- AKT-DD) in DMEM medium containing 10% heat-
inactivated serum.  The viral supernatant was collected 48 hours after transfection and centrifuged 
to pellet cell components.  The target EC cells were incubated with the cleared viral supernatant 
for 6-8 hours before changing to culture media.  The infection was repeated 3 times to achieve 
sufficient viral transduction and robust mutant AKT expression (approximately 4-fold increase of 
endogenous level).  EC cells transduced with pBabe-puro or pBabe-AKT-E17K were subjected to 
puromycin selection (10 µg/ml) and cells expressing pBMN-I-GFP or pBMN-AKT-DD were 
selected with 600 µg/ml of G418 for at least four passage before subsequent analysis by soft agarose 
colony formation assays.   
 
2.15 Adenoviral-mediated overexpression and soft agarose colony formation assay 
Adenoviral vectors expressing either LacZ, PKCα, or kinase-dead PKCα were amplified in 
HEK293 packaging cells and the titer of viral supernatants was determined using Adeno-X Rapid 




Cells (5×105) were transduced with adenovirus at indicated moi in reduced (2.5%) serum medium 
for 24 hours and then incubated in complete culture medium. 48 hours post transduction, cells (1-
5×103 cells per well) were plated in 0.6% low-melting agarose as described in (Pysz et al., 2009) in 
duplicate, and colonies were allowed to grow for 1-4 weeks prior to staining with crystal violet. 
Whole plates were then scanned and visible colonies were counted.  
 
For AKT mutant-expressing cells lines, Cells (3×105) were transduced with the lowest moi (at 
which Ad-PKCα inhibits colony formation) in 2.5% serum medium for 24 hours.  2 days after 
infection, 2×104 cells were plated in 0.6% low-melting agarose as previously described, and allow 
to grow for 7 days before analysis. For analysis of the effect of co-expression of AKT mutants and 
PKCα, images from 4 independent fields per well were taken at 5X magnification at 4 different 
focal planes. Images of colonies in different focal planes were superimposed in Adobe Photoshop 
CC software and the number of colonies per field was determined using the particle analysis tool 
in ImageJ software. 
 
2.16 Correlation between PKCα mRNA and protein levels  
To perform parallel analysis of PKCα mRNA and protein levels in endometrial tumors, total RNA 
was isolated from frozen samples of 50 of the tumors included in the TMA.  PKCα mRNA levels 
were measured by qRT-PCR. A score was given to the tumors based on PKCα signal intensity from 
the IHC analysis. Results from the mRNA analysis were paired with the corresponding IHC score 
for the 50 tumors.  The correlation between PKCα mRNA and protein levels was determined by 
Spearman Rank Correlation analysis. 
 




For quantification of uterine tumor burden in mice, two to four longitudinal sections per animal 
were stained for pAKT Ser473 to identify endometrial lesions (Wang et al., 2002) and positive 
signal was quantified using DEFINIENS software and expressed relative to total endometrial 
epithelium area (as %). For determination of pAKT intensity relative to PKCα expression, staining 
corresponding to negative-low, medium and high pAKT staining was determined for each slide 
without knowledge of corresponding PKCα staining.  Analysis was performed using Adobe 
Photoshop CC.  pAKT staining was abstracted from the image using the Color Range tool and 
copied to a separate layer.  Thresholds corresponding to the boundaries between staining levels 
were set and used to trace areas corresponding to each level.  Areas of positivity on slides probed 
for PKCα were similarly identified and abstracted to a separate layer without reference to pAKT 
staining.  Staining layers from consecutive slides stained for PKCα and pAKT were overlaid and 
the area (in pixels) corresponding to each level of pAKT staining in PKCα positive and PKCα 
negative areas was determined. 
2.18 Statistical analysis  
Data are presented as the mean ± SEM of three or more independent experiments unless otherwise 
stated. Statistical analysis was performed using Microsoft Excel, GraphPad Prism or SAS software 
version 9.3 (SAS Institute Inc., Cary, NC).  p-values of less than 0.05 were considered statistically 
significant. Significance was assessed using Student's t-test for comparison of means, Chi-square 
or Fisher’s exact test for categorical analysis of two groups, Wilcoxon rank-sum test for 
nonparametic comparison of two samples, or two-way ANOVA test for multiple comparisons. 
Pairwise comparisons were adjusted for multiple comparisons with Tukey’s method. Model 


















Portions of the content covered in this chapter are the subject of an article under 







3.1.1 Biology of the endometrium 
The main function of the uterus, which develops from the Müllerian tubes (also referred to as 
the female ducts or paramesonephric ducts), is to house the developing embryo during its early life. 
The uterus consists of two compartments - the myometrium, the smooth muscle that controls uterine 
contraction, and the endometrium that lines the inner cavity of the uterus. Functionally, the 
endometrium facilitates the transport of the sperm and provides the nurturing environment for 
implantation and embryo development. The endometrium is one of the most dynamic tissues in the 
body, undergoing periodic remodeling throughout the reproductive period.  In each cycle, both the 
stroma and epithelium of the endometrium are restructured in response to the rise and fall of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) produced from the pituitary 
gland, and estrogen (E2) and progesterone (P4) secreted by the ovaries. This intricate hormonal 
balance governs the proliferation, differentiation, and regression of the endometrium.  Disruption 
of this tightly regulated process triggers the onset of menopause or, in the event of molecular 
dysregulation, results in uncontrolled, hyperplastic growth of the endometrium and the eventual 
development of endometrial carcinoma.  This next section describes the regeneration of the 
endometrium during the menstrual cycle (human) and estrous cycle (mouse), and actions of E2 and 
P4 during these events.  
 
3.1.2 Human estrous cycle 
In humans, the endometrium regenerates every 28-30 days through a process that is defined 
as the menstrual cycle.  This breakdown and rebuilding of the endometrium was first observed in 
other primates (Bartelmez, 1951; Bartelmez et al., 1946).  Subsequent studies identified the basalis 
layer of the endometrium situated immediately atop the myometrium to be quiescent at the 




thought to reside in this layer as depletion of the basalis abolished the regenerative capability of the 
endometrium (Wyss et al., 1996). With the increase in E2 levels in the follicular phase, a follicle 
starts to develop and mature in the ovary. This process generally spans the first 14 days of a typical 
28-day cycle. During this time, the stromal and epithelial cells, as well as endothelial vasculature 
in the basalis of the endometrium, proliferate in response to estrogenic stimulation, giving rise to 
the functionalis layer of the thickening endometrium.  This phase is referred to as the “proliferative” 
phase of the endometrium.  At the end of this phase, E2, LH, and FSH reach peak levels and rapidly 
decline following ovulation or the release of the oocyte. This marks the entry to the ovarian luteal 
phase (or the secretory phase of the endometrium). At this time, although there is moderate amount 
of E2, P4 is the predominant steroid, stimulating cell differentiation and secretion of growth factors 
in the endometrium and leading to decidualization.  In the case of successful fertilization, P4 levels 
are maintained throughout pregnancy. Otherwise, the fall of P4 levels leads to shedding of the 
functionalis, leaving only the basalis to regenerate the endometrium for the next cycle.  Because of 
advances in cell-based therapy, there has been effort to identify and isolate progenitor cells from 
the endometrium as a source of stem/ progenitor cells (Emmerson and Gargett, 2016).   
 
3.1.3 Rodent estrous cycle 
The rodent uterus is a widely used model for reproductive studies because of the ease with 
which it can be physically and genetically manipulated. While the rodent endometrium shares many 
similarities with its primate counterpart, there are distinct features that maximize rodent fertility.  
The rodent uterus is a ‘Y” shaped organ with horns that are joined at the cervix. This unique shape 
allows the implantation and development of multiple embryos in a single pregnancy.  Unlike the 
human menstrual cycle, the rodent estrous cycle typically lasts 4-6 days and has four phases: 
proestrus, estrus, metestrus, and diestrus. Each phase can be differentiated by the physical 




beginning of proestrus, a new batch of eggs enters the maturation process.  The accompanying 
surge of E2 at proestrus induces cell proliferation in the endometrium leading to the thickening and 
enlargement of the mouse uterus (Wood et al., 2007). In rodents, E2 peaks prior to ovulation and 
the surge of P4, LH, and FSH soon follows (Yoshinaga, 1973). Levels of these hormones sharply 
fall after ovulation. The rise of P4 converts the endometrium from a growth to a receptive state. 
Without implantation, the cycle proceeds to metestrus and diestrus at which time the endometrium 
is resorbed and primed to start the next cycle. These last two phases are equivalent to the secretory 
phase of the human menstrual cycle. Many studies have profiled the proliferation activities of the 
endometrium during the estrous cycle.  Maximal proliferation is observed in proestrus followed by 
metestrus and diestrus, while estrus is repeatedly associated with minimal proliferation (Marusak 
et al., 2007; Mendoza-Rodriguez et al., 2003; Wood et al., 2007).  In addition, increased apoptosis 
is also reported during estrus (Dery et al., 2003; Marusak et al., 2007).  As part of our study to 
understand the role of PKCα in endometrial cancer, we examined the expression and activation of 
PKCα in the normal mouse endometrium and its correlation with proliferation as indicated by Ki67 
immunohistochemistry.  
 
3.1.4 Effects of steroid hormone signaling: estrogenic response  
The cyclic endometrium remodeling is orchestrated by the fluctuation of follicular E2 and P4 
and the activation of their cognate nuclear receptors.  Rising E2, observed in proestrus of the estrous 
cycle or the proliferative phase of the menstrual cycle, initiates early events associated with the 
induction of uterine growth.  Sustained estrogen receptor (ER) activation and E2 bioavailability 
then leads to late E2 responses that result in uterine epithelial proliferation. Thus, E2 functions as a 
pro-proliferative signal in the uterus. Increased P4 levels, following E2 induction, opposes ER 
activation to mediate cell differentiation, switching the uterus from a proliferative to a receptive 




The surging E2 stimulates both physiological and molecular changes in the uterus (Barton 
et al., 1998).  The early events, which occur between one to six hours after E2 induction, include 
increases in RNA and protein synthesis and nuclear ER occupancy (Hewitt et al., 2016). These 
changes prime the endometrial epithelial cells for subsequent proliferation.  Physiologically, there 
is also an increase in water intake of the uterus (or water imbibition) and influx of blood and 
immune infiltration.  Sustained E2 elicits late uterine responses that peak 24 to 72 hours after the 
initial E2 surge.  At this time, there is continuing increase in DNA synthesis and significant mitosis 
in the uterus, which leads to an increase in uterine weight.  There is also further accumulation of 
immune cells.  Together, these events ensure that the physical fitness of the uterus is permissive 
for a subsequent P4-mediated switch from proliferating to differentiated endometrium.  
Studies using transgenic models have provided strong evidence that these uterine changes 
in response to E2 are mainly mediated by ERα.  There are two isoforms of ER expressed in the 
uterus, - ERα and ERβ - encoded by two distinct genes.  Although the ligand-binding domain is 
conserved and E2 indiscriminately binds to both receptor subtypes, ERα is the predominant isoform 
expressed in the endometrium, while ERβ is expressed at a lower level (Lecce et al., 2001).  
Furthermore, the uteri of ERα knockout mice (ERαKO) were shown to be hypoplastic and 
unresponsive to E2 stimulation.  In contrast, the uteri of ERβ knockout (ERβKO) mice were not 
different from those of wild type (WT) mice and were able to undergo cyclic remodeling when 
stimulated with E2 (Hewitt et al., 2016; Krege et al., 1998; Lubahn et al., 1993).  Gene expression 
analysis has also shown that ERα is responsible for the E2-induced genomic responses. The ERβKO 
and WT mice had indistinguishable expression profiles in response to E2 stimulation, whereas the 
ERαKO uterus showed no changes in gene expression. The genes induced by E2 also clustered into 
two profiles, mirroring the previously described biphasic physiological response to E2 stimulation 
in the uterus (Hewitt et al., 2003). These observations indicate that E2 induces its major effects in 
the endometrium through ERα activation and that ERα but not ERβ is essential for normal 




Ovariectomized mouse models are commonly used in studies of hormonal response in vivo, 
taking advantage of the ease of manipulation and the similarities between rodent and human 
reproductive biology.  Studies have shown that E2 stimulates an ERα-dependent biphasic response 
in the uterus (Hewitt et al., 2003). In early response to E2 stimulation, events such as ER nuclear 
occupancy, transcription of early response genes (including c-fos and c-jun), increased protein and 
RNA synthesis, and water imbibition occur within hours.  Nuclear ER occupancy peaks again 
approximately at 8 hours after E2 stimulation, followed by late responses such as transcription of 
late phase genes (e.g. lactoferrin), DNA synthesis, mitosis, accumulation of immune cells, and 
increase in uterine weight (Groothuis et al., 2007; Hewitt et al., 2003).   
The binding of E2 triggers a conformational change in ER through which ER assumes its 
transcriptionally active state capable of promoting gene expression via interaction with estrogen 
responsive elements (ERE) and other transcriptional mediators (Hewitt et al., 2016).  The activated 
ER leads to the expression of genes involved in crucial biological processes such as cell cycle 
progression, growth factor-mediated signaling, and apoptosis (Basu and Rowan, 2005; Murphy, 
1991).  In the case of ERα, one of the genes upregulated through direct interaction with ERE is 
insulin-like growth factor 1 (Igf1), an important signaling molecule in stimulating uterine 
proliferation (Adesanya et al., 1999; Hewitt et al., 2009; Zhu and Pollard, 2007).  Although 
elevation of IGF-1 production occurs in all compartments of the endometrium, it was most apparent 
in the uterine stroma (Cunha et al., 2004; Zhu and Pollard, 2007).  IGF-1 is essential for E2-
stimulated uterine proliferation, as administration of E2 fails to induce a proliferative response in 
mice lacking Igf1 genes (Adesanya et al., 1999).  IGF-1 binds to IGF-1 receptor (IGF-1R) to 
activate downstream signaling mediators and inhibit negative regulators including IRS1 (Richards 
et al., 1996), AKT, and GSK3β (Zhu and Pollard, 2007), leading to growth promoting effects such 
as nuclear accumulation of cyclin D1 (Tong and Pollard, 1999). 
In addition to the IGF-1-mediated activation of PI3K/AKT signaling, E2 also exerts 




pathway. In vitro studies have shown that estradiol activates MAPK in breast, bone, and neuronal 
cells (Endoh et al., 1997; Migliaccio et al., 1996; Watters et al., 1997).  In the endometrium, 
administration of E2 in ovariectomized mice leads to phosphorylation of ERK in uterine epithelium 
(Wang et al., 2015). The activation of ERK prominently upregulates the activity of AP-1 
transcription factors such as c-Fos and c-Jun in response to E2 or tamoxifen stimulation (Babu et 
al., 2013; Karin et al., 1997; Treisman, 1996; Whitmarsh and Davis, 1996).  AP-1 proteins then 
form active dimers (homodimers or heterodimers) to regulate genes that play important roles in cell 
proliferation and survival – for example, upregulation of cyclin D1 and cyclin D3 to promote 
growth or repression of growth inhibitory effectors such as p21, p27, and p53 (Shaulian, 2010; 
Shaulian and Karin, 2001; Zhuang et al., 2001).   
Continuing research of E2 actions in the endometrium has revealed other mechanisms by 
which E2 promotes the proliferation of endometrial cells (e.g., induction of non-genomic effects 
through the G-protein coupled receptor 30 (GPR30)) (Bamberger et al., 2007; Gielen et al., 2007).  
Elevated exposure to E2 or tamoxifen is one of the main risk factors for endometrial cancer, 
increasing the risk of developing this malignancy (Morice et al., 2016) by supporting the pro- 
proliferative and -survival properties of E2 and ER signaling in the endometrium.  
 
3.1.5 Effects of steroid hormone signaling: progesterone 
The main role of progesterone (P4) in the uterus is to oppose the actions of E2 to maintain 
uterine homeostasis by inhibiting cell growth and inducing differentiation, through binding to the 
progesterone receptor (PR).  Like ER, there are two isoforms of PR – PR-A and PR-B.  Rather 
than being encoded by two separate genes (like ERα and ERβ), the two PRs share a single PR gene 
located on chromosome 11, regulated by different transcriptional start sites, thus generating two 
mRNA transcripts encoding either PR-A or PR-B (Conneely et al., 1989).  While both PR-A and 




and PR-B is the predominant PR in the epithelial compartment (Mote et al., 2006; Mote et al., 
1999).  In the uterus, E2 stimulation decreases PR levels in the epithelium while stromal PR is 
elevated in response to E2 (Patel et al., 2015; Tibbetts et al., 1998). Yet, both epithelial and stromal 
PR act to antagonize E2-responsive proliferation, while epithelial PR mediates expression of P4-
targeted genes and inhibition of proliferation (Franco et al., 2012; Liu et al., 2009b; Smid-
Koopman et al., 2003; Zhang et al., 2013). With the understanding of differential PR isoform levels 
in the uterine compartments, this suggests that PR-A and PR-B have distinct functions in regulating 
uterine growth and homeostasis.   
The predominance of each PR isoform in different endometrial compartments suggests there 
is differential response to estrogenic stimulation mediated by these molecules.  Interestingly, 
elevated PR levels and activation, in turn, suppress ERα expression (Haluska et al., 1990; Mote et 
al., 2006), generating a feedback loop to maintain the intricate balance of ER and PR signaling and 
uterine homeostasis.  The essential role of PR in the reproductive tract was further demonstrated 
by transgenic models.  When lacking both PRs, the mice were infertile due to defects in ovulation 
and implantation.  The animals also showed evidence of uterine hypertrophy and inflammation of 
the glandular epithelium of the endometrium (Mulac-Jericevic et al., 2000).  Using isoform specific 
knockout models (PRAKO for PR-A knockout and PRBKO for PR-B knockout), it was shown that 
functional PR-A alone is sufficient and necessary for normal ovarian and uterine functions as 
PRAKO mice were infertile (similar to PR-null animals), while normal implantation and 
decidualization were observed in PRBKO mice (Mulac-Jericevic et al., 2003; Mulac-Jericevic et 
al., 2000).  PRAKO mice also showed increase endometrial hyperplasia and inflammation (Mulac-
Jericevic et al., 2000). Unexpectedly, P4 stimulated abnormal epithelial proliferation in the uterus 
in PRAKO mice that was not observed in PR null mice, suggesting P4 promotes uterine epithelial 
proliferation through PR-B activation, and that PR-A acts to limit PR-B-mediated proliferation 




demonstrated 1) PR-A is required in the anti-proliferative response of PR signaling and; 2) the P4-
mediated uterine response is essential for maintenance of uterine homeostasis, blastocyst 
implantation and pregnancy.  
P4 can exert its functions in the uterus through a genomic pathway by binding and activating 
the transcriptional activity of PR or by non-genomic activation of signal transduction.  The ligand 
bound PR (both PR-A and PR-B) can form either homodimers or heterodimers, leading to receptor 
phosphorylation, and subsequent interaction with hormone responsive promoters to regulate 
targeted gene expression (Conneely et al., 2003).  In addition, P4 also induces non-genomic 
responses through PR-dependent activation of Src/RAS/MAPK signal transduction and PR-
independent activation of membrane receptors, whose physiological contribution is less clear 
(Ballaré et al., 2006; Mulac-Jericevic and Conneely, 2004).  In general, P4 antagonizes the action 
of E2 by negatively impacting the regulation of genes activated by ER signaling (Yang et al., 2011).  
In contrast to the induction of AP-1 expression by E2, P4 downregulates growth promoting proteins 
such as the AP-1 family of transcription factors, particularly c-Jun, cyclin D1, and  
minichromosome maintenance proteins (MCMs) (Chen et al., 2005; Dai et al., 2003; Pan et al., 
2017; Yang et al., 2011).  P4 also exerts its growth inhibitory effect through reprogramming of the 
AP-1 mediated transcriptional network, leading to opposing effects on many of the E2-reponsive 
genes. In addition to shunting AP-1 from binding to growth promoting effectors such as cyclin D1, 
P4 also upregulates the expression of p53 and CDKIs such as p21, p27 by enhancing the binding 
of AP-1 to their respective promoters (Dai et al., 2003; Hagan et al., 2011; Yang et al., 2011).  
Other PR-responsive genes, such as FOXO-1 that mediates cell senescence, have been shown to 
be anti-proliferative (Kyo et al., 2011; Ward et al., 2008). Although P4 binds to both PR-A and PR-
B, the receptors have distinct, isoform-specific genomic functions, providing a likely explanation 
for the aforementioned differential physiological roles of PR isoforms. Studies have found that 




1997; McDonnell et al., 1994; Vegeto et al., 1993), while PR-B exhibits stronger transcriptional 
activating capability than PR-A (Jacobsen et al., 2002; Kumar et al., 1998; Leslie et al., 1997; 
Vegeto et al., 1993).  However, only a subset of PR-responsive genes are regulated by PR-B.  
Among the genes related to implantation (e.g., calcitonin, histidine decarboxylase, lactoferrin), 
RNA analysis showed that PR-B alone was sufficient for P4-mediated transcriptional changes in 
histidine decarboxylase and lactoferrin but not calcitonin (Mulac-Jericevic et al., 2000).  
Interestingly, despite the hyper-proliferative effect of P4 in PRAKO mice, PR-B activation 
upregulated IGFBP-1, which exerts P4-induced anti-proliferative effects in cooperation with 
FOXO-1(Nakamura et al., 2013). 
There is mounting evidence that steroid hormones can modulate gene expression profiles 
through regulation of microRNAs (miRNAs) (Nothnick et al., 2010).  Alteration in miRNAs is 
associated with uterine abnormalities including endometriosis, uterine leiomyoma and endometrial 
carcinoma (Burney et al., 2009; Kuokkanen et al., 2010), strengthening the important regulatory 
role of miRNAs in the endometrium.  In a high-throughput miRNA analysis in the endometrial 
epithelium of ovariectomized mice under hormone stimulation, P4 was found to upregulate many 
miRNAs with known biological importance, including inhibition of proliferation (Lim et al., 2005; 
Yuan et al., 2014).  For example, miR-133a has been shown to target cyclin D2 to exert its P4-
induced anti-proliferative response (Liu et al., 2008; Pan et al., 2017).  Other P4-induced miRNAs, 
such as miR-145/143 and miR-152, are involved in P4 related growth inhibition by suppressing 
levels of cyclin D2 and Wnt-1, respectively (Yuan et al., 2015).  It remains elusive whether there 
are PR isoform-selective effects on the regulation of miRNA and its downstream targets.  
 
3.1.6 PKC signaling in the endometrium 
Several PKC isozymes (e.g., PKCα, βII, δ, η, and ζ) have been detected in the rat uterus, 




(Jofre et al., 2013; Kim et al., 1999).  PKC activity has been shown to upregulate urocortin 
production through activation of the urcortin promoter (Bamberger et al., 2007).  The fine-tuning 
of PKC activation has been implicated in the control of myometrial contractility and determining 
the duration of gestation (Karteris et al., 2004; Vitale et al., 2016).  Activated PKC has also been 
found to induce COX2 levels, allowing the production of prostaglandin to mediate uterine 
contractility (Wouters et al., 2014).  In contrast to the inductive effect of PKC activation in uterine 
myometrium contractility, PKCα activity, not its abundance, was reported to significantly increase 
in preterm women (not in labor) when the myometrium is quiescent (Jofre et al., 2013), suggesting 
that PKCα is important in regulating the duration of pregnancy.  This is in accordance with the role 
of PKCα as an inhibitor of smooth muscle contractility in the heart (Braz et al., 2004; Hambleton 
et al., 2006; Liu et al., 2009a).  Clearly, further investigation is needed to elucidate the isozyme 
specific effects of PKCs on uterine contractility.    
There is limited knowledge of the role of PKCs in the endometrium. PKC signaling has been 
shown to be involved in generating a suitable environment for embryo implantation.  Many 
reproduction-related signaling molecules, such as Lewis Y antigens and calcitonin, which are 
actively secreted by the endometrial epithelial cells during implantation, were found to activate 
Ca2+-dependent PKCs to facilitate trophoblast-endometrial interaction (Kalbag et al., 1991; Li et 
al., 2008; Li et al., 2009).   The work of Pollard and coworkers on hormone-regulated changes in 
the uterine epithelium suggested the involvement of PKC in the normal physiology of endometrial 
epithelium.  They reported that E2  exerts mitogenic effects through 1) IGF-1 signaling that 
activates PI3K/AKT pathways, leading to cyclin D1 nuclear accumulation, cell cycle progression, 
and DNA synthesis (Zhu and Pollard, 2007); 2) retention and chromatin loading of 
minichromosome maintenance proteins (MCMs) to permit DNA replication licensing (Pan et al., 
2006); and 3) regulation of protein synthesis by a PKC-ERK-mTOR signaling pathway (Wang et 




1/PI3K/AKT signaling axis, ERK-mTOR dependent protein synthesis was undisturbed (Wang et 
al., 2015).  Interestingly, the induction of PKC activity, as indicated by the phosphorylation of 
MARCKS (myristoylated alanine-rich protein kinase C substrate), coincided with the switch from 
non-receptive to receptive state in the uterus, which is regulated predominantly by P4 in 
cooperation with nidatory E2 (Chen et al., 2003).  Activation of PKC was found to be involved in 
P4-mediated gene expression such as induction of immune response gene-1 (Irg1) (Chen et al., 
2003), suggesting that the PKC signaling pathway may modulate steroid hormone responsiveness 
of the uterine epithelium.  Together, these studies suggest that PKC signaling may have important 
roles in regulating the physiological changes of the uterus and female fertility, although little is 
known about isoform-specific functions in these processes.  
While the main focus of our study is to decipher the functional role of PKCα in endometrial 
cancer, it is important to survey its expression in the normal endometrium.  The following section 
reports our findings on PKCα levels and activation in the cycling human and mouse endometrium.  
 
3.2 Results 
3.2.1 Survey of PKCα expression in the endometrium 
As a first step in characterizing PKCα expression in the endometrium, we analyzed PKCα 
levels in human uterine tissue using immunohistochemistry.  While PKCα was detected in all 
samples, there was disparity in its levels among the different endometrial compartments (Figure. 
3-1A).  In both the secretory and proliferative uterine tissue, there were high levels of PKCα in 
the stroma, as indicated by strong IHC signal. In contrast, PKCα was expressed at a much lower 
level in the epithelium when compared to adjacent stroma. It has been shown previously that the 
activation of PKCs is associated with membrane translocation of the enzyme (Black and Black, 
2012). Therefore, a membrane-associated pattern of PKC staining is indicative of its activation. 




not in the proliferative epithelium (Figure. 3-1B), suggesting that PKCα is activated when the 
endometrium switches from a proliferative to a secretory state and that activity of this enzyme 
might have a signaling role relating to the secretory uterine phenotype. 
 
 
Fig. 3-1: PKCα expression in normal human uterus 
(A) IHC analysis of PKCα expression in secretory and proliferative endometrium, S indicates the 
stromal compartment of the tissue.  Arrow points to the endometrial epithelium.  (B) Membrane 
associated PKCα in secretory endometrium.  Arrow indicates epithelial regions with membrane-






3.2.2 PKCα expression in mouse estrous cycle phases 
The uterus undergoes significant physiological changes and remodeling throughout the 
estrous cycle. These changes are governed by an intricate network of signal transduction.  As part 
of the effort to understand if PKCα plays a role in regulating uterine physiology, we performed 
IHC analysis on uterine tissues from all four estrous phases: proestrus, estrus, metestrus, and 
diestrus, aiming to assess PKCα expression in relation to the murine estrous cycle.  The estrous 
phases of the animals were determined from the cytological makeup of the vaginal smear. Vaginal 
secretion was collected from sexually mature (5-6 weeks), virgin female mice and examined using 
microscopy.  In our previous studies of the intestinal epithelium, we have shown that PKCα is 
activated at the crypt-villus junction where there is a program switch from proliferation to 
differentiation (Frey et al., 2000). As the cycling of the endometrium also involves a physiological 
switch between these states as it progresses through the estrous cycle, we hypothesized that PKCα 
may also be growth inhibitory in the endometrium and play a role in mediating this proliferation-
to-differentiation switch.  To test this hypothesis, we investigated the correlation between PKCα 
expression and proliferation, marked by positive Ki67 staining, in formalin-fixed, paraffin-
embedded uterine tissue collected from mice at each phase.  PKCα was detectable in all four phases 
of the estrous cycle (Figure 3-2).  Levels of PKCα were relatively lower in metestrus, diestrus, and 
proestrus.  The enzyme was predominantly cytoplasmic during these phases.  However, in estrus, 
PKCα showed robust expression.  Interestingly, there was reduced staining for the proliferation 
marker Ki67 in the same phase.  These observations suggest a negative correlation between PKCα 
































Fig. 3-2: Correlation between PKCα and Ki67 expression during the estrous cycle 
IHC analysis of PKCα expression and proliferative activity as indicated by Ki67 staining in.uterine 
tissues from mice at different phases of the estrous cycle: proestrus, estrus, metestrus, and diestrus, as 




3.2.3 Membrane-associated PKCα at estrous phase 
Upon closer examination, we found that PKCα exhibited a distinct membrane-associated 
staining pattern in both late proestrus and estrous phases (Figure 3-3A).  In late proestrus, PKCα 
was predominantly inactive, as most of the detected PKCα resided in the cytoplasm.  However, the 
glandular epithelium not only had higher PKCα levels, but staining for PKCα displayed a 
membrane-associated pattern, indicating that the enzyme was in its active form.  This membrane-
associated PKCα staining intensified in estrous tissue, extending to both the glandular and luminal 
epithelium and providing evidence for continuous strengthening of PKCα activating signals as the 
cycle progresses from proestrus to estrus.  However, PKCα maintained a cytoplasmic localization 
in both metestrus and diestrus indicating a cessation of activating signals in the later phases of the 
estrous cycle as shown in Figure 3-2. The membrane-associated staining in proestrous and estrous 






Fig. 3-3: Membrane-associated PKCα at estrous  
(A) IHC analysis of PKCα in the luminal (LE) and glandular (G) compartments of uterine tissue during 
late proestrus and estrus. Membrane-associated localization of PKCα indicates activation of the kinase. 
In proestrus, PKCα expression is cytoplasmic in the luminal compartment but membrane-associated in 
the glands (arrows). In estrus, membrane association of PKCα is detected in both the luminal and 
glandular epithelium (arrows).  (B) Immunofluorescence staining for PKCα in frozen sections of luminal 





3.2.4 Inverse correlation between PKCα activation and cell proliferation 
Thus far, our data have shown that membrane association of PKCα was most evident in 
the estrous phase, where the least proliferation was detected.  In order to further confirm if there is 
a correlation between PKCα activation and cell proliferation, we examined PKCα 
expression/subcellular distribution and Ki67-marked proliferation by performing IHC analysis on 
serially sectioned uterine tissue at proestrus and estrus phases. As shown by images in Figure 3-4, 
proliferative activity was restricted to the luminal epithelium (indicated by arrowhead) and the 
glandular epithelium was completely devoid of Ki67 signal (shown by arrow).  Interestingly, this 
compartmental delineation of staining correlated with PKCα levels and activation.  Furthermore, 
in the lower panel, there was a striking correspondence between a Ki-67 negative region and strong 
membrane association of PKCα as indicated with arrows. Taken together, these observations 
demonstrated a negative correlation between PKCα activation and epithelial proliferation in the 







Fig. 3-4: PKCα expression during the estrous cycle 
 
Serial sections from late proestrus and estrus phase uterine epithelium were analyzed for PKCα and the 
proliferation marker, Ki67. Top Panels: Survey sections show markedly reduced proliferation in the 
luminal epithelium (LE) during estrus phase; glands (G) are negative for Ki67 staining in both late 
proestrus and estrus phases. Block arrows in the lower panels indicate areas of PKCα membrane 
association/activation; arrowheads indicate areas that lack membrane-associated PKCα. Note the strong 
nuclear Ki67 staining in areas which lack membrane-associated PKCα. In contrast, areas with low levels 






The constant remodeling of the endometrium makes it one of the most dynamic tissues in 
the body.  The cyclic breakdown and rebuilding of this tissue requires a complex signaling network 
that is intricately regulated to ensure appropriate proliferation, differentiation, and apoptosis of the 
epithelium. Molecular aberrations that tip this balance lead to outgrowth of the endometrium, 
resulting in tumor development in this tissue.  As part of our effort to decipher the role of PKCα in 
endometrial cancer, we first profiled PKCα expression in the normal endometrium.  Through IHC 
analysis, we found that PKCα is ubiquitously expressed in the both human and mouse 
endometrium, regardless of the stage of the menstrual cycle or estrous cycle, respectively.  
However, PKCα levels are significantly lower in the endometrium when compared to the adjacent 
stroma in the human uterus and in the mouse uterus in estrous phase, while there was little 
difference between these two compartments in the mouse uterus in other phases. In the human 
tissue, membrane-associated PKCα was only observed in the secretory phase, while this staining 
pattern was detected in both late proestrus and estrus phases in the murine endometrium. This 
observation, which was consistent in our analysis of paraffin-embedded and frozen murine uterine 
tissues, suggests that activation of PKCα is initiated in proestrus and continues in estrus of the 
mouse estrous cycle.  Interestingly, there was minimal epithelial proliferation, as marked by 
reduced Ki67-positive staining, when active PKCα was detected. This led us to hypothesize that 
PKCα signaling may be anti-proliferative and tumor suppressive in the endometrium. The data 
presented in this section provide the basis for future studies to further investigate the hormonal 
regulation of PKCα activation and the signaling effects of PKCα in the endometrium.  
A limited number of studies have demonstrated that E2- and P2- mediated responses in the 
uterus require PKC activation (Chen et al., 2003; Wang et al., 2015).  Chen et al. showed that PKC 
activity is involved in implantation-related uterine responses induced by the synergistic actions of 
P4 and E2 and the upregulation of P4-regulated genes.  However, a subsequent study from the same 




(Wang et al., 2015).  Because of the opposing actions of E2 and P4 in the endometrium, these 
findings raise questions on how these hormones regulate PKC activation in this tissue.  Both of 
these studies assessed PKC activation using whole cell lysates prepared from uterine epithelial cells 
isolated from ovariectomized mice after hormone treatment in vivo.  PKC activity was then 
determined by the phosphorylation of MARCKS, shown by Western blotting.  Although the 
hormone administration was performed in vivo, assessment of PKC activity was indirect and used 
a non-selective PKC substrate. Additionally, previous studies have also shown uneven distribution 
of ERα/β and PR-A/B expression in the different compartments of the endometrium; thus, the 
purity of the epithelial isolate might be a confounding factor. Because of the high PKC levels in 
the endometrial stroma (in the human), it is not clear whether epithelial or stromal PKC is 
responsible for the hormone-induced responses in the uterus, or if there is isoform selectivity in 
PKC-mediated signaling programs in the endometrium. In our study, active PKCα, demonstrated 
by its membrane-associated staining, was detected at late proestrus and estrus, suggesting that 
PKCα activation might be a late response to E2 stimulation or the result of rising P4.  Staining of 
the uterine tissue directly assesses the presence of active enzyme in the uterine tissue and allows us 
to visualize its compartmental localization in vivo. However, the current data are observational and 
can only demonstrate a correlative relationship between PKCα activation and the cycling 
endometrium.  To establish a mechanistic link between hormonal stimulation and PKCα activation, 
we propose to examine PKCα localization in uterine tissue from ovariectomized mice after 
treatment with E2, P4 or E2P4.   
In a previous study, estradiol was shown to stimulate endometrial proliferation and induce 
sustained PKC activation for at least 8 hours (Wang et al., 2015).  Another study has demonstrated 
elevated PKCα mRNA in response to tamoxifen and E2 in isolated human endometrial cells (Wu 
et al., 2005).  However, it was unclear whether the enzyme was in its active state. Based on our 
examination of uterine sections from proestrus and estrus, PKCα activation was associated with 




is increased in pregnant women when sustained P4 is necessary to maintain pregnancy, which 
supports the notion that PKCα activation is more closely associated with PR signaling. Thus, 
although E2 might induce activation of other PKC isozymes, PKCα activation is likely to be 
regulated by P4.  We expect to detect strongest membrane-associated PKCα staining in the uterus 
when the animals are given E2P4 synergistically as the presence of low E2 levels is necessary for 
the proper activation of PR signaling (Chen et al., 2003). It is also possible that P4 alone can induce 
PKCα activation; however, we expect it would be at a much lower level than in the E2P4 treated 
group. Meanwhile, the tissue will also be assessed for proliferation by Ki67 staining and for 
downstream signaling effects on cyclin D1, p-mTOR, and pRPS6, whose expression or 
phosphorylation have been shown to be hormonally regulated in the endometrium (Wang et al., 
2015).  If our data demonstrate PR-mediated activation of PKCα, this will support a role for this 
kinase in exerting anti-proliferative signaling in the endometrium and highlight its involvement in 
the transition from a proliferative to differentiated state. Alternatively, we might observe 
membrane-associated PKCα when mice are given E2 alone if PKCα is activated by ER.  
Together with the current data, results from the proposed studies will provide a more 
comprehensive view of the role of PKCα signaling in the biology of normal, cycling endometrium, 
as well as a basis for its effects during endometrial tumorigenesis.  Further investigation in ER or 










Chapter 4: Crosstalk Between PKCα and PI3K/AKT Signaling 
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4.1 Endometrial cancer 
Endometrial cancer (EC) is the most common gynecological malignancy in the United States, 
with an estimated 60,380 new cases and 10,920 deaths in 2017 (Siegel et al., 2017). With an overall 
5-year survival rate of >80%, EC has attracted less public attention than other cancers. Most cases 
are diagnosed at an early stage when the patients experience unusual spotting, heavy bleeding or 
severe menstrual pain.  When diagnosed early, patients are treated with surgery.  For more advanced 
cases, chemotherapy or radiation may follow.  However, advanced (which has spread beyond the 
uterine cavity) and recurrent disease is refractory to treatment and the prognosis for these patients 
is dismal, with survival estimates of less than one year (Engelsen et al., 2009). Because of its high 
incidence, EC is the sixth leading cause of cancer death in women, accounting for more deaths than 
melanoma, cervical cancer, glioblastoma, all lymphomas, or all leukemias (Siegel et al., 2017). 
Alarmingly, the incidence and mortality for EC are on the rise, with a >40% increase since 2005. 
Since obesity is a major risk factor for the disease (Fader et al., 2009), EC will become an even 
greater health concern as the effects of increased societal obesity become evident in coming years.  
  
4.1.1 Clinical and molecular classification 
EC has historically been classified into two histopathological subtypes. Type I tumors (85-90% 
of cases) are of endometrioid histology, while Type II non-endometrioid tumors can be further 
classified by histological appearance as serous, clear cell, mixed cell, or malignant mixed Mullerian 
tumors (MMMT), with serous being the predominant subtype in this category (Suarez et al., 2017).  
The original landmark paper published in 1983 described the clinical features observed in each of 
the subtypes (Bokhman, 1983).  A majority of EC patients are diagnosed with Type I or 
endometrioid subtype.  Many of these patients are post-menopausal women who are also likely to 
have elevated estrogen exposure (related to hormone replacement therapy, obesity, late onset of 




ECs follows a sequential course of progression initiated by hyperplasia, atypical hyperplasia, and 
benign hyperplasia, followed by premalignant neoplasia (Dedes et al., 2011). Disease in these 
patients often presents as low grade hyperplasia, with histology resembling the proliferative 
epithelium, anovulatory bleeding, and sometimes infertility (in women at reproductive age). Type 
I tumors have lower invasive potential, often only penetrating the superficial surface of the 
myometrium.  These tumors are more sensitive to progesterone-mediated growth inhibition.  Most 
of type I patients are successfully treated with surgery, progestin therapy, and radiation for more 
advanced cases.  Patients with Type I disease have more favorable prognosis and have an overall 
5-year survival rate of 85% (Morice et al., 2016). 
As discussed above, Type II non-endometrioid tumors encompass several histological types 
including serous, clear cell, malignant mixed Mullerian tumors, and mixed epithelial types.  These 
cancers generally have an accelerated course of disease progression, and tumors are more invasive 
with a higher likelihood of recurrence.  Although Type II EC only accounts for ~20% of all 
endometrial cancer cases, it is responsible for 50% of EC-related mortality (Lobo and Thomas, 
2016). At the time of diagnosis, these tumors have usually already invaded the myometrium and 
lymphovasculature and are often are metastatic.  Despite the difference in disease type, patients 
with Type II EC also receive surgery as first line therapy.  Due to the more aggressive nature of the 
disease, patients with Type II EC also receive adjuvant radiation and combinational chemotherapy 
to limit recurrence. Progestin therapy is rarely administered to these patients as Type II tumors are 
often insensitive to P4. However, if the disease recurs, the tumors are often resistant to existing 
therapies and the prognosis for these patients is dismal (median survival of 8-16 months) (Dellinger 
and Monk, 2009).  The simplistic classification of EC established in 1983 has guided clinical 
prognosis and treatment for this disease in the following decades.  As the EC field gains more 





The first evolution of this two-category classification of EC disease was fueled by advances in 
the molecular understanding of ECs (Table 4-1) (Dedes et al., 2011). Molecular analysis of these 
tumors has identified genetic alterations that are more prevalent in each EC type. Because of the 
high prevalence of mutations in PTEN (83%), loss of PTEN function is considered a primary 
feature of Type I tumors (Mutter et al., 2000; Risinger et al., 1998). Additional oncogenic mutations 
are found in other molecules in the PI3K/AKT pathway, including activating mutations in PIK3CA 
(~ 30%) and AKT (3%) (Catasus et al., 2008; Miyake et al., 2008; Shoji et al., 2009).  The frequent 
co-existence of mutations in PI3K subunits and PTEN highlights the tumorigenic advantage of 
hyperactive AKT signaling in endometrial carcinogenesis (Oda et al., 2005).  The microsatellite 
instability phenotype of Type I ECs has been attributed to inactivation of DNA repair genes (e.g. 
MLH1, MSH2, MSH6, and PMS2) (MacDonald et al., 2000; Mackay et al., 2010; Miturski et al., 
2002)  Other molecular aberrations commonly found in Type I ECs include KRAS mutations, 
FGFR2 mutations, and nuclear accumulation of β-catenin (Koul et al., 2002; Lax et al., 2000; 
MacDonald et al., 2000; Pollock et al., 2007; Schlosshauer et al., 2000; Stefansson et al., 2004). In 







Type I (%) 
Prevalence in 
Type II (%) 
PIK3CA mutation ~ 30 ~ 20 
PIK3CA amplification 2-14 46 
KRAS mutation 11-26 2 
AKT  mutation 3 0 
PTEN loss of function 83 5 
Microsatellite instability 20-45 0-5 
Nuclear accumulation of β-
catenin 
18-47 0 
E-Cadherin loss 5-50 62-87 
TP53 mutation ~ 20 ~ 90 
p16 loss of function 8 45 
HER2 overexpression 3-10 32 
HER2 amplification 1 17 
FGFR2 mutations 12-16 1 
 
Table 4-1: Molecular alterations in endometrial cancer. Adapted from (Dedes et al., 2011) 
 
The most commonly observed aberration in Type II EC disease is mutation in p53, which 
is found in 90% of Type II tumors, particularly in the serous subtype (Jia et al., 2008; Khalifa et 
al., 1994; Lax et al., 2000).  In serous EC, somatic mutations of p53 are believed to be an initiating 
event (O'Hara and Bell, 2012).  Interestingly, serous ECs share clinical and pathological similarities 
with serous ovarian tumors in which p53 mutations have significant pathogenic and therapeutic 
impact (Di Cristofano and Ellenson, 2007).  Alterations in p16 levels are more commonly detected 




binding to cyclin dependent kinases Cdk4 and Cdk6 and is, thus, considered a tumor suppressor 
(Liggett and Sidransky, 1998).  Loss of p16 in EC is associated with aggressive disease with poor 
prognosis (Ignatov et al., 2008; Salvesen et al., 2000).  However, other studies have reported 
overexpression of p16 in ECs (O'Hara and Bell, 2012).  Elevated p16 is thought to be indicative of 
oncogene-induced senescence in benign or pre-malignant hyperplasia, or the result of the cell’s 
effort to arrest proliferation when the Rb pathway is defective (Romagosa et al., 2011).  Other 
molecular alterations that are more commonly associated with Type II EC include loss of E-
Cadherin and elevated levels of HER2 due to overexpression or gene amplification.  Although 
molecular profiling provided a more detailed distinction of EC types, some aberrations are found 
in both types.  For example, mutations in PIK3CA are found at similar frequencies in both Type I 
and II ECs (although there appears to be a preference for mutations in exon 20 in Type II disease, 
whereas Type I ECs have mutations in both exon 9 and 20 of PIK3CA) (Catasus et al., 2008). 
Interestingly, PIK3CA amplification is more prevalent in Type II than Type I ECs. The classical 
subtyping of EC disease based on tumor histology was particularly problematic for high-grade 
endometrioid tumors (Clarke and Gilks, 2010).  Newly identified molecular alterations in ECs can 
serve as biomarkers to facilitate more accurate subtyping and better guidance in treatment selection 
(Alkushi et al., 2010; Darvishian et al., 2004; Yemelyanova et al., 2009).  Using phenotypic 
markers such as MLH1, MSH2, p16, cyclin D1, ERBB2, and p53, 37% of grade 3 tumors exhibited 
molecular profiles of endometrioid tumors while 63% of the cases shared molecular similarities 
with serous carcinomas (Alvarez et al., 2012).  This suggests that a comprehensive molecular 
profiling is needed to maximize the accuracy of the classification of ECs.  Together, these findings 
provided new insights into the molecular alterations in ECs and the prognostic potential of these 
molecules, and also revealed opportunities for targeted therapy for the disease.   
 In 2013, The Cancer Genome Atlas project (TCGA) completed their integrated genomic, 
transcriptomic, and proteomic analysis of 373 ECs including 307 low or high grade endometrioid, 











POLE ultramutated POLE Polymerase epsilon, catalytic subunits 100 %  
 PTEN Phosphatase and tensin homolog 94%  
 CSMD3* CUB and Sushi multiple domains 3 94% 
 TAF1 TAF1 RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 250KDa 
83% 
 FBXW7 F-box and WD repeat domain containing, E3 





PTEN Phosphatase and tensin homolog 88% 
 PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha 
54% 
 PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 
(alpha) 
40%  
Copy number low/ 
microsatellite-stable 
PTEN Phosphatase and tensin homolog 77%  
 PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha 
53% 
 CTNNB1 Catenin, beta 1, 88 KDa 52% 
 ARID1A AT rich interactive domain 1A (SWI-like) 42% 
Copy number high/ 
serous like 
TP53 Tumor protein 53 92% 
 PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha 
47% 
 PPP2R1A Protein phosphatase 1, regulatory subunit A, alpha 22% 
 FBXW7 F-box and WD repeat domain containing, E3 
ubiquitin protein ligase 
22% 
Table 4-2: Top 3 most significantly mutated genes in 4 molecular subtypes of EC. *High 





While mutations in known EC-associated genes were detected, this comprehensive 
analysis revealed many more significantly altered genes that were not identified to drive 
endometrial tumorigenesis (e.g. BCOR, MECOM, ARID5B, and NKAP etc.).  Based on results from 
this analysis, four molecular subgroups of ECs have been recognized: POLE ultramutated, 
hypermutated/microsatellite-unstable (MSI), copy number low/microsatellite-stable (MSS), and 
copy number high/serous like, as reviewed in (Le Gallo and Bell, 2014).  This marked the second 
evolution of EC classification.  DNA polymerase ε (POLE) exonuclease, encoded by the POLE 
gene, catalyzes the synthesis of the leading strand during DNA replication (Pursell and Kunkel, 
2008).  Mutations in the POLE gene, such as those identified in ECs, disrupt the enzyme’s 
proofreading ability leading to an ultramutated phenotype (232 × 10-6 mutations/Mb; 867-9714 
mutations/tumor), as well as high incidence of C>A transversions.  Other studies have also reported 
POLE mutations in EC (Church et al., 2013).  Despite the extraordinarily high mutation numbers 
in POLE ultramutated tumors, patients in this group have the most favorable prognosis among all 
EC subgroups. All POLE ultramutated tumors are of endometrioid histology, accounting for 10% 
of all endometrioid tumors examined (6.4% of low grade and 17.4% of high grade endometrioid 
tumors). Another subgroup that exclusively consists of endometrioid tumors is the 
hypermutated/MSI category. As its name indicates, the hypermutated phenotype in these tumors is 
the result of reduced expression of the mismatch-repair protein MLH1 and frequent methylation of 
the MLH1 promoter.  This is also consistent with previous reports of high MSI frequencies in ECs 
(An et al., 2007; Konopka et al., 2007; Zighelboim et al., 2007). MSI tumors comprise 28.6% of 
low grade and 54.3% high grade endometrioid cases in the TCGA cohort. The next subgroup 
includes the copy number low/MSS tumors. The MSS tumors account for 60% of all low grade 
endometrioid tumors, making it the most common subgroup of endometrioid tumors. Unlike the 
previous two subgroups, the MSS subtype includes serous and mixed-histology carcinomas. In 




CTNNB1 mutations are more common in MSS endometrioid tumors (Byron et al., 2012). Despite 
the frequent occurrence of high grade endometrioid histology in MSI tumors and the inclusion of 
the more aggressive serous or mixed-histology MSS carcinomas, these two subtypes displayed 
similar trends in progression free survival. The most distinct subgroup of ECs is known as copy 
number high/serous-like.  Almost all serous cases are categorized in this subgroup (97.7% of serous 
and 75% of mixed-histology).  Phenotypically, these tumors are more similar to high-grade serous 
ovarian tumors than to other ECs (Merritt and Cramer, 2010).   Genetic profiling of serous EC has 
also identified prominent mutations in TP53 in these tumors, mirroring serous ovarian tumors, 
which suggests that mutant p53 is the main driver for formation of serous EC.  Mutation in other 
genes such as PTEN, CTNNB1, and PIK3R1 that are highly prevalent in other subgroups are 
significantly less frequent in serous EC, although they are still present.  As expected, these tumors 
generally also have decreased pAKT levels, differing from the AKT hyperactivation that commonly 
drives carcinogenesis in other EC subtypes. In addition, TCGA analysis also identified focal 
amplification of MYC, ERBB2, and CCNE1 in 23-25% in this subgroup. Because of distinct 
molecular features and the close resemblance between serous endometrial and ovarian tumors, 
targeted therapies developed against high grade serous ovarian tumors might also be effective in 
copy number high/serous-like EC (Iijima et al., 2017).   
The rapid advances in sequencing technology and high-throughput omics analysis sparked the 
second evolution of EC classification.  The concerted effort by the TCGA research network 
provided a comprehensive view of EC tumor biology, and strongly urged re-definition of EC 
classification, which will also impact clinical decisions on appropriate treatments based on the 








4.2.1 Transcriptional suppression of PKCα is associated with high-grade EC 
As a first step toward understanding the role of PKCα signaling in EC, we performed IHC 
analysis to profile its expression in a panel of 436 human endometrial tumors (330 endometrioid; 
106 non-endometrioid) in tissue microarray (TMA) format. While PKCα was detected in normal 
secretory and proliferative endometrium (as shown in the Figure 3-1) and was retained in some 
lesions, the enzyme was absent or markedly reduced in >60% of endometrioid ECs and >50% of 
all non-endometrioid tumors, with the proportion of PKCα deficient tumors ranging from 31% of 
MMMT to 70% of clear cell ECs (Figure 4-1, middle panel).   
The availability of frozen tissue for a subset of these ECs (24 endometrioid; 26 non-
endometrioid) allowed parallel quantification of PKCα mRNA by qRT-PCR. A significant 
correlation was noted between PKCα mRNA and protein levels in both tumor subtypes (Figure 4-
1, bottom table), indicating that downregulation of PKCα protein in human EC is controlled 
primarily at the level of mRNA expression.  Analysis of TCGA data confirmed that PKCα mRNA 
is markedly downregulated in human ECs (p=2.77e-9), and pointed to increased or decreased 
expression of several additional PKC family members in these tumors (Figure 4-2).  Like PKCα, 
PKCβ, ε, η, and θ, showed reduced mRNA expression in tumors relative to normal endometrial 
tissue, while levels of other PKC isozymes were elevated (e.g. PKCδ and ξ) or unchanged (e.g. 
PKCγ and ι) (Figure 4-2).  Note that PKCα is one of the most profoundly downregulated PKCs in 
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Fig. 4-1: PKCα expression in EC 
IHC analysis of a panel of ECs including endometrioid and non-endometrioid subtypes. Decreased 
PKCα expression was found in over 60% of endometrioid tumors and 50% of non-endometrioid 
subtypes. PKCα signal in the stroma (S) serves as a positive control for IHC staining in Grade 3 tumors. 
Scale bars, 50 µm. Spearman Rank correlation analysis of PKCα protein and mRNA in endometrial 







Fig. 4-2: Alterations in PKC isozyme mRNA expression in ECs s 
PKC isozyme mRNA levels in normal vs. tumor tissue based on analysis of TCGA database. Expression 
of PKCα, β, ε, η, and θ mRNA is reduced in endometrial tumors, while ECs have increased levels of 
PKCδ and ξ mRNA.  Levels of PKCγ and ι mRNA are comparable in the normal endometrium and 





To further examine the regulation of PKCα in EC, we determined its expression in a panel 
of 16 well-characterized human EC cell lines harboring a variety of genetic mutations characteristic 
of human endometrial tumors (Table 4-3) (Weigelt et al., 2013). Six of these cell lines were found 
to express markedly reduced levels of PKCα (Figures 4-3, top panel) and, consistent with findings 
in EC tissues, a significant correlation was observed between PKCα protein and mRNA levels 
across the panel of EC cell lines analyzed (Figure 4-3). To test for changes in mRNA transcription, 
RNA was pulse-labeled with 5-ethynyl uridine (EU) in two PKCαhigh (HEC-1-A; HEC-50Co) and 
two PKCαlow (RL-95; Ishikawa) EC cell lines. PKCαlow cells incorporated markedly lower amounts 
of EU into PKCα mRNA than PKCαhigh cells, with the extent of labeling closely paralleling the 
differences in overall levels of PKCα mRNA in the cells (Figure 4-4). Together, these data confirm 
that PKCα is downregulated in a significant fraction of human ECs and EC cell lines, and that 
PKCα deficiency primarily reflects a reduction in the transcription rate of the PKCα gene.  
Further analysis of the TMA data revealed a positive correlation between decreased levels 
of PKCα and disease aggressiveness in the endometrioid EC subtype, with 56% of grade 1, 61% of 
grade 2, and 76% of grade 3 lesions showing loss of the enzyme (Figure 4-5, top panel). A 
significant association was also observed between loss of PKCα and risk of high-grade 
endometrioid disease (OR = 3.4) (Figure 4-5, bottom panel). PKCα deficiency also correlated with 
disease severity when only PTEN negative endometrioid tumors were considered (OR = 2.8), 
indicating that PKCα loss is a risk factor for aggressiveness in human EC even in the presence of 
activating mutations in the PI3K/AKT pathway. Consistent with this conclusion, reverse phase 
protein array analysis of 244 EC cases (~80% endometrioid (Liang et al., 2012)) from The Cancer 
Proteome Atlas (TCPA) showed that PKCα expression trends with enhanced survival of EC 
patients (Figure 4-6).  In contrast, lower expression of PKCε or ι was associated with higher 
survival probability, consistent with the oncogenic properties of these isozymes in other systems 
(Bae et al., 2007; Benavides et al., 2011; Cacace et al., 1996; Eder et al., 2005; Murray et al., 2004; 




and that PKCα deficiency is associated with more aggressive disease, pointing to a potential tumor 
suppressive function of PKCα signaling in the endometrium. 
 
Cell line PTEN PIK3CA PIK3R1 
HEC-1-A WT G1049R   
HEC-1-B WT G1049R   
HEC-50 WT   E468InsGEYDRLYE 
KLE WT     
AN3CA R130fs  R557_K561>Q 
Ishikawa V317fs; V290fs   L570P 
RL95-2 M134I; R173H; N323fs R386G   
SNG-II K6fs   
SNG-M K164fs; V290fs   R88Q 
HEC-6 V85fs; V290fs R108H; C420fs   
HEC-59 Y46H; R233X; P246L; L265fs R38C K567E; S460fs 
HEC-108 K6fs; E288fs  A331V 
HEC-116 R55_L70>S; R173C R88Q   
HEC-151 I33del; Y76fs C420R   
HEC-251 S10N; E299X M1043I   
HEC-265 L318fs  H180fs; Q586fs 
 







Fig. 4-3: Correlation between PKCα mRNA and protein levels in EC cell lines 
Survey of PKCα protein and mRNA levels in a panel of EC cell lines using WB analysis and qRT-PCR 
respectively.  The mRNA quantification was normalized against 18s rRNA.  Vertical lines in the upper 
panel indicate rearrangement of lanes from a single membrane for clarity. Black bars: PKCαhigh. Grey 
bars: PKCαlow.  Spearman Rank correlation analysis of PKCα protein and mRNA in EC cell lines. 
Together, these data demonstrated a correlation between PKCα mRNA and protein levels. Data 














Fig. 4-4: Alterations in PKCα transcription in EC cells 
RNA was pulse-labeled with EU in PKCαhigh and PKCαlow EC cell lines.  Levels of labeled PKCα mRNA 
were measured by qRT-PCR. PKCαhigh EC cells incorporated significantly higher amounts of EU than 
PKCαlow cells, pointing to differential transcription rates in these cells.  Data represent results from 2-3 








Fig. 4-5: Loss of PKCα is associated with higher-grade EC 
The bar graph depicts PKCα expression status in endometrioid tumors of different grades.  Included in 
the table is the odds ratio of tumor grade based on PKCα expression.  Grade 1 and 2 tumors are 
considered low grade and Grade 3 tumors are high grade.  ** p < 0.01, *** p < 0.005 (2-sided Fisher’s 







Fig. 4-6: Survival probability of EC patients with high and low PKC expression 
Patients with higher levels of PKCα have higher survival probability.  Additionally, patients that have 
lower levels of PKCε or ι also have better survival prognosis. Results were obtained from analysis of 





4.2.2 PKCα expression is lost in mouse models of endometrial hyperplasia 
The expression of PKCα was also explored in endometrial lesions arising in mice with 
single allele knockin of Pten mutations seen in Cowden syndrome patients (frameshift/truncation 
PtenΔ4-5/+ mutation, and missense PtenG129E/+ or PtenC124R/+ mutations). These mice develop 
endometrial hyperplasia with high penetrance upon loss of expression of the wild-type (WT) Pten 
allele (Figure 4-7A) (Wang et al., 2010). Loss of the WT allele is reflected in absence of PTEN 
staining in PtenΔ4-5/+ lesions and a reduction in PTEN staining in PtenG129E/+ or PtenC124R/+ lesions 
(Figure 4-7B, C). As expected, loss of PTEN function was accompanied by a marked increase in 
AKT activity, as indicated by enhanced pAKTSer473 signal. Remarkably, these lesions uniformly 
lacked PKCα protein expression, with a perfect correspondence between PTEN deficiency, AKT 
activation, and PKCα loss. The sharp delineation between PKCα-expressing normal endometrial 
tissue and PKCα-deficient, pAKT positive lesions is clearly evident in these images (arrows and 
boxed areas, and Figure 4-7D). qRT-PCR analysis of normal and tumor tissue collected by laser 
capture microdissection demonstrated that loss of PKCα protein is associated with a  reduction in 
PKCα mRNA in these early lesions (Figure 4-8). PKCα loss was also observed in uterine tumors 
of mice with cre-mediated conditional endometrial deletion of Pten in the epithelium and stroma 
(Ptenpr-/-) or the epithelium alone (Ptenltf-/-), regulated by the progesterone receptor promoter or the 
lactoferrin promoter, respectively (Figure 4-9) (Daikoku et al., 2008; Daikoku et al., 2014). 
Interestingly, these lesions expressed increased levels of Id1, a gene known to be suppressed by 
PKCα signaling (Figure 4-10) (Hao et al., 2011). The loss of PKCα in multiple in vivo models of 









Fig. 4-7: Concurrent loss of PKCα and PTEN correlates with pAKT 






Immunohistochemical analysis of PTEN, pAKT, and PKCα expression in consecutive uterine sections 
from three strains of Pten-mutant mice - PtenΔ4-5/+ (A), PtenC124R/+ (B), and PtenG129E/+ (C).  Arrows 
indicate hyperplastic lesions lacking functional PTEN and PKCα expression, and strongly positive for 
pAKT.  In (B), inserted are magnified images of the boxed regions. (D) Image depicting the loss in PKC 
in the endometrial hyperplasia and its retention in the adjacent normal endometrium (NE) and 
endometrial hyperplasia (EH).  Scale bar, 50 µm. Images are representative of all hyperplastic lesions 














Fig. 4-8: Laser Microdissection of pAKT- and PKCα-labeled uterine epithelium for qRT-PCR 
analysis of PKCα mRNA levels. 
Immunoflourescence analysis of serial sections of frozen uterine tissue from 9 month PtenΔ4-5/+;Prkca+/+ 
mouse identifies normal epithelium (PKCαpos; pAKTneg, indicated by large arrows) and tumor lesions 
(PKCαneg; pAKTpos, indicated by small arrows).  The tissues were isolated by laser microdissection and  









Fig. 4-9: Loss of PKCα in uterine tumors of mice with cre-mediated conditional endometrial 
deletion of Pten. 
Immunohistochemical staining of PKCα in uterine tumors of mice with cre-mediated conditional 
endometrial deletion of Pten in the epithelium and stroma (Ptenpr-/-) or the epithelium alone (Ptenltf-/-), 
regulated by the progesterone receptor promoter or the lactoferrin promoter, respectively. Note the 









Fig. 4-10: Enhanced Id1 expression in endometrial hyperplasia correlates with loss of PKCα 
IHC analysis of PKCα and Id1 expression in endometrium from PtenG129E/+ and PtenC124R/+ mice. Note 
the strong nuclear staining for Id-1 in hyperplastic regions that lack PKCα (block arrows).  Arrowheads 
indicate normal endometrial glands with high PKCα and low Id1 expression.  IHC staining performed 





4.2.3 PKCα deficiency in EC is not a direct result of PTEN loss/ AKT activation and does 
not appear to drive loss of PTEN 
To determine if PKCα deficiency in EC is a direct consequence of PTEN loss of 
function/AKT activation, PTEN was stably knocked down in three PTEN WT, PKCαhigh human 
EC cell lines (Figure 4-11A). While the functional consequences of PTEN knockdown were 
confirmed by increased AKT phosphorylation, loss of PTEN did not affect the levels of PKCα (or 
of any other PKC isozyme, Figure 4-12). Similarly, inhibition of aberrant AKT activity in PTEN 
mutant/PKCαlow EC cell lines by restoration of PTEN expression (Figure 4-11B) or treatment with 
AKT or PI3K inhibitors (MK-2206 or LY294002, respectively) (Figure 4-11C), failed to affect 
PKCα levels. Taken together, these data indicate that PKCα deficiency is not a mere passenger 
event of PI3K/AKT hyperactivation, and suggest that loss of the enzyme may contribute directly 
to endometrial tumor development. To test the possibility that PKCα deficiency drives loss of 
PTEN in endometrial cells, we explored the effects of PKCα knockdown in PTEN WT, PKCαhigh 
EC cell lines. As shown in Figure 4-11D, PKCα knockdown failed to affect PTEN levels in these 






Fig. 4-11: PKCα deficiency in EC is not a direct result of PTEN loss or AKT activation and does 
not affect PTEN levels 
Western blot analysis of PKCα levels in EC cells with A) stable expression of PTEN shRNA, B)   
adenoviral restoration of PTEN, and C) treatment with AKT (MK-2206) or PI3K (LY294002) 
inhibitors. siRNA-mediated knockdown of PKCα, in turn, failed to affect PTEN levels (D). Data 















Fig. 4-12: PTEN knockdown did not alter the expression of other members of the PKC family 
Western blot analysis of the expression of indicated PKC isozymes in EC cells stably expressing shRNA 





4.2.4 PKCα inhibits endometrial tumorigenesis in vivo and in vitro 
To directly examine the effects of PKCα deficiency on endometrial tumor development, 
we generated Prkca+/+;PtenΔ4-5/+ and Prkca-/-;PtenΔ4-5/+ mice.  Uterine tissue was collected at 1, 3, 5, 
7, and 9 months and hyperplastic lesions were identified by pAKTSer473 staining and 
histopathological analysis (Wang et al., 2002) (Figure 4-13, top and middle panels). Quantification 
of the proportion of pAKT positive endometrium pointed to a statistically significant 3-fold 
increase in tumor burden in PKCα-/- animals at both 1 and 3 months compared with PKCα+/+ 
littermate controls (Figure 4-13, bottom graph). However, this difference diminished at later times. 
Blinded histological analysis of H&E stained sections by a pathologist (Dr. Yuri Sheinin) 
confirmed this conclusion (not shown). Since hyperplastic lesions arising in Prkca+/+;PtenΔ4-5/+ mice 
uniformly lacked PKCα, the increased tumor burden in Prcka-/-;PtenΔ4-5/+ mice indicates that PKCα 
loss is a rate limiting step in endometrial tumorigenesis in this model.  
To test the effects of PKCα on the transformed phenotype of human EC cells, PKCα 
expression was restored in PKCαlow cell lines by adenoviral transduction or silenced in PKCαhigh 
cells using siRNA, and anchorage-independent growth was assessed by colony formation in soft 
agarose. Exogenous PKCα markedly inhibited colony formation of PKCαlow EC cells, and colonies 
that did form were substantially smaller than those of LacZ-transduced cells (Figure 4-14). One 
infection unit/cell (moi) of PKCα adenovirus was sufficient to suppress anchorage-independent 
growth of these cells (Figure 4-15), pointing to a strong tumor suppressive activity of PKCα in 
human EC cells. The requirement for PKCα kinase activity in these effects was tested using kinase 
dead enzyme (KD-PKCα). Since KD-PKCα is unstable in cells (Pysz et al., 2009), 25 or 50 moi of 
KD-PKCα adenovirus were used to ensure levels of mutant protein expression comparable with 
WT PKCα at 1 moi. KD-PKCα failed to affect colony formation, even at the highest level of 
expression (Figure 4-15). The effects of PKCα knockdown were examined in PKCαhigh HEC-6 
cells, which grow less efficiently in soft agarose than other EC cells in our panel (Figure 4-16). 








Fig. 4-13: PKCα inhibits endometrial tumorigenesis in vivo 
Uterine tissue from PtenΔ4-5/+;Prkca+/+ and PtenΔ4-5/+;Prkca-/- transgenic mice aged for 1, 3, 5, 7, or 9 
months was analyzed for pAKT by immunohistochemistry, as shown in the representative images from 
1- and 3-month cohorts.  At least two sections were analyzed for each animal. Percent pAKT-positive 
uterine epithelium was measured as a proportion of the total epithelial compartment of the endometrium.  
* indicates p < 0.05 as determined by Wilcoxon Rank Sum test. Grey circles, PtenΔ4-5/+;Prkca+/+. Black 










Fig. 4-14: PKCα inhibits endometrial tumorigenesis in vitro 
PKCαlow endometrial cancer cell lines (Ishikawa, RL95-2, HEC-59, HEC-116, HEC-251) were infected 
with adenoviral vectors expressing either PKCα (α) or LacZ (Z) at a moi of 20 and analyzed for PKCα 
expression by immunoblotting; β-actin serves as a loading control (upper panel). Infected cells were 
plated in soft agarose and quantification of colony formation is presented relative to the LacZ control 









Fig. 4-15: PKCα kinase activity is required for its tumor suppressive function 
Assessment of anchorage independent growth of EC cells transduced with WT-PKCα or KD-PKCα.  
The higher mobility of KD-PKCα reflects the absence of priming phosphorylation of the enzyme 
(Carpenter et al., 2004). * p < 0.05, ** < 0.01, or ns (not significant) as calculated by 2-sided student’s 



















Fig. 4-16: siRNA-mediated knockdown of PKCα promotes tumorigenesis 
Assessment of anchorage independent growth of EC cells with siRNA-mediated knockdown of PKCα.  
* p < 0.05, ** < 0.01, or ns (not significant) as calculated by 2-sided student’s t test.  Error bars indicate 




4.2.5 PKCα activity inhibits PI3K/AKT signaling in EC cells via a PHLPP 1/2-independent, 
okadaic acid/ calyculin A-sensitive mechanism 
Since a majority of ECs are highly dependent on PI3K/AKT signaling (Weigelt et al., 
2013), we next examined the effects of PKCα activity on this pathway using a panel of human EC 
cell lines (Table 4-3). Treatment of PKCαhigh cells with the PKC agonist phorbol 12-myristate 13-
actetate (PMA) markedly decreased the phosphorylation of AKT as well as its downstream 
substrate, PRAS40 (Figure 4-17A).  Similarly, the short-chain diacylglycerol 1,2-
dioctanoylglycerol (DiC8), a more physiological PKC activator, also led to decreased pAKTSer473 
levels (Figures 4-17B). Consistent with the involvement of PKCα, PMA treatment did not affect 
AKT phosphorylation in PKCαlow cells (Figure 4-17C), an effect that was rescued by restoration of 
PKCα by adenoviral transduction (Figure 4-17D). Furthermore, PKCα inhibition with Gö6976, 
which targets the classical PKCs, blocked the ability of PMA to reduce pAKT in PKCαhigh cells 
(Figure 4-18). Finally, knockdown of PKCα in PKCαhigh cells with two different siRNAs prevented 
PMA-induced AKT hypophosphorylation (Figure 4-19). Since PKCα siRNA had no notable effect 
on the expression of other PKC isozymes (Figure 4-20), these data confirm a requisite role for 
PKCα in suppression of AKT activity in EC cells. Interestingly, PKCα knockdown also led to 
increased basal AKTSer473 phosphorylation, pointing to a tonic repressive effect of the enzyme on 
PI3K/AKT signaling in these cells (Figure 4-19, compare lane 1 with lanes 3-6 in both panels). Full 
activation of AKT requires phosphorylation at both S473 and T308 residues. Both of these residues 
are targeted by PKCα in EC cells, as indicated by (a) the parallel decrease in their phosphorylation 
following PMA treatment, a sustained effect that is supported by the continued activation of PKCα 
(Figure 4-21), and (b) the robust increase in phosphorylation at both sites induced by PKCα 










Fig. 4-17: PMA-induced activation of PKCα reduces AKT phosphorylation 
Western blot analysis of the phosphorylation status of AKT and its downstream target PRAS40 in 
PKCαhigh and PKCαlow EC cell lines treated with vehicle (C) or 100 nM PMA (P) for various times as 
indicated (A and C) or with 20 µg DiC8 for 6 hr (B). DiC8 was added in fresh medium every 30 min to 
account for its rapid metabolism in cells. (D) Adenoviral restoration of PKCα rescued the effect of PKC 
agonists in PKCαlow cells. Data are representative of at least 3 biological replications. β-actin or total 















Fig. 4-18: The cPKC inhibitor Gӧ6976 blocks PMA-induced AKT hypophosphorylation 
Treatment with Gӧ6976 (2.5 µM for 30 min prior to addition of PMA), which inhibits cPKCs, blocked 
the ability of PMA to reduce AKT phosphorylation. Data are representative of at least 3 biological 













Fig. 4-19: siRNA-mediated knockdown of PKCα prevents PMA-induced hypophosphorylation 
of AKT 
Western blot analysis of AKT phosphorylation in EC cells transfected with non-targeting (nt) or PKCα 
siRNAs (siRNA 1 or 2). Note the increase in steady-state levels of pAKT on PKCα knockdown.  Data 

















Fig. 4-20: Knockdown of PKCα does not affect the expression of other members of the PKC 
family in EC cells 
Western blot analysis of PKC isozymes in EC cells transfected with non-targeting (nt) siRNA or siRNA 







Fig. 4-21: The effects of PMA on PKCα and AKT activity are sustained in EC cells 
A) Western blot analysis of the effects of PMA on the phosphorylation of both Thr308 and Ser473 
residues of AKT in a time course PMA treatment. Despite the progressive downregulation of PKCα, 
AKT phosphorylation remains suppressed over the 6 h period. Immunofluorescence staining (B) and 
subcellular fractionation (C) confirmed the presence of active, membrane-associated PKCα after 6 h of 
PMA treatment. β-actin and AKT serve as loading controls. Arrows in (B) indicate membrane-
associated PKCαlpha.  In (C), Particulate indicates the membrane fraction. Data are representative of 3 













Fig. 4-22: Knockdown of PKCα enhances steady-state AKT activation 
PKCα was silenced in KLE, HEC-6 and SNG-M EC cells and effects on phosphorylation/activity of 
AKT were determined by Western blot analysis of pAKT473 and pAKT308 and of AKT substrates 
FOXO1 or PRAS40. Data are representative of 3 biological replicates.  Western blot analysis performed 





Coincident mutations in PTEN, PIK3CA and PIK3R1/2 are commonly seen in EC (Weigelt 
et al., 2013). To determine if PKCα signaling can inhibit AKT activity in EC cells with coexisting 
PI3K/AKT pathway alterations, PTEN was knocked down in PKCαhigh, PTEN WT HEC-1-A and 
HEC-50Co cells, which harbor activating mutations in the catalytic (PIK3CA) and regulatory 
(PIK3R1) subunits of PI3K, respectively (Weigelt et al., 2013). As expected, PTEN knockdown 
further increased PI3K/AKT signaling, as indicated by enhanced basal levels of phosphorylated 
AKT (at both Ser473 and Thr308) and its downstream effector PRAS40 (Figure 4-23). However, 
loss of PTEN did not prevent PMA-induced hypophosphorylation of these sites, indicating that 
PKCα signaling can suppress AKT even in the face of multiple activating events in the pathway.  
This finding is consistent with the ability of PKCα to inhibit AKT in SNG-M and HEC-6 cells, 
which naturally harbor coincident mutations in PTEN and PI3K subunits. These data, combined 
with evidence for downregulation of the PKCα target gene Id1 (Figure 4-24), a master regulator of 
tumor aggressiveness (Hao et al., 2011), further support a role for PKCα as a tumor suppressor in 
EC.  
Since PP2A and PHLPPs have been identified as the main phosphatases that reverse AKT 
phosphorylation (Gao et al., 2005; Van Kanegan et al., 2005), we investigated their involvement in 
PKCα-mediated AKT hypophosphorylation in EC cells. These phosphatases are expressed and 
functional in EC cells (Figure 4-25). A role for PHLPP1/2 in regulation of AKT in EC cells was 
confirmed by the ability of the PHLPP1/2 inhibitors NCS45586 and NCS117079 (Sierecki et al., 
2010) to increase basal AKT phosphorylation (Figure 4-26A). Enhanced AKT phosphorylation was 
similarly observed following inhibition of PP1 and PP2A with calyculin A, or PP2A alone with 
okadaic acid (Figure 4-26B). PMA was still able to suppress pAKT in the presence of the 
PHLPP1/2 inhibitors, indicating that the effects of PKCα are independent of PHLPP1/2 (Figure 4-
26A). In contrast, both calyculin A and okadaic acid blocked PMA-induced AKT 
hypophosphorylation, pointing to a PP2A-dependent mechanism (Figure 4-26B). More 




immunoprecipitation phosphatase assays that was abolished by siRNA-mediated PKCα 
knockdown (Figure 4-27). The involvement of PP2A was further explored by siRNA-mediated 
knockdown of the catalytic subunit of the phosphatase (PP2AC). PP2AC knockdown enhanced 
basal AKT phosphorylation and inhibited the ability of PMA/PKCα to reduce pAKT levels (Figure 
4-28), although the effect was less pronounced than seen with pharmacological inhibition, likely 
reflecting the incomplete knockdown of PP2AC achieved with siRNA. Together, these results 
indicate that PKCα inhibits PI3K/AKT signaling through a PHLPP-independent, PP2A-dependent 
mechanism.  It should be noted that, although PP2A may preferentially dephosphorylate AKT on 
the T308 site, it can also dephosphorylate AKT on the S473 site, as described in numerous reports 















Fig. 4-23: PKCα signaling can inhibit AKT activity in EC cells with hyperactivation of the 
PI3K/AKT pathway due to coexisting alterations in more than one pathway component 
EC cells harboring mutations in the catalytic (PIK3CA, HEC-1-A) or regulatory (PIK3R1, HEC50Co) 
subunits of PI3K and stably expressing non-targeting (nt) or two different PTEN (PTEN1+2) shRNA 
were treated with EtOH (C) or PMA (P) and subjected to Western blot analysis for the indicated proteins. 
Data are representative of 3 biological replicates.  β-actin serves as a loading control.  Western blot 



















Fig. 4-24: PKCα downregulates Id1 in EC cells 
Western blot analysis showing downregulation of Id1, a growth/ tumor promoter, following treatment 
with ethanol (C) or PMA (P) in PKCαhigh but not PKCαlow cells. Data are representative of 3 biological 













Fig. 4-25: Expression of PHLPPs and PP2A in EC cells 
Assessment of the expression of two families of phosphatases that are known to modulate AKT 
phosphorylation, PHLPPs and PP2AC (the catalytic subunit of PP2A), in EC cells by qTR-PCR or 
Western blot analysis. The mRNA quantification was normalized against 18s rRNA. β-actin serves as a 











Fig. 4-26: PP2A but not PHLPP inhibitors blocked PMA-mediated hypophosphorylation of 
AKT 
EC cells were pretreated with A) 50 mM PHLPP inhibitor NSC 45586 or 117079 (15 min), or B) 10 nM 
calyculin A (CA) (15 min) or 2.5 µM okadaic acid (OA) (30 min) prior to treatment with vehicle (C) or 
100 nM PMA (P) for 6 hr. Western blot analysis demonstrated the effects of phosphatase inhibition on 
AKT phosphorylation.  β-actin serves as a loading control and data are representative of 3 biological 










Fig. 4-27: PMA induces PP2A activity in EC cells 
Measurement of PP2A activity using a malachite green based assay in PKCα knockdown EC cells 
(achieved  by a combination of 2 siRNAs targeting PKCα) treated with vehicle (C) or 100 nM PMA (P) 
for 10 min.  Non-targeting siRNA was used as a control. Results are representative of multiple biological 
replicates and error bars indicated mean ± SEM.  *** p < 0.005, n.s. not significant.  Experiment 













Fig. 4-28: PP2A knockdown reduces the effects of PKCα signaling on AKT 
phosphorylation/activity in EC cells 
Immunoblot analysis of AKT phosphorylation in EC cells transfected with non-targeting (nt) siRNA or 
a combination of two siRNAs targeting the catalytic subunit of PP2A (siPP2AC).  β-actin serves as a 





4.2.6 PKCα loss is associated with increased AKT activity in endometrial lesions in vivo 
While universal loss of PKCα was seen in uterine lesions from PtenΔ4-5/+, PtenG129E/+ and 
PtenC124R/+ mouse models, PKCα-retaining areas were detected in lesions arising in the Ptenpr-/- 
mouse. This allowed comparison of AKT activity in PKCα-retaining and PKCα-deficient cells in 
situ. pAKT staining was stratified as none-low, medium or high and association between pAKT 
staining intensity and the presence or absence of PKCα signal was quantified in serial sections. 
PKCα expression was associated with significant differences in AKT staining intensity (p < 
0.0001), with PKCα negative areas predominantly exhibiting high intensity pAKT staining, and 
PKCα positive areas largely coinciding with low intensity pAKT staining (Figure 4-29, compare 
areas indicated with block and open arrows). This correspondence supports a role for PKCα in 




Fig. 4-29: PKCα loss is associated with increased pAKT in endometrial lesions in vivo 
Serial sections of uterine tissue from Ptenpr-/- mice immunostained for PKCα or pAKT(Ser473). 
Quantification of different intensities of pAKT staining (none-low, medium, or high) in PKCα positive 
and negative areas. Data are representative of 3 independent experiments. Error bars indicate SEM.  




4.2.7 Inhibition of AKT activity is an important component of the PKCα tumor-suppressive 
axis in EC cells 
The role of inhibition of PI3K/AKT signaling in the tumor suppressive effects of PKCα in 
EC cells was tested using constitutively active AKT: myristoylated AKT1 (myr-AKT), AKT-DD 
(T308D, S473D), and AKT-E17K (an active mutant identified in EC (Mancini et al., 2016; Rudolph 
et al., 2016)). These constructs were introduced into PKCαlow HEC-59, RL95-2, HEC-116, 
Ishikawa, or HEC-251 EC cells by adenoviral or retroviral transduction and the ability of 
exogenous PKCα to inhibit anchorage-independent growth was assessed. The amount of 
constitutively active AKT introduced into EC cells was titrated to produce a 2- to 5-fold increase 
in basal pAKT levels, as determined by quantification of immunoblots.  In the context of strong 
endogenous AKT activation in EC cells, this increase in AKT activity had only slight effects on 
anchorage-independent growth on its own, with myr-AKT, AKT-DD, and AKT-E17K causing a 
modest increase in overall colony size (Figures 4-30, 4-31) and a small, non-statistically significant 
increase in colony number in some cell lines. In contrast, constitutively active AKT had a marked 
effect in cells transduced with PKCα, restoring both colony number and overall colony size, albeit 
to different extents in different cell lines (Figures 4-30, 4-31). While the inability of constitutive to 
fully reverse the effects of PKCα suggests that other factors may be involved, these data point to 
inhibition of PI3K/AKT signaling as a key mechanism mediating the tumor suppressive actions of 









Fig. 4-30: Inhibition of AKT activity is a component of the PKCα tumor-suppressive axis in EC 
cells 
Colony formation in soft agarose of EC cells transduced with adenovirus expressing LacZ (moi = 50), 
myr-AKT1 (moi = 50), and/or PKCα (moi = 1) as indicated. * p < 0.05; **p < 0.01 (2-sided student’s t 
test). Error bars indicate SEM from 3 independent experiments.  Quantification was performed with 






Fig. 4-31: Mutant AKT partially rescues PKCα-mediated growth suppression 
Colony formation in soft agarose of EC cells stably expressing mutant AKT generated by transduction 
with AKT-DD or E17K or empty retroviral vectors.  Mutant AKT-expressing or control cells were  
subsequently transduced with Ad-LacZ or Ad-PKCα as indicated. * p < 0.05; **p < 0.01; ***p < 0.005 
(2-sided student’s t test). Error bars indicate SEM from 3 independent experiments.  Quantification was 






The current study provides the first evidence for a tumor suppressive role of PKCα 
signaling in PI3K/AKT-driven EC, via a mechanism that involves PP2A-mediated inactivation of 
AKT. The role of PKCα in tumorigenesis appears to be multifaceted. While the enzyme has been 
linked to tumor promotion in some systems, our studies add to a growing list of tumor types (e.g., 
colon and lung) in which PKCα signaling has tumor suppressive effects.  
Our IHC and qRT-PCR analysis of human ECs revealed loss of PKCα protein and mRNA 
in a majority of cases. Notably, more than half of grade 1 ECs showed deficiency of the enzyme, 
indicating that PKCα suppression can occur early during human endometrial tumorigenesis. This 
notion is supported by our analysis of mouse models of PI3K/AKT-driven endometrial neoplasia, 
which demonstrated loss of PKCα expression in pre-malignant hyperplasia regardless of the nature 
of PTEN dysregulation. Additional supportive evidence is provided by previous transcriptome 
analysis of early Type I ECs, which demonstrated a 3-fold downregulation of PKCα mRNA in 
tumors relative to normal endometrium (Risinger et al., 2013; Saghir et al., 2010), and by IHC 
analysis of a limited set of grade 1 ECs, which revealed regions of low or undetectable PKCα 
protein in a subset of lesions (Haughian and Bradford, 2009).  
 Although loss of PKCα mRNA and protein has been noted in other tumor types (e.g., colon 
cancer (Verstovsek et al., 1998), non-small cell lung cancer (Hill et al., 2014), basal cell carcinoma 
(Neill et al., 2003), T-cell Acute Lymphoblastic Leukemia (T-ALL) (Milani et al., 2014)), the 
mechanisms underlying PKCα deficiency have yet to be defined. Our qRT-PCR and IHC analysis 
argues that decreased mRNA expression is the major mechanism involved in disabling PKCα 
functions in the endometrium, although TCGA data indicate that PKCα may be inactivated by 
mutation in up to 5 % of ECs (Antal et al., 2015). We also show, for the first time, that PKCα loss 
can be mediated by transcriptional repression of the PKCα gene. Initial mechanistic analysis 
excluded methylation of the PKCα promoter in EC (data not shown) or differential promoter 




region of PKCα found differential methylation of the CpG shores, defined as 2kb up- or down-
stream of the CpG island, with hypermethylation of the right CpG shores in cells with reduced 
PKCα mRNA (Figure 4-32A).  In line with this new finding, we have observed increased PKCα 
expression when EC cells are treated with decitabine, a DNA hypomethylating agent (Figure 4-














































Fig. 4-32: Methylation of PKCα CpG shores in cancer cells 
A) Methylation analysis showed hypermethylation in the right CpG shore in PKCαlow cell lines, as 
indicated in red, whereas the same region is generally hypomethylated in cell lines with high PKCα 
expression. B) Increased PKCα levels in PKCαlow cells (Ishikawa) treated with decitabine.  Methylation 





The precise correspondence between PKCα loss, PTEN deficiency, and AKT activation in 
murine endometrial lesions suggested that transcriptional suppression of PKCα could be a direct 
result of hyperactivation of the PI3K/AKT pathway, at least in some ECs. However, modulation of 
PTEN expression or AKT activity in human EC cells excluded this possibility, indicating that 
PKCα downregulation is not merely a passenger effect of aberrant PI3K/AKT signaling but, 
instead, is an alteration that is selected for because of specific contributions to endometrial tumor 
development. The possibility that PKCα deficiency drives the loss of PTEN was also tested and 
excluded in PKCα knockdown experiments.  Anchorage-independent colony formation assays 
provided direct evidence for a tumor suppressive function of PKCα in human endometrial cells: 
restoration of PKCα expression/activity profoundly inhibited colony formation of human EC cells 
in soft agarose, while PKCα knockdown enhanced the transformed properties of EC cells that 
retained expression of the enzyme. The importance of early loss of PKCα was highlighted by the 
marked acceleration in uterine hyperplastic transformation observed in PKCα deficient PtenΔ4-5/+ 
mice, a finding that pointed to abrogation of PKCα signaling as a rate limiting step for tumor 
initiation in the endometrium. In advanced cases of human EC, the proportion of PKCα negative 
tumors increased to >75%, suggesting that PKCα deficiency defines a subset of ECs with high risk 
of progression, a notion that is consistent with TCPA data pointing to an association between 
reduced PKCα expression and decreased survival of EC patients. The finding that PKCα deficiency 
is associated with a 3-fold increase in risk of high grade disease is consistent with previous reports 
in other tumor types. Genetic deletion of PKCα led to increased tumor burden, adenoma-to-
carcinoma progression, and reduced survival in the APCMin/+ mouse model of intestinal neoplasia 
(Oster and Leitges, 2006) and in KRas-mediated models of lung tumorigenesis (Hill et al., 2014). 
Low PKCα expression identified a new subgroup of childhood T-ALL with an extremely poor 
outcome (Milani et al., 2014) and appears to enhance the tumorigenic potential of Gli1 in basal cell 




PKCα loss in these tumor types. 
A majority of ECs harbor coexisting alterations in two or more PI3K/AKT pathway 
components, with additive effects on AKT activation that are crucial for EC development (Chen et 
al., 2006; Oda et al., 2005; Weigelt et al., 2013). Remarkably, knockdown of PKCα in cells with 
genetic hyperactivation of the PI3K/AKT pathway further enhanced the activity of AKT, 
highlighting the ability of PKCα deficiency to contribute to the strength of PI3K/AKT signaling in 
EC cells. The demonstration that PKCα negative uterine regions in Ptenpr-/- mice are associated 
with significantly higher levels of pAKT than PKCα-retaining regions indicates that PKCα loss 
also contributes to PI3K/AKT hyperactivation during endometrial tumorigenesis in vivo. PKCα 
activity may also restrain AKT in the normal endometrium, since increased expression and 
membrane association of the enzyme coincide with the reported downregulation of AKT activity 
during the proestrus-to-estrus transition in rats (Dery et al., 2003). These findings, together with 
the demonstration that agonist-induced PKCα activation suppresses AKT in EC cells, identify 
PKCα as a potent inhibitor of PI3K/AKT signaling in the endometrium, capable of disabling the 
AKT oncoprotein even in the context of multiple activating mutations in upstream signaling 
intermediates (e.g., PTEN and PIK3CA in HEC-251 cells; PTEN, PIK3CA and KRAS in SNG-M 
cells).  
Inactivation of AKT appears to be a key component of the tumor suppressive actions of 
PKCα in endometrial cells, since constitutively active AKT [myr-AKT, AKTDD (T308D, 
S473D), and AKT(E17K)] markedly diminished the inhibitory effects of PKCα on EC cell colony 
formation in soft agar. Together, our findings support the idea that disruption of PKCα signaling 
may be critical for achieving the robust PI3K/AKT pathway activation that is required to drive EC 
development and progression (Figure 4-8D). To demonstrate the potential clinical impact of PKCα 
loss in EC, future experiments will investigate whether PKCα deficiency will enhance the 
sensitivity of EC tumors to AKT inhibitors or other targeted agents.  The efficacy of agents that are 




(Manning and Toker, 2017).  As cells with PIK3CA mutations exhibited increased sensitivity to 
agents targeting the PI3K/AKT pathway (e.g. PI3K inhibitors, AKT inhibitors, and mTOR 
inhibitors), the loss of PKCα-mediated negative regulation of AKT activation may similarly 
enhance the sensitivity of these cells to PI3K/AKT pathway inhibition.  Thus, PKCα deficiency 
may provide an additional layer of patient stratification, indicative of therapeutic responsiveness to 
PI3K/AKT targeting agents in clinical trials.   
Crosstalk between PKCα and the PI3K/AKT pathway has been noted in other systems. 
PKCα can inactivate upstream modulators of PI3K such as growth factor receptors and scaffolding 
proteins (Koese et al., 2013; Oriente et al., 2005) and can dampen PI3K activity directly (Hoshino 
et al., 2012; Sipeki et al., 2006). Here, we demonstrate that PKCα activates the serine/threonine 
phosphatase PP2A in EC cells and inactivates AKT via a PP2A-dependent mechanism. PKCα-
induced AKT inactivation may involve direct effects of PP2A on activating phosphorylation at 
T308 and S473  (Manning and Toker, 2017), although potential effects on upstream regulators of 
AKT activity remain to be formally excluded. A role of PP2A in the antitumor effects of PKCα in 
the endometrium is consistent with known functions of the phosphatase as a bona fide tumor 
suppressor, with key activities in maintenance of cellular homeostasis (Perrotti and Neviani, 2013). 
Future studies will explore the specific PP2A trimeric holoenzyme complex(es) responsible for 
mediating PKCα-induced inactivation of AKT. 
Together, our findings highlight disruption of a PKCα→PP2A⟞AKT signaling module as 
a key step in the development of EC, ensuring robust, unopposed AKT activation and promoting 
transformation of endometrial cells (Figure 4-8D). These studies provide a foundation for exploring 
the prognostic value of PKCα expression in EC and the potential of harnessing the PKCα→PP2A 


















PKCα is ubiquitously expressed in many tissues and regulates the physiology of a cell by 
relaying signals to a wide molecular network. Understanding the functional role of PKCα in 
maintenance of tissue homeostasis and its involvement in the carcinogenesis process in different 
systems has been a long-standing interest of our laboratory. Past work from our lab, focusing on 
the intestinal system, found PKCα signaling to be growth inhibitory and tumor suppressive. In this 
study, we examined the expression and activation of PKCα in the normal endometrium. Previous 
studies have shown that PKCα mediates growth, invasion and survival response to DNA damage 
in endometrial cancer cells (Haughian and Bradford, 2009; Haughian et al., 2006; Haughian et al., 
2009). However, its impact on oncogenic PI3K signaling, the driving force of the majority of 
endometrial tumors, remained elusive.  Therefore, as part of our effort to understand the functional 
role of PKCα in cancer, we investigated how signaling mediated by this kinase impacts endometrial 
carcinogenesis driven by hyperactive PI3K/AKT signaling.  
 
5.1 PKCα as a potential anti-proliferative regulator in the endometrium 
The endometrium undergoes cyclic remodeling, in which the stroma and epithelium 
proliferate and regress/shed in response to hormonal fluctuation.  Aberrations in this tightly 
regulated process disrupt the homeostasis of the endometrium and, eventually, results in 
uncontrolled growth and tumor formation.  PKCα is among the several isozymes that have been 
reported to be expressed in the uterus (Jofre et al., 2013; Kim et al., 1999). However, little is known 
of its specific functions in this tissue.  Unlike other isozymes, which have been shown to induce 
uterine contraction, activation of PKCα was observed in preterm uterus when the myometrium is 
quiescent and PKCα has been shown to inhibit myometrium contractility by regulating the 
expression of prostaglandin and urocortin, in order to maintain pregnancy (Bamberger et al., 2007; 
Jofre et al., 2013; Wouters et al., 2014). In the epithelium, PKC has been implicated in promoting 




PKC activation was also shown to coincide with the switch to the secretory phase that is 
predominantly regulated by P4 (Chen et al., 2013).  Based on these studies, it is not clear how PKCα 
is involved is regulating E2/P4 responses and epithelial remodeling in the endometrium or which 
PKC isozyme(s) is the major regulator of these events.  
Current understanding indicates that PKC functions are dependent on cellular context and 
that individual isozymes can have overlapping or opposing actions (Garg et al., 2014).  To decipher 
the role of PKCα in cancer, it is crucial to first understand its involvement in the normal physiology 
in the tissue of interest.  In our study, we observed PKCα expression in the stromal and epithelial 
compartments of the uterus, though expression was higher in the stroma in both human and murine 
uterine tissues (Figure 3-1).  In the human endometrium, PKCα activation, as indicated by its 
membrane association, was observed in the secretory phase.  In mouse, there was regional 
membrane-associated PKCα in the epithelium in proestrus, which became more prevalent in the 
subsequent estrous phase (Figure 3-3). This increase in PKCα activation negatively correlated with 
proliferation, as shown by the reduced Ki67 signal in estrus compared with other phases (Figure 3-
2, 3-4). Interestingly, this timing coincided with a transition from massive proliferation to a state 
primed for embryo implantation. Together, our data linked the expression and activation of PKCα 
to hormone-driven cycling of the tissue, suggesting that PKCα signaling may trigger an anti-
proliferative program that is involved in endometrial remodeling, implantation, and maintenance 
of pregnancy. Our IHC analysis also revealed a regional staining pattern for PKCα, suggesting that 
the endometrial epithelium might be heterogeneous, exhibiting differential responses or temporal 
discrepancies in their response to hormone fluctuation (Figure 3-3, 3-4).  To further explore the 
role of PKCα in the endometrium, mechanistic studies focusing on how E2 and P4 influence PKCα 
signaling (and other PKCs) may reveal the role of this kinase in regulating endometrium 
regeneration, thus painting a more complete picture of how these enzymes function cooperatively 




5.2 PKCα suppresses endometrial carcinogenesis 
The question of whether PKCs promote or suppress cancer has been a subject of long-
lasting debate in the field. Historically, PKCs are mostly recognized for their association with the 
carcinogenic phorbol esters, and their ability to promote tumor formation that encouraged the 
development of PKC inhibitors as cancer therapeutics of which had disappointing results in clinic 
trials (Garg et al., 2014; Mochly-Rosen et al., 2012). Subsequent studies revealed that these 
enzymes possess tumor suppressive ability, an observation that is bolstered by the recent survey of 
cancer-associated PKC mutations, which found these mutations to cause loss of kinase function 
(Antal et al., 2015; Hill et al., 2014; Newton and Brognard, 2017; Oster and Leitges, 2006). 
Previous work from our laboratory has shown that PKCα inhibits intestinal tumor formation 
through downregulation of cyclin D1 and Id1 and increased expression of p21 (Frey et al., 2000; 
Hao et al., 2011; Pysz et al., 2009). In this study, we demonstrated that PKCα acts as a tumor 
suppressor in the endometrium by negatively regulating AKT activation. Together, our work 
further supports the current paradigm shift in the function of PKCs in cancer. 
Our analysis and TCGA data both point to reduced PKCα expression in ECs due to 
alterations in its gene transcription (Figure 4-1 – 4-3). Although loss of PKCα protein and mRNA 
has been reported in other cancer types, we provided the first evidence that transcriptional 
repression is responsible for its absence in cancer (Figure 4-4). Furthermore, loss of PKCα 
correlated with poorer prognosis as it was associated with more aggressive disease and reduced 
patient survival probability (Figure 4-5, 4-6).  In multiple mouse EC models carrying mutant PTEN 
or generated by allelic PTEN deletion, PKCα loss was uniformly observed in lesions arising in the 
endometrium (Figure 4-7, 4-9). However, it is unlikely that loss of PTEN led directly to reduced 
PKCα transcription as we did not observe changes in PKCα levels in EC cells with PTEN 
knockdown or overexpression, or with inhibition of PI3K/AKT signaling (Figure 4-11). 
Conversely, manipulation of PKCα expression did not affect PTEN levels, indicating that PKCα 




specific mechanisms that cause the reduction in PKCα transcription remain elusive.  Although our 
initial analysis has excluded methylation at the PKCα promoter as a means of regulating its 
expression (data not shown), future experiments will explore other possible mechanisms such as 
differential binding of regulatory elements (e.g., transcription factors, co-activators, or co-
repressors) or methylation of other regulatory regions (e.g., CpG shores).  
Our study finds that PKCα acts as a tumor suppressor and the reduced expression of this 
kinase diminishes protection against endometrial transformation.  In mice carrying loss-of-function 
Pten mutations, concurrent PKCα deficiency increased tumor burden by 3-fold at 1- and 3-months, 
although the differences diminished at later times of disease progression (Figure 4-13).  This 
suggests that PKCα acts as a “gatekeeper” and loss of this kinase is likely a rate-limiting event in 
endometrial tumorigenesis.  Indeed, re-introduction of PKCα markedly inhibits EC cell growth 
under anchorage-independent conditions (Figure 4-14 ), while PKCα knockdown has the opposite 
effect.  Interestingly, kinase-dead PKCα had no effects, demonstrating that the tumor suppressive 
effects of PKCα in EC are indeed due to its kinase function (Figure 4-15).  Data from this study 
further demonstrated that PKCα activation stimulates PP2A activity and leads to 
hypophosphorylation of AKT and its downstream targets PRAS40 and FOXO1 (Figure. 4-17, 4-
22).  This negative regulation of AKT can be abolished by inhibitors of PKCα or PP2A or by 
PKCα/PP2A RNA interference (Figure 4-18, 4-22, 4-26, 4-28). However, the co-expression of 
constitutively active AKT (myr-AKT or AKT-DD) or hyperactive AKT found in breast and 
endometrial tumors (AKT-E17K) only partially rescues the growth inhibitory/tumor suppressive 
effects of PKCα in EC cells (Figure 4-30, 4-31)), suggesting that PKC can suppress EC 
tumorigenesis through other mechanisms in addition to negative regulation of AKT activity. PKCα 
has been shown to downregulate the expression of Id1 family proteins (Figure 4-10, 4-24), which 
promote cell cycle progression, tumor cell growth and migration, through ERK-dependent 
signaling (Hao et al., 2011). Our analysis also demonstrated an inverse correlation between PKCα 




of EC.  However, in-depth mechanistic studies are needed to confirm this hypothesis and also to 
explore other pathways by which PKCα functions as a tumor suppressor in EC.   
The present study also showed that PP2A but not PHLPP is involved in PKCα-mediated 
hypophosphorylation of AKT (Figure 4-26).  In contrast to previous studies showing a residue- 
specific dephosphorylation of AKT by PP2A and PHLPP on threonine 308 and serine 473, 
respectively, PP2A was responsible for PKCα-mediated dephosphorylation of AKT at both of these 
sites (Figure 4-26, 4-28).  The specificity of the PP2A holoenzyme is determined by the B, or 
regulatory, subunits in the complex (Chen et al., 2013; Eichhorn et al., 2009; Sents et al., 2013).  
Although our data demonstrated that PKCα activation induces PP2A activity (Figure 4-27), we do 
not know the specific makeup of the holoenzyme involved in the effect.  To determine how PKCα 
mediates PP2A activation, future studies will examine the formation of PP2A holoenzymes 
following PKCα activation, and how the individual holoenzyme(s) accounts for the 
dephosphorylation of AKT.  
In comparison with other more widely studied cancer types, EC patients have a relatively 
optimistic prognosis as 1) many EC cases are symptomatic and detected at an early stage, and 2) 
the disease is usually contained in the uterus at the time of diagnosis, thus curative through 
hysterectomy (Engelsen et al., 2009). However, approximately 20% of EC patients experience 
recurrent disease that is resistant to radiation or currently available chemotherapeutics.  Recurrent 
disease is usually aggressive and accounts for a majority of EC-related mortality (Engelsen et al., 
2009).  Molecular analysis of EC tumors has found most ECs are driven by hyperactivation of 
PI3K/AKT signaling, most commonly due to loss of PTEN, activating mutations in PI3K or AKT, 
or the combination of multiple genetic aberrations in this pathway (Dedes et al., 2011). As PTEN 
loss and AKT hyperactivation are prevalent in many cancers, small molecule inhibitors of AKT 
have received much attention as an emerging class of targeted therapeutic against  ECs (Manning 
and Toker, 2017).  However, results from clinical trials thus far have been disappointing as the 




Saura et al., 2017).  Apart from developing new agents that are less toxic, a system that can stratify 
patients who are more sensitive to AKT inhibition, and thus more likely to respond at a lower 
dosage, would also be beneficial to the clinical outcome of these trials (Manning and Toker, 2017).  
From our study of the role of PKCα in endometrial tumorigenesis, we have shown that PKCα acts 
as a negative regulator of AKT activation (Figure 4-17).  While PTEN loss and oncogenic PI3K 
mutation indeed result in elevated phosphorylated AKT, PKCα signaling can still exert negative 
pressure on the kinase (Figure 4-23).  Therefore, concurrent loss of PKCα leads to robust, 
unopposed AKT activation and more aggressive EC phenotypes (as depicted in our model in Figure 
5-1). Our data strongly supports a PKCα-PP2A-mediated mechanism  that acts directly on AKT; 
however, the possibility that crosstalk exists between PKCα-PP2A and other components of PI3K 
signaling (e.g. upstream receptor tyrosine kinases or PTEN) should also be considered. 
Additionally, future experiments examining whether PKCα status affects the sensitivity of EC cells 
to currently available AKT inhibitors could improve the clinical benefits of these inhibitors.  Based 
on our findings, PKCα is able to suppress AKT phosphorylation regardless of the status of PTEN 
or PI3K, suggesting it is a potent inhibitor of AKT activation.  It is likely that EC cells that have 
PKCα and, by extension, retain part of the regulation of AKT activation, could be more sensitive 
to small molecule AKT inhibitors, allowing them to inhibit tumor growth with limited, better 















Fig. 5-1: Schematic representation of PI3K/PTEN and PKCα as regulators of AKT activation 
endometrial cancer. 
The model depicts that in addition to the well-known PI3K/PTEN signaling pathway, PKCα-PP2A 
mediates another regulatory axis that maintains balanced activation of AKT in EC cells.  Mutations of 
PI3K and PTEN have been shown to result in hyperactivation of AKT.  However, our study 
demonstrated that disruption of the PKCα-PP2A regulatory axis ensures robust, unopposed AKT 




Appendix A: Estrogenic stimulation of PKCα expression 
Rationale:  
Based on our examination of normal mouse endometrium under estrous cycle, PKCα 
expression increased during later proestrous and was robustly expressed during estrous, 
coinciding with the peak of estrogen level.   
Results/Discussion: 
To yesy whether estrogenic stimulation induces PKCα expression, Ishikawa, an EC cell 
line that retained ER expression, was treated with estradiol (E2).  Both PKCα mRNA and protein 
were examined at 3 and 24 hours following E2 stimulation.  Cells were maintained in charcoal-
cleared culture medium and experiments were performed with assistance from the laboratory of 
Dr. Vimla Band. 
Results from our analysis showed that E2 robustly increased PKCα mRNA expression 
after 24 hours but no change in protein level was observed.  The induction of cyclin D1, a well-
known E2-responsive target, following E2 treatment demonstrated that the cells were indeed 
responsive to the stimulation.  Our finding is consistent with previous report showing that 
estrogenic stimulation induced PKCα expression in primary endometrial cancer cells (Wu et al., 
2005). However, failure to translate PKCα mRNA to protein indicated possible translational 
defect in Ishikawa, a human EC cell line, which might account for the decreased PKCα 











Fig. A.1: PKCα expression following E2 stimulation of EC cells.   
The graph showed PKCα mRNA levels at 3 and 24 hours after stimulation with E2 or vehicle control 
(Ethanol) measure by qRT-PCR analysis relative to 18sRNA.  Shown in bottom panel is Western Blot 
analysis of PKCα protein levels following E2 stimulation.  Cyclin D1, a well-known E2 target gene, was 




Appendix B: Regulation of PKCα Expression 
Rationale:  
Parallel analysis of PKCα mRNA and protein from human endometrial tumors, mouse 
endometrial lesions, and endometrial cancer cell lines revealed that reduced PKCα mRNA 
correlated with lower protein levels.  We explored possible mechanisms that might be involved in 
regulating PKCα expression in EC cells including differential promoter activity, mRNA stability, 
and protein stability. 
Results/Discussion: 
To explore mechanism that might be involved in regulating PKCα expression in EC cells, 
we assessed promoter activity, mRNA stability, and protein stability of PKCα using methods 
described below:  
1) PKCα promoter activity assay  
Plasmids encoding firefly luciferase regulated by PKCα promoters (-1571/+277, -
1571/+77, -331/+77, -279/+77, -260/+77) were transfected into EC cells using Fugene 6 or 
XtremeGENE 9 as per manufacturer’s protocol.  Plasmids encoding renilla luciferase regulated 
by thymidine kinase promoter was transfected in all samples and served as normalization for 
transfection efficiency PKCα promoters within a cell line.  Promoter activity was expressed at 
relative to the minimal PKCα promoter (-260/+77) 
2) mRNA stability  
To examine PKCα mRNA stability, EC cells were treated with α-amanitin, a selective 
RNA polymerase II and III inhibitor, or vehicle control (ethanol) for 12 hours.  PKCα mRNA 
levels were assessed by qRT-PCR and normalized to the vehicle control.  
3) Protein stability 




with cycloheximide, which inhibits protein synthesis or the vehicle control (DMSO).  PKCα 
protein levels were assessed by Western Blotting analysis.  
 Results from these experiments did not present a general mechanism that regulates the 
broad alteration of PKCα expression in these cell lines.  The promoter analysis showed possible 
repressive element binding to the PKCα promoters in 4 out of the 7 EC cell lines (SK-UT-1B, 
Ishikawa, AN3CA, KLE) examined, as demonstrated by the decreasing luciferase activity with 
increase PKCα promoter length (Figure B.1.). In three EC cell lines (SN3CA, Ishikawa, SK-UT-
1B), there was reduced PKCα mRNA when mRNA synthesis was inhibited by α-amanitin (Figure 
B.2.).  Interestingly, despite the long half-life of PKCα protein, it was more readily degraded in 
AN3CA than other PKCαlow cells (e.g. SK-UT-1B) (Figure B.3.).  Together, these results 
demonstrated that multiple mechanisms may be involved in the regulating PKCα expression in 
EC cells.  However, the mechanisms explored here did not explain the broad PKCα loss in EC 












Fig. B.1: Figure PKCα promoter activity in human EC cells.  
Plasmids of PKCα promoter-regulated firefly luciferase plasmids were used to measure promoter 
activity. All expressions were represented as relative to the minimal promoter (-260/+77) of each cell 
lines and normalized to renilla luciferase expression to account for transfection efficiency.  Error bars 














Fig. B.2: PKCα mRNA levels under RNA polymerase inhibition. 
 PKCα mRNA was measured using qRT-PCR after 12 hours of treatment with the a-amanitin, a RNA 
polymerase inhibitor or vehicle control  (ethanol), and quantified relative to 18rRNA.  Error bars indicate 







Fig. B.3: PKCα levels under inhibition of protein synthesis.  
EC cells treated with cycloheximide to inhibit protein synthesis or vehicle control (DMSO) in a time 
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